SE|00000000||tx|1|text|On the contrary, neurotensin and tuftsin were agonists in induction of analgesia.
SE|00000000||tx|1|entity|C0027930|Neurotensin|aapp,horm,nsba|||neurotensin||||1000|18|28
SE|00000000||tx|1|entity|C0041350|Tuftsin|aapp,imft|||tuftsin||||1000|34|40
SE|00000000||tx|1|entity|C0243192|agonists|phsu|||agonists||||1000|47|54
SE|00000000||tx|1|entity|C0205263|Induce (action)|ftcn|||induction||||1000|59|67
SE|00000000||tx|1|entity|C3202977|Analgesia|topp|||analgesia||||1000|72|80

SE|00000000||tx|2|text|Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine.
SE|00000000||tx|2|entity|C0012010|Diazepam|orch,phsu|||Diazepam||||1000|1|8
SE|00000000||tx|2|entity|C0178602|Dosage|qnco|||doses||||1000|13|17
SE|00000000||tx|2|entity|C0439272|ug/g|qnco|||mg/kg||||861|27|31
SE|00000000||tx|2|entity|C0450346|2/5|qnco|||2.5||||888|37|39
SE|00000000||tx|2|entity|C0439272|ug/g|qnco|||mg/kg||||888|41|45
SE|00000000||tx|2|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|61|68
SE|00000000||tx|2|entity|C1280500|Effect|qlco|||effect||||861|112|117
SE|00000000||tx|2|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|122|129
SE|00000000||tx|2|relation|5|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|61|68|NOM|INTERACTS_WITH||112|117|1|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|122|129

SE|00000000||tx|3|text|We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
SE|00000000||tx|3|entity|C0963856|ADL 8-2698|orch,phsu|||ADL 8-2698||||1000|18|27
SE|00000000||tx|3|entity|C0026549|Morphine|orch,phsu|||morphine-||||851|38|46
SE|00000000||tx|3|entity|C0205263|Induce (action)|ftcn|||induced||||851|47|53
SE|00000000||tx|3|entity|C0442805|Increase|ftcn|||increases||||851|55|63
SE|00000000||tx|3|entity|C0232484|Gastrointestinal transit time|ortf|||gastrointestinal transit time||||1000|68|96
SE|00000000||tx|3|entity|C0205100|Peripheral|spco|||peripheral||||583|120|129
SE|00000000||tx|3|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||583|131|136
SE|00000000||tx|3|entity|C0392760|Affecting|ftcn|||affecting||||843|158|166
SE|00000000||tx|3|entity|C1879652|Central Minus|lbpr|||central||||843|168|174
SE|00000000||tx|3|entity|C0002772|Analgesics, Opioid|orch,phsu|||opioid analgesia||||843|176|191

SE|00000000||tx|4|text|Clinical implications of warfarin interactions with five sedatives.
SE|00000000||tx|4|entity|C0205210|Clinical|qlco|||Clinical||||694|1|8
SE|00000000||tx|4|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||872|26|33
SE|00000000||tx|4|entity|C1704675|Interaction|ftcn|||interactions||||872|35|46
SE|00000000||tx|4|entity|C0205451|Five|qnco|||five||||888|53|56
SE|00000000||tx|4|entity|C0036557|Sedatives|phsu|||sedatives||||888|58|66
SE|00000000||tx|4|relation|1|1|C0036557|Sedatives|phsu|phsu|||sedatives||||888|58|66|NOM|INTERACTS_WITH||35|46|1|0|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||872|26|33

SE|00000000||tx|5|text|Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005);
SE|00000000||tx|5|entity|C0026549|Morphine|orch,phsu|||Morphine||||1000|1|8
SE|00000000||tx|5|entity|C0232484|Gastrointestinal transit time|ortf|||gastrointestinal transit time||||1000|20|48
SE|00000000||tx|5|entity|C0700321|Small|qnco|||minutes||||861|65|71
SE|00000000||tx|5|relation|1|1|C0026549|Morphine|orch,phsu|orch|||Morphine||||1000|1|8|VERB|AFFECTS||10|18|3|1|C0232484|Gastrointestinal transit time|ortf|ortf|||gastrointestinal transit time||||1000|20|48

SE|00000000||tx|6|text|this was prevented by ADL 8-2698 (P = .004).
SE|00000000||tx|6|entity|C0963856|ADL 8-2698|orch,phsu|||ADL 8-2698||||1000|23|32

SE|00000000||tx|7|text|Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated.
SE|00000000||tx|7|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||861|1|10
SE|00000000||tx|7|entity|C0449297|Clearance|qlco|||clearance||||1000|36|44
SE|00000000||tx|7|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|49|57
SE|00000000||tx|7|entity|C0663716|25-desacetylrifabutin|orch,phsu|||25-O-desacetylrifabutin||||913|63|85
SE|00000000||tx|7|entity|C0205195|Combined|qlco|||combination||||1000|96|106
SE|00000000||tx|7|entity|C0205169|Bad|qlco|||poorly||||1000|111|116
SE|00000000||tx|7|relation|1|1|C0754188|Amprenavir|orch,phsu|orch|||Amprenavir||||861|1|10|VERB|INHIBITS||26|34|4|2|C0140575|Rifabutin|antb,orch|antb|||rifabutin||||1000|49|57

SE|00000000||tx|8|text|Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;
SE|00000000||tx|8|entity|C0020737|Ibogaine|bacs,orch,phsu|||ibogaine||||1000|6|13
SE|00000000||tx|8|entity|C0332206|Blocking|ftcn|||block||||827|25|29
SE|00000000||tx|8|entity|C0026549|Morphine|orch,phsu|||morphine-||||888|31|39
SE|00000000||tx|8|entity|C0205263|Induce (action)|ftcn|||induced||||888|40|46
SE|00000000||tx|8|entity|C0028040|Nicotine|hops,orch,phsu|||nicotine||||833|52|59
SE|00000000||tx|8|entity|C0205263|Induce (action)|ftcn|||induced||||833|61|67
SE|00000000||tx|8|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||833|69|76
SE|00000000||tx|8|entity|C0391871|Released (action)|ftcn|||release||||833|78|84
SE|00000000||tx|8|entity|C0028633|Nucleus Accumbens|bpoc|||nucleus accumbens||||1000|93|109
SE|00000000||tx|8|relation|2|2|C0020737|Ibogaine|bacs,orch,phsu|orch|||ibogaine||||1000|6|13|ADJ|AUGMENTS||40|46|2|2|C0028633|Nucleus Accumbens|bpoc|bpoc|||nucleus accumbens||||1000|93|109

SE|00000000||tx|9|text|Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.
SE|00000000||tx|9|entity|C0008161|Chloral Hydrate|orch,phsu|||Chloral hydrate||||1000|1|15
SE|00000000||tx|9|entity|C0025627|Methaqualone|orch,phsu|||methaqualone||||1000|21|32
SE|00000000||tx|9|entity|C0442027|Oral|spco|||orally||||824|66|71
SE|00000000||tx|9|entity|C0003280|Anticoagulants|phsu|||anticoagulant agents||||824|86|105
SE|00000000||tx|9|entity|C1280500|Effect|qlco|||effect||||1000|116|121
SE|00000000||tx|9|entity|C1273937|Not significant|fndg|||not clinically significant||||913|126|151
SE|00000000||tx|9|relation|2|1|C0025627|Methaqualone|orch,phsu|orch|||methaqualone||||1000|21|32|VERB|INTERACTS_WITH||34|41|3|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulant agents||||824|86|105
SE|00000000||tx|9|relation|2|1|C0008161|Chloral Hydrate|orch,phsu|orch|||Chloral hydrate||||1000|1|15|VERB|INTERACTS_WITH||34|41|3|1|C0003280|Anticoagulants|phsu|phsu|||anticoagulant agents||||824|86|105

SE|00000000||tx|10|text|With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.
SE|00000000||tx|10|entity|C0205195|Combined|qlco|||combined||||888|6|13
SE|00000000||tx|10|entity|C0042153|utilization qualifier|ftcn|||use||||888|15|17
SE|00000000||tx|10|entity|C0871685|Clinician|prog|||clinicians||||1000|20|29
SE|00000000||tx|10|entity|C0004448|Awareness|menp|||aware||||1000|41|45
SE|00000000||tx|10|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||1000|53|61
SE|00000000||tx|10|entity|C3245505|Potential|qlco|||potential||||1000|80|88
SE|00000000||tx|10|entity|C2707265|Pulmonary:-:Point in time:^Patient:-|clna|||pulmonary||||694|112|120
SE|00000000||tx|10|entity|C0441994|Lower - spatial qualifier|spco|||lowered||||852|144|150
SE|00000000||tx|10|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||852|158|169
SE|00000000||tx|10|entity|C0683149|serum drug concentration|qnco|||serum theophylline concentrations||||852|152|184

SE|00000000||tx|11|text|The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis.
SE|00000000||tx|11|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000||tx|11|entity|C0003240|Macrolide Antibiotics|antb,orch|||macrolide antibiotics||||1000|35|55
SE|00000000||tx|11|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors||||966|67|129
SE|00000000||tx|11|entity|C0205156|Previous|tmco|||previous||||888|148|155
SE|00000000||tx|11|entity|C0035410|Rhabdomyolysis|patf|||rhabdomyolysis||||1000|168|181

SE|00000000||tx|12|text|Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy.
SE|00000000||tx|12|entity|C1280500|Effect|qlco|||effect||||1000|15|20
SE|00000000||tx|12|entity|C1292426|4 Hours|tmco|||4 hours||||1000|67|73
SE|00000000||tx|12|entity|C0082608|fluvastatin|orch,phsu|||fluvastatin||||1000|84|94
SE|00000000||tx|12|entity|C0040808|Treatment Protocols|topp|||regimen||||1000|102|108
SE|00000000||tx|12|entity|C1518422|Negation|ftcn|||not||||1000|114|116
SE|00000000||tx|12|entity|C0205216|Decreased|qnco|||diminished||||888|128|137
SE|00000000||tx|12|entity|C1280519|Effectiveness|qlco|||efficacy||||888|139|146

SE|00000000||tx|13|text|In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.
SE|00000000||tx|13|entity|C0031330|Pharmacology|bmod|||pharmacological||||888|21|35
SE|00000000||tx|13|entity|C1704675|Interaction|ftcn|||interaction||||888|37|47
SE|00000000||tx|13|entity|C0205314|New|tmco|||novel||||901|74|78
SE|00000000||tx|13|entity|C0596319|chemical reaction|phpr|||chemical reaction||||901|80|96
SE|00000000||tx|13|entity|C0039468|Temazepam|orch,phsu|||temazepam||||1000|106|114
SE|00000000||tx|13|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||1000|119|132
SE|00000000||tx|13|entity|C0001962|Ethanol|orch|||ethanol||||1000|139|145
SE|00000000||tx|13|entity|C0001128|Acids|chem|||acidic||||872|153|158
SE|00000000||tx|13|entity|C0348080|Condition|qlco|||conditions||||872|160|169
SE|00000000||tx|13|entity|C2348205|Similarity|qlco|||similar||||1000|171|177
SE|00000000||tx|13|entity|C0037088|Signs and Symptoms|sosy|||found||||966|188|192
SE|00000000||tx|13|entity|C1514468|product|enty|||product||||827|232|238

SE|00000000||tx|14|text|Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs.
SE|00000000||tx|14|entity|C0004745|Barbiturates|orch,phsu|||Barbiturates||||1000|1|12
SE|00000000||tx|14|entity|C0017845|Glutethimide|orch,phsu|||glutethimide||||1000|18|29
SE|00000000||tx|14|entity|C1518422|Negation|ftcn|||not||||1000|38|40
SE|00000000||tx|14|entity|C0030705|Patients|podg|||patients||||1000|61|68
SE|00000000||tx|14|entity|C0010206|coumarin|orch,phsu|||coumarin||||888|80|87
SE|00000000||tx|14|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|89|93
SE|00000000||tx|14|relation|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin||||888|80|87|MOD/HEAD|ISA||80|93|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|89|93
SE|00000000||tx|14|relation|2|1|C0017845|Glutethimide|orch,phsu|orch|||glutethimide||||1000|18|29|VERB|ADMINISTERED_TO||45|56|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|61|68
SE|00000000||tx|14|relation|2|1|C0004745|Barbiturates|orch,phsu|orch|||Barbiturates||||1000|1|12|VERB|ADMINISTERED_TO||45|56|2|1|C0030705|Patients|podg,humn|humn|||patients||||1000|61|68
SE|00000000||tx|14|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|89|93|VERB|ADMINISTERED_TO||70|78|3|1|C0030705|Patients|podg,humn|humn|||patients||||1000|61|68
SE|00000000||tx|14|relation|0|0|C0010206|coumarin|orch,phsu|orch|||coumarin||||888|80|87|INFER|ADMINISTERED_TO(SPEC)||80|93|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|61|68

SE|00000000||tx|15|text|Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem.
SE|00000000||tx|15|entity|C0750489|apparent|idcn|||Apparent||||851|1|8
SE|00000000||tx|15|entity|C0442027|Oral|spco|||oral||||851|10|13
SE|00000000||tx|15|entity|C0449297|Clearance|qlco|||clearance||||851|15|23
SE|00000000||tx|15|entity|C0449468|Volume|qnco|||volume||||1000|29|34
SE|00000000||tx|15|entity|C1704711|Distribution|ftcn|||distribution||||1000|39|50
SE|00000000||tx|15|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|55|63
SE|00000000||tx|15|entity|C0450361|38|inpr|||38%||||1000|80|82
SE|00000000||tx|15|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|112|120
SE|00000000||tx|15|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|137|145
SE|00000000||tx|15|relation|1|1|C0012373|Diltiazem|orch,phsu|orch|||diltiazem||||1000|137|145|VERB|COEXISTS_WITH||126|130|5|1|C0072980|Sirolimus|antb,orch|antb|||sirolimus||||1000|112|120

SE|00000000|CONCLUSIONS|tx|16|text|CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus.
SE|00000000|CONCLUSIONS|tx|16|entity|C1707478|Conclusion|idcn|||CONCLUSIONS||||1000|1|11
SE|00000000|CONCLUSIONS|tx|16|entity|C0205171|Singular|qnco|||Single-||||608|14|20
SE|00000000|CONCLUSIONS|tx|16|entity|C1114758|Dose number:Number:Point in time:^Patient:Quantitative|clna|||dose||||608|21|24
SE|00000000|CONCLUSIONS|tx|16|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||608|26|34
SE|00000000|CONCLUSIONS|tx|16|entity|C0205250|High|qlco|||higher||||606|62|67
SE|00000000|CONCLUSIONS|tx|16|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||606|69|77
SE|00000000|CONCLUSIONS|tx|16|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|103|112
SE|00000000|CONCLUSIONS|tx|16|entity|C0444693|First pass|tmco|||first-pass||||901|121|130
SE|00000000|CONCLUSIONS|tx|16|entity|C0025520|metabolic aspects|ftcn|||metabolism||||901|132|141
SE|00000000|CONCLUSIONS|tx|16|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|146|154
SE|00000000|CONCLUSIONS|tx|16|relation|3|1|C0072980|Sirolimus|antb,orch|antb|||sirolimus||||606|69|77|NOM|INHIBITS||103|112|2|2|C0072980|Sirolimus|antb,orch|antb|||sirolimus||||1000|146|154

SE|00000000|CONCLUSIONS|tx|17|text|Amiodarone is known to raise serum digoxin levels.
SE|00000000|CONCLUSIONS|tx|17|entity|C0002598|Amiodarone|orch,phsu|||Amiodarone||||1000|1|10
SE|00000000|CONCLUSIONS|tx|17|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin levels||||983|30|49

SE|00000000|CONCLUSIONS|tx|18|text|Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage.
SE|00000000|CONCLUSIONS|tx|18|entity|C0074774|sodium thiosulfate|inch,phsu|||Sodium thiosulfate||||1000|1|18
SE|00000000|CONCLUSIONS|tx|18|entity|C0450442|Agent|chvf|||agent||||861|38|42
SE|00000000|CONCLUSIONS|tx|18|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|48|56
SE|00000000|CONCLUSIONS|tx|18|entity|C0022646|Kidney|bpoc|||renal||||888|80|84
SE|00000000|CONCLUSIONS|tx|18|entity|C1883709|Damage|ftcn|||damage||||888|86|91
SE|00000000|CONCLUSIONS|tx|18|relation|0|0|C0074774|sodium thiosulfate|inch,phsu|inch|||Sodium thiosulfate||||1000|1|18|SPEC|ISA||1|42|0|0|C0450442|Agent|chvf|chvf|||agent||||861|38|42

SE|00000000|CONCLUSIONS|tx|19|text|CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).
SE|00000000|CONCLUSIONS|tx|19|entity|C1707478|Conclusion|idcn|||CONCLUSIONS||||1000|1|11
SE|00000000|CONCLUSIONS|tx|19|entity|C0003240|Macrolide Antibiotics|antb,orch|||Macrolide antibiotics||||1000|14|34
SE|00000000|CONCLUSIONS|tx|19|entity|C0025519|Metabolism|orgf|||metabolism||||1000|48|57
SE|00000000|CONCLUSIONS|tx|19|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||HMG-CoA reductase inhibitors||||966|62|89
SE|00000000|CONCLUSIONS|tx|19|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|115|120
SE|00000000|CONCLUSIONS|tx|19|entity|C0286651|atorvastatin|orch,phsu|||atorvastatin||||1000|129|140
SE|00000000|CONCLUSIONS|tx|19|entity|C0528023|cerivastatin|orch,phsu|||cerivastatin||||1000|143|154
SE|00000000|CONCLUSIONS|tx|19|entity|C0024027|Lovastatin|orch,phsu|||lovastatin||||1000|157|166
SE|00000000|CONCLUSIONS|tx|19|entity|C0074554|Simvastatin|orch,phsu|||simvastatin||||1000|169|179
SE|00000000|CONCLUSIONS|tx|19|relation|2|1|C0003240|Macrolide Antibiotics|antb,orch|antb|||Macrolide antibiotics||||1000|14|34|VERB|INHIBITS||36|42|8|2|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||966|62|89
SE|00000000|CONCLUSIONS|tx|19|relation|6|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|115|120|VERB|INTERACTS_WITH||100|110|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||HMG-CoA reductase inhibitors||||966|62|89

SE|00000000|CONCLUSIONS|tx|20|text|However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin.
SE|00000000|CONCLUSIONS|tx|20|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||1000|10|24
SE|00000000|CONCLUSIONS|tx|20|entity|C1518422|Negation|ftcn|||not||||861|46|48
SE|00000000|CONCLUSIONS|tx|20|entity|C1514485|Proliferation|ftcn|||proliferation||||1000|73|85
SE|00000000|CONCLUSIONS|tx|20|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|106|112
SE|00000000|CONCLUSIONS|tx|20|relation|2|2|C0073109|retinol acetate|orch,phsu,vita|orch|||retinyl acetate||||1000|10|24|NOM|COEXISTS_WITH||94|101|1|1|C0021641|Insulin|aapp,gngm,horm,phsu|aapp|||insulin||||1000|106|112

SE|00000000|CONCLUSIONS|tx|21|text|PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin.
SE|00000000|CONCLUSIONS|tx|21|entity|C0012471|Dinoprost|eico,horm,phsu|||PGF2alpha||||1000|1|9
SE|00000000|CONCLUSIONS|tx|21|entity|C0442805|Increase|ftcn|||increased||||790|34|42
SE|00000000|CONCLUSIONS|tx|21|entity|C0042396|Vascular constriction (function)|ortf|||vasoconstriction||||790|44|59
SE|00000000|CONCLUSIONS|tx|21|entity|C0087136|Unmarried|fndg|||single||||888|69|74
SE|00000000|CONCLUSIONS|tx|21|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin||||1000|94|101

SE|00000000|CONCLUSIONS|tx|22|text|Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
SE|00000000|CONCLUSIONS|tx|22|entity|C0035410|Rhabdomyolysis|patf|||Rhabdomyolysis||||1000|1|14
SE|00000000|CONCLUSIONS|tx|22|entity|C0205436|second (number)|qnco|||secondary||||1000|16|24
SE|00000000|CONCLUSIONS|tx|22|entity|C0687133|Drug Interactions|moft|||drug interaction||||1000|31|46
SE|00000000|CONCLUSIONS|tx|22|entity|C0074554|Simvastatin|orch,phsu|||simvastatin||||1000|56|66
SE|00000000|CONCLUSIONS|tx|22|entity|C0055856|Clarithromycin|antb,orch|||clarithromycin||||1000|72|85

SE|00000000|CONCLUSIONS|tx|23|text|Our data suggest that TAM significantly potentiates the reduction in cell number induced by 1,25(OH)2D3 alone.
SE|00000000|CONCLUSIONS|tx|23|entity|C1511726|Data|idcn|||data||||1000|5|8
SE|00000000|CONCLUSIONS|tx|23|entity|C1834582|MYELOPROLIFERATIVE SYNDROME, TRANSIENT|neop|||TAM||||861|23|25
SE|00000000|CONCLUSIONS|tx|23|entity|C0392756|Reduced|qlco|||reduction||||1000|57|65
SE|00000000|CONCLUSIONS|tx|23|entity|C0007584|Cell Count|lbpr|||cell number||||1000|70|80
SE|00000000|CONCLUSIONS|tx|23|entity|C0205171|Singular|qnco|||alone||||1000|105|109

SE|00000000|CONCLUSIONS|tx|24|text|Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release.
SE|00000000|CONCLUSIONS|tx|24|entity|C0026845|Muscle|tisu|||muscle||||1000|17|22
SE|00000000|CONCLUSIONS|tx|24|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|27|33
SE|00000000|CONCLUSIONS|tx|24|entity|C0522501|Massive|qlco|||markedly||||694|46|53
SE|00000000|CONCLUSIONS|tx|24|entity|C0030899|Pentoxifylline|orch,phsu|||PTX||||851|69|71
SE|00000000|CONCLUSIONS|tx|24|entity|C0205263|Induce (action)|ftcn|||induced||||851|73|79
SE|00000000|CONCLUSIONS|tx|24|entity|C0391871|Released (action)|ftcn|||release||||851|81|87

SE|00000000|CONCLUSIONS|tx|25|text|Injection of estradiol 5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to endotoxin.
SE|00000000|CONCLUSIONS|tx|25|entity|C1533685|Injection procedure|topp|||Injection||||1000|1|9
SE|00000000|CONCLUSIONS|tx|25|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol||||802|14|22
SE|00000000|CONCLUSIONS|tx|25|entity|C0702093|/minute|tmco|||min||||802|26|28
SE|00000000|CONCLUSIONS|tx|25|entity|C0178602|Dosage|qnco|||dose||||861|49|52
SE|00000000|CONCLUSIONS|tx|25|entity|C0014264|Endotoxins|carb,hops,lipd|||endotoxin||||1000|57|65
SE|00000000|CONCLUSIONS|tx|25|entity|C0229671|Serum|bdsu|||serum||||676|79|83
SE|00000000|CONCLUSIONS|tx|25|entity|C0036884|Gonadal Steroid Hormones|horm,phsu|||sex steroid hormone||||676|85|103
SE|00000000|CONCLUSIONS|tx|25|entity|C1706429|Male, Self-Reported|orga|||male||||888|117|120
SE|00000000|CONCLUSIONS|tx|25|entity|C0034693|Rattus norvegicus|mamm|||rats||||888|122|125
SE|00000000|CONCLUSIONS|tx|25|entity|C0014264|Endotoxins|carb,hops,lipd|||endotoxin||||1000|130|138

SE|00000000|CONCLUSIONS|tx|26|text|This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration.
SE|00000000|CONCLUSIONS|tx|26|entity|C0205448|Two|qnco|||two||||888|23|25
SE|00000000|CONCLUSIONS|tx|26|entity|C1533148|Case unit dose|qnco|||cases||||888|27|31
SE|00000000|CONCLUSIONS|tx|26|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||888|42|53
SE|00000000|CONCLUSIONS|tx|26|entity|C0449297|Clearance|qlco|||clearance||||888|55|63
SE|00000000|CONCLUSIONS|tx|26|entity|C0522501|Massive|qlco|||markedly||||1000|77|84
SE|00000000|CONCLUSIONS|tx|26|entity|C0521115|Simultaneous|tmco|||concomitant||||851|91|101
SE|00000000|CONCLUSIONS|tx|26|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||851|103|111

SE|00000000|CONCLUSIONS|tx|27|text|Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains.
SE|00000000|CONCLUSIONS|tx|27|entity|C0453882|Combinations|mnob|||Combinations||||1000|1|12
SE|00000000|CONCLUSIONS|tx|27|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|17|27
SE|00000000|CONCLUSIONS|tx|27|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|33|42
SE|00000000|CONCLUSIONS|tx|27|entity|C0332238|Indifferent|qlco|||indifferent||||1000|49|59
SE|00000000|CONCLUSIONS|tx|27|entity|C2986495|Synergistic|qlco|||synergistic||||1000|72|82
SE|00000000|CONCLUSIONS|tx|27|entity|C2827757|Antimicrobial Resistance Result|lbtr|||resistant||||888|98|106
SE|00000000|CONCLUSIONS|tx|27|entity|C0080194|Muscle strain|inpo|||strains||||888|108|114

SE|00000000|CONCLUSIONS|tx|28|text|Treatment with antidepressant drugs can directly interfere with blood glucose levels or may interact with hypoglycemic agents.
SE|00000000|CONCLUSIONS|tx|28|entity|C0087111|Therapeutic procedure|topp|||Treatment||||1000|1|9
SE|00000000|CONCLUSIONS|tx|28|entity|C0003289|Antidepressive Agents|phsu|||antidepressant drugs||||1000|16|35
SE|00000000|CONCLUSIONS|tx|28|entity|C1947931|Direct (qualifier)|qlco|||directly||||1000|41|48
SE|00000000|CONCLUSIONS|tx|28|entity|C0428554|Finding of blood glucose level|lbtr|||blood glucose levels||||1000|65|84
SE|00000000|CONCLUSIONS|tx|28|entity|C0020616|Hypoglycemic Agents|phsu|||hypoglycemic agents||||1000|107|125
SE|00000000|CONCLUSIONS|tx|28|relation|1|1|C0087111|Therapeutic procedure|topp|topp|||Treatment||||1000|1|9|PREP|USES||11|14|3|1|C0003289|Antidepressive Agents|phsu|phsu|||antidepressant drugs||||1000|16|35

SE|00000000|CONCLUSIONS|tx|29|text|Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.
SE|00000000|CONCLUSIONS|tx|29|entity|C1621583|Administer|ftcn|||Administering||||627|1|13
SE|00000000|CONCLUSIONS|tx|29|entity|C0205263|Induce (action)|ftcn|||induced||||750|75|81
SE|00000000|CONCLUSIONS|tx|29|entity|C0871261|Response process|orga|||responses||||750|83|91
SE|00000000|CONCLUSIONS|tx|29|entity|C0871261|Response process|orga|||responses||||861|118|126
SE|00000000|CONCLUSIONS|tx|29|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||734|134|147

SE|00000000|CONCLUSIONS|tx|30|text|Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by allopurinol and Vitamin E.
SE|00000000|CONCLUSIONS|tx|30|entity|C1274040|Result|ftcn|||results||||1000|11|17
SE|00000000|CONCLUSIONS|tx|30|entity|C0056849|cypermethrin|hops,orch|||cypermethrin||||694|32|43
SE|00000000|CONCLUSIONS|tx|30|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|57|60
SE|00000000|CONCLUSIONS|tx|30|entity|C0016693|Free Radicals|bacs,chvs|||free radical||||857|73|84
SE|00000000|CONCLUSIONS|tx|30|entity|C0127400|Mediator brand of benfluorex hydrochloride|orch,phsu|||mediated||||857|86|93
SE|00000000|CONCLUSIONS|tx|30|entity|C0010957|Tissue damage|inpo|||tissue damage||||857|95|107
SE|00000000|CONCLUSIONS|tx|30|entity|C3163633|Elevated|qlco|||elevated||||694|126|133
SE|00000000|CONCLUSIONS|tx|30|entity|C0205054|Hepatic|blor|||hepatic||||901|148|154
SE|00000000|CONCLUSIONS|tx|30|entity|C0023775|Lipid Peroxidation|moft|||lipid peroxidation||||901|156|173
SE|00000000|CONCLUSIONS|tx|30|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|199|209
SE|00000000|CONCLUSIONS|tx|30|entity|C0042874|Vitamin E|lipd,phsu,vita|||Vitamin E||||1000|215|223
SE|00000000|CONCLUSIONS|tx|30|relation|6|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|57|60|PREP|LOCATION_OF||54|55|2|1|C0056849|cypermethrin|hops,orch|hops|||cypermethrin||||694|32|43
SE|00000000|CONCLUSIONS|tx|30|relation|3|2|C0056849|cypermethrin|hops,orch|hops|||cypermethrin||||694|32|43|VERB|CAUSES||62|68|5|1|C0010957|Tissue damage|inpo|inpo|||tissue damage||||857|95|107

SE|00000000|CONCLUSIONS|tx|31|text|The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone.
SE|00000000|CONCLUSIONS|tx|31|entity|C0018517|Half-Life|tmco|||half-life||||1000|5|13
SE|00000000|CONCLUSIONS|tx|31|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|18|25
SE|00000000|CONCLUSIONS|tx|31|entity|C0032105|Plasma|bdsu|||plasma||||1000|30|35
SE|00000000|CONCLUSIONS|tx|31|entity|C0006104|Brain|bpoc|||brain||||1000|41|45
SE|00000000|CONCLUSIONS|tx|31|entity|C0205166|Long|qlco|||longer||||966|51|56
SE|00000000|CONCLUSIONS|tx|31|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|77|85
SE|00000000|CONCLUSIONS|tx|31|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|97|104
SE|00000000|CONCLUSIONS|tx|31|entity|C0205171|Singular|qnco|||alone||||1000|116|120
SE|00000000|CONCLUSIONS|tx|31|relation|5|4|C0022614|Ketamine|orch,phsu|orch|||ketamine||||1000|18|25|NOM|COEXISTS_WITH||65|72|3|1|C0018549|Halothane|orch,phsu|orch|||halothane||||1000|77|85

SE|00000000|CONCLUSIONS|tx|32|text|Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine.
SE|00000000|CONCLUSIONS|tx|32|entity|C0021495|Injections, Intraventricular|topp|||Intraventricular injection||||1000|1|26
SE|00000000|CONCLUSIONS|tx|32|entity|C0027358|Naloxone|orch,phsu|||naloxone||||1000|31|38
SE|00000000|CONCLUSIONS|tx|32|entity|C0178602|Dosage|qnco|||doses||||1000|43|47
SE|00000000|CONCLUSIONS|tx|32|entity|C0580272|1/2|inpr|||1.2||||1000|52|54
SE|00000000|CONCLUSIONS|tx|32|entity|C0439211|microgram|qnco|||micrograms||||827|62|71
SE|00000000|CONCLUSIONS|tx|32|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||734|98|111
SE|00000000|CONCLUSIONS|tx|32|entity|C0039259|Tail|bpoc|||tail-||||802|124|128
SE|00000000|CONCLUSIONS|tx|32|entity|C1628982|Percent inhibition|qnco|||inhibition||||802|135|144
SE|00000000|CONCLUSIONS|tx|32|entity|C1517569|Intraventricular|blor|||intraventricular||||901|157|172
SE|00000000|CONCLUSIONS|tx|32|entity|C0005210|beta-Endorphin|aapp,nsba|||beta-endorphin||||901|174|187
SE|00000000|CONCLUSIONS|tx|32|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|193|200
SE|00000000|CONCLUSIONS|tx|32|relation|2|1|C0005210|beta-Endorphin|aapp,gngm,nsba|aapp|||beta-endorphin||||901|174|187|VERB|STIMULATES||146|152|6|5|C0027358|Naloxone|orch,phsu|orch|||naloxone||||1000|31|38
SE|00000000|CONCLUSIONS|tx|32|relation|2|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|193|200|VERB|STIMULATES||146|152|6|5|C0027358|Naloxone|orch,phsu|orch|||naloxone||||1000|31|38
SE|00000000|CONCLUSIONS|tx|32|relation|0|0|C0005210|beta-Endorphin|aapp,gngm,nsba|gngm|||beta-endorphin||||901|174|187|MOD/HEAD|PART_OF||157|187|0|0|C1517569|Intraventricular|blor|blor|||intraventricular||||901|157|172

SE|00000000|CONCLUSIONS|tx|33|text|Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
SE|00000000|CONCLUSIONS|tx|33|entity|C0085228|Fluvoxamine|orch,phsu|||Fluvoxamine||||1000|1|11
SE|00000000|CONCLUSIONS|tx|33|entity|||gngm|1559|CYP2C9|CYP2C9||||1000|26|31
SE|00000000|CONCLUSIONS|tx|33|entity|C0220798|biotransformational|ftcn|||biotransformation||||1000|43|59
SE|00000000|CONCLUSIONS|tx|33|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|64|74
SE|00000000|CONCLUSIONS|tx|33|relation|1|1|C0085228|Fluvoxamine|orch,phsu|orch|||Fluvoxamine||||1000|1|11|VERB|INHIBITS||13|20|3|1|||gngm,aapp|gngm|1559|CYP2C9|CYP2C9||||1000|26|31

SE|00000000|CONCLUSIONS|tx|34|text|Pretreatment of rats with allopurinol (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h.
SE|00000000|CONCLUSIONS|tx|34|entity|C1550147|Pretreatment|sbst|||Pretreatment||||1000|1|12
SE|00000000|CONCLUSIONS|tx|34|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|17|20
SE|00000000|CONCLUSIONS|tx|34|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|27|37
SE|00000000|CONCLUSIONS|tx|34|entity|C0439272|ug/g|qnco|||mg/kg||||901|44|48
SE|00000000|CONCLUSIONS|tx|34|entity|C0042874|Vitamin E|lipd,phsu,vita|||Vitamin E||||1000|58|66
SE|00000000|CONCLUSIONS|tx|34|entity|C0439272|ug/g|qnco|||mg/kg||||901|73|77
SE|00000000|CONCLUSIONS|tx|34|entity|C0439228|day|tmco|||day||||1000|83|85
SE|00000000|CONCLUSIONS|tx|34|entity|C1442459|3 Days|tmco|||3 days||||1000|96|101
SE|00000000|CONCLUSIONS|tx|34|entity|C0178602|Dosage|qnco|||dose||||1000|109|112
SE|00000000|CONCLUSIONS|tx|34|entity|C0439272|ug/g|qnco|||mg/kg||||901|120|124
SE|00000000|CONCLUSIONS|tx|34|entity|C0205438|Fourth|qnco|||4th||||888|133|135
SE|00000000|CONCLUSIONS|tx|34|entity|C0439228|day|tmco|||day||||888|137|139
SE|00000000|CONCLUSIONS|tx|34|entity|C0237881|Statistical Significance|qnco|||significant||||888|151|161
SE|00000000|CONCLUSIONS|tx|34|entity|C1545588|Protection|fndg|||protection||||888|163|172
SE|00000000|CONCLUSIONS|tx|34|entity|C0702240|Elevation|spco|||elevation||||1000|186|194
SE|00000000|CONCLUSIONS|tx|34|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||TBARS||||861|199|203
SE|00000000|CONCLUSIONS|tx|34|entity|C0736268|Liver parenchyma|bpoc|||hepatic tissues||||983|228|242
SE|00000000|CONCLUSIONS|tx|34|entity|C0205171|Singular|qnco|||single||||901|256|261
SE|00000000|CONCLUSIONS|tx|34|entity|C0444956|High dose|qnco|||high dose||||901|263|271
SE|00000000|CONCLUSIONS|tx|34|entity|C0056849|cypermethrin|hops,orch|||cypermethrin||||901|281|292
SE|00000000|CONCLUSIONS|tx|34|entity|C0001563|Administration, Oral|topp|||oral cypermethrin administration||||901|276|307
SE|00000000|CONCLUSIONS|tx|34|relation|20|2|C0002144|Allopurinol|orch,phsu|phsu|||allopurinol||||1000|27|37|NOM|TREATS||1|12|20|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|17|20

SE|00000000|CONCLUSIONS|tx|35|text|Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
SE|00000000|CONCLUSIONS|tx|35|entity|C0026218|Misonidazole|orch,phsu|||Misonidazole||||1000|1|12
SE|00000000|CONCLUSIONS|tx|35|entity|C0025914|House mice|mamm|||mouse||||888|23|27
SE|00000000|CONCLUSIONS|tx|35|entity|C0027651|Neoplasms|neop|||tumour||||888|29|34
SE|00000000|CONCLUSIONS|tx|35|entity|C0040300|Body tissue|tisu|||normal tissues||||983|40|53
SE|00000000|CONCLUSIONS|tx|35|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|64|71
SE|00000000|CONCLUSIONS|tx|35|entity|C0442027|Oral|spco|||oral||||888|76|79
SE|00000000|CONCLUSIONS|tx|35|entity|C0687700|CCNU|orch,phsu|||CCNU||||888|81|84
SE|00000000|CONCLUSIONS|tx|35|relation|0|0|C0027651|Neoplasms|neop|neop|||tumour||||888|29|34|MOD/HEAD|PROCESS_OF||23|34|0|0|C0025914|House mice|mamm|mamm|||mouse||||888|23|27

SE|00000000|CONCLUSIONS|tx|36|text|When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished.
SE|00000000|CONCLUSIONS|tx|36|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|6|12
SE|00000000|CONCLUSIONS|tx|36|entity|C0026845|Muscle|tisu|||muscle||||1000|33|38
SE|00000000|CONCLUSIONS|tx|36|entity|C0031448|Phentolamine|orch,phsu|||phentolamine||||1000|59|70
SE|00000000|CONCLUSIONS|tx|36|entity|C1279901|Firstly|qlco|||first||||1000|78|82
SE|00000000|CONCLUSIONS|tx|36|entity|C0457385|seconds|tmco|||second||||851|88|93
SE|00000000|CONCLUSIONS|tx|36|entity|C0026820|Muscle Contraction|phsf|||contractile||||851|95|105
SE|00000000|CONCLUSIONS|tx|36|entity|C0871261|Response process|orga|||responses||||851|107|115
SE|00000000|CONCLUSIONS|tx|36|entity|C0030899|Pentoxifylline|orch,phsu|||PTX||||1000|120|122
SE|00000000|CONCLUSIONS|tx|36|relation|2|2|C0029904|Ouabain|carb,phsu,strd|carb|||ouabain||||1000|6|12|NOM|COEXISTS_WITH||47|54|4|1|C0031448|Phentolamine|orch,phsu|orch|||phentolamine||||1000|59|70

SE|00000000|CONCLUSIONS|tx|37|text|Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
SE|00000000|CONCLUSIONS|tx|37|entity|C0011777|Dexamethasone|phsu,strd|||Dexamethasone||||1000|1|13
SE|00000000|CONCLUSIONS|tx|37|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||901|19|33
SE|00000000|CONCLUSIONS|tx|37|entity|||gngm|1950|EGF|EGF||||1000|67|69
SE|00000000|CONCLUSIONS|tx|37|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||851|75|81
SE|00000000|CONCLUSIONS|tx|37|entity|C0205263|Induce (action)|ftcn|||induced||||851|83|89
SE|00000000|CONCLUSIONS|tx|37|entity|C1514485|Proliferation|ftcn|||proliferation||||851|91|103
SE|00000000|CONCLUSIONS|tx|37|entity|C1179826|Prostatic epithelium|tisu|||prostatic epithelium||||1000|108|127
SE|00000000|CONCLUSIONS|tx|37|relation|2|1|C0073109|retinol acetate|orch,phsu,vita|orch|||retinyl acetate||||901|19|33|VERB|STIMULATES||57|65|3|1|||gngm,aapp|gngm|1950|EGF|EGF||||1000|67|69
SE|00000000|CONCLUSIONS|tx|37|relation|2|1|C0011777|Dexamethasone|phsu,strd|phsu|||Dexamethasone||||1000|1|13|VERB|STIMULATES||57|65|3|1|||gngm,aapp|gngm|1950|EGF|EGF||||1000|67|69

SE|00000000|CONCLUSIONS|tx|38|text|Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine.
SE|00000000|CONCLUSIONS|tx|38|entity|C1300517|Nucleic acid hybridization procedure|lbpr|||hybridization||||861|15|27
SE|00000000|CONCLUSIONS|tx|38|entity|C0025611|Methamphetamine|hops,orch|||METH||||1000|47|50
SE|00000000|CONCLUSIONS|tx|38|entity|C0439831|Rapid|qlco|||rapid||||1000|61|65
SE|00000000|CONCLUSIONS|tx|38|entity|C0205374|Transitory|tmco|||transient||||861|71|79
SE|00000000|CONCLUSIONS|tx|38|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||861|81|94
SE|00000000|CONCLUSIONS|tx|38|entity|C0442805|Increase|ftcn|||increase||||861|96|103
SE|00000000|CONCLUSIONS|tx|38|entity|C1859722|Arthrogryposis renal dysfunction cholestasis syndrome|dsyn|||arc||||840|108|110
SE|00000000|CONCLUSIONS|tx|38|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA||||840|112|115
SE|00000000|CONCLUSIONS|tx|38|entity|C2946261|Level|phsu|||level||||840|117|121
SE|00000000|CONCLUSIONS|tx|38|entity|C0162512|Neostriatum|bpoc|||striatum||||1000|130|137
SE|00000000|CONCLUSIONS|tx|38|entity|C2700441|Bark - plant part|plnt|||cortex||||1000|143|148
SE|00000000|CONCLUSIONS|tx|38|entity|C1550147|Pretreatment|sbst|||pretreatment||||1000|172|183
SE|00000000|CONCLUSIONS|tx|38|entity|C0242702|Dopamine Antagonists|nsba,phsu|||dopamine D1 receptor antagonist||||818|203|233
SE|00000000|CONCLUSIONS|tx|38|entity|C0080138|SCH 23390|orch,phsu|||SCH-23390||||818|235|243
SE|00000000|CONCLUSIONS|tx|38|entity|C1518422|Negation|ftcn|||not||||1000|249|251
SE|00000000|CONCLUSIONS|tx|38|entity|C0741302|atypia morphology|fndg|||atypical||||851|259|266
SE|00000000|CONCLUSIONS|tx|38|entity|C0040615|Antipsychotic Agents|phsu|||neuroleptic||||851|268|278
SE|00000000|CONCLUSIONS|tx|38|entity|C0009079|Clozapine|orch,phsu|||clozapine||||851|280|288
SE|00000000|CONCLUSIONS|tx|38|relation|0|0|C0009079|Clozapine|orch,phsu|orch|||clozapine||||851|280|288|MOD/HEAD|ISA||268|288|0|0|C0040615|Antipsychotic Agents|phsu|phsu|||neuroleptic||||851|268|278
SE|00000000|CONCLUSIONS|tx|38|relation|4|4|C1300517|Nucleic acid hybridization procedure|lbpr|lbpr|||hybridization||||861|15|27|PREP|DIAGNOSES||105|106|5|1|C1859722|Arthrogryposis renal dysfunction cholestasis syndrome|dsyn|dsyn|||arc||||840|108|110
SE|00000000|CONCLUSIONS|tx|38|relation|4|1|C0162512|Neostriatum|bpoc|bpoc|||striatum||||1000|130|137|PREP|LOCATION_OF||123|124|5|1|C1859722|Arthrogryposis renal dysfunction cholestasis syndrome|dsyn|dsyn|||arc||||840|108|110

SE|00000000|CONCLUSIONS|tx|39|text|Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively).
SE|00000000|CONCLUSIONS|tx|39|entity|C0225957|Structure of anulus fibrosus of aorta|bpoc|||Aortic rings||||983|1|12
SE|00000000|CONCLUSIONS|tx|39|entity|C0205266|Intact|qlco|||intact||||888|19|24
SE|00000000|CONCLUSIONS|tx|39|entity|C0014257|Endothelium|tisu|||endothelium||||888|26|36
SE|00000000|CONCLUSIONS|tx|39|entity|C0444956|High dose|qnco|||high-dose||||1000|47|55
SE|00000000|CONCLUSIONS|tx|39|entity|C0439400|mg/day/kg|qnco|||mg/kg/day||||916|60|68
SE|00000000|CONCLUSIONS|tx|39|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol||||888|71|79
SE|00000000|CONCLUSIONS|tx|39|entity|C0441833|Groups|idcn|||group||||888|81|85
SE|00000000|CONCLUSIONS|tx|39|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline||||1000|110|122
SE|00000000|CONCLUSIONS|tx|39|entity|C0445550|Low dose|qnco|||low-dose||||1000|151|158
SE|00000000|CONCLUSIONS|tx|39|entity|C1627892|Microgram per Kilogram|qnco|||microg/kg||||880|164|172
SE|00000000|CONCLUSIONS|tx|39|entity|C1547061|10 days|tmco|||10 microg/kg/day||||880|161|176
SE|00000000|CONCLUSIONS|tx|39|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol||||888|179|187
SE|00000000|CONCLUSIONS|tx|39|entity|C0441833|Groups|idcn|||groups||||888|189|194
SE|00000000|CONCLUSIONS|tx|39|entity|C1826536|PAF1 gene|gngm|54623|PAF1|pD2||||888|197|199
SE|00000000|CONCLUSIONS|tx|39|entity|C0042295|Values|qlco|||values||||888|201|206
SE|00000000|CONCLUSIONS|tx|39|relation|11|1|C0014257|Endothelium|tisu|tisu|||endothelium||||888|26|36|PREP|PART_OF||14|17|1|1|C0225957|Structure of anulus fibrosus of aorta|bpoc|bpoc|||Aortic rings||||983|1|12

SE|00000000|CONCLUSIONS|tx|40|text|Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.
SE|00000000|CONCLUSIONS|tx|40|entity|C0031849|Physostigmine|orch,phsu|||Physostigmine||||888|1|13
SE|00000000|CONCLUSIONS|tx|40|entity|C1550147|Pretreatment|sbst|||pretreatment||||888|15|26
SE|00000000|CONCLUSIONS|tx|40|entity|C1280500|Effect|qlco|||effect||||861|53|58
SE|00000000|CONCLUSIONS|tx|40|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|63|69
SE|00000000|CONCLUSIONS|tx|40|entity|C1279919|Early|tmco|||early||||623|78|82
SE|00000000|CONCLUSIONS|tx|40|entity|C0449432|Component object|mnob|||components||||623|84|93
SE|00000000|CONCLUSIONS|tx|40|entity|C0001975|Alcohols|orch,phsu|||alcohol's||||853|124|132
SE|00000000|CONCLUSIONS|tx|40|entity|C0021399|Influentials|idcn|||influence||||853|134|142
SE|00000000|CONCLUSIONS|tx|40|entity|C0449432|Component object|mnob|||components||||888|147|156
SE|00000000|CONCLUSIONS|tx|40|relation|5|3|C0001975|Alcohols|orch,phsu|orch|||alcohol||||1000|63|69|NOM|INTERACTS_WITH||134|142|5|0|C0001975|Alcohols|orch,phsu|orch|||alcohol's||||853|124|132

SE|00000000|CONCLUSIONS|tx|41|text|Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.
SE|00000000|CONCLUSIONS|tx|41|entity|C0205250|High|qlco|||Higher||||872|1|6
SE|00000000|CONCLUSIONS|tx|41|entity|C0086045|Mental concentration|menp|||concentrations||||872|8|21
SE|00000000|CONCLUSIONS|tx|41|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|26|38
SE|00000000|CONCLUSIONS|tx|41|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||1000|63|77
SE|00000000|CONCLUSIONS|tx|41|entity|C1752930|mitogenic activity|celf|||mitogenic activity||||1000|115|132
SE|00000000|CONCLUSIONS|tx|41|entity|||gngm|1950|EGF|EGF||||1000|137|139

SE|00000000|CONCLUSIONS|tx|42|text|The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm.
SE|00000000|CONCLUSIONS|tx|42|entity|C0000097|1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|hops,orch|||MPTP||||833|5|8
SE|00000000|CONCLUSIONS|tx|42|entity|C0205263|Induce (action)|ftcn|||induced||||833|10|16
SE|00000000|CONCLUSIONS|tx|42|entity|C1883709|Damage|ftcn|||damage||||833|27|32
SE|00000000|CONCLUSIONS|tx|42|entity|C1704410|Tolerance|qlco|||tolerance||||1000|45|53
SE|00000000|CONCLUSIONS|tx|42|entity|C1280500|Effect|qlco|||effects||||861|73|79
SE|00000000|CONCLUSIONS|tx|42|entity|C0002658|Amphetamine|nsba,orch,phsu|||amphetamine||||1000|84|94
SE|00000000|CONCLUSIONS|tx|42|entity|C1280500|Effect|qlco|||effects||||861|137|143
SE|00000000|CONCLUSIONS|tx|42|entity|C0003596|Apomorphine|orch,phsu|||apomorphine||||1000|148|158
SE|00000000|CONCLUSIONS|tx|42|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|163|166
SE|00000000|CONCLUSIONS|tx|42|entity|C0681797|paradigm|resa|||paradigm||||1000|204|211
SE|00000000|CONCLUSIONS|tx|42|relation|7|4|C0003596|Apomorphine|orch,phsu|orch|||apomorphine||||1000|148|158|NOM|INTERACTS_WITH||73|79|7|1|C0002658|Amphetamine|nsba,orch,phsu|nsba|||amphetamine||||1000|84|94
SE|00000000|CONCLUSIONS|tx|42|relation|7|1|C0003596|Apomorphine|orch,phsu|phsu|||apomorphine||||1000|148|158|PREP|TREATS||160|161|3|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|163|166

SE|00000000|CONCLUSIONS|tx|43|text|Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms).
SE|00000000|CONCLUSIONS|tx|43|entity|C1533685|Injection procedure|topp|||injection||||861|13|21
SE|00000000|CONCLUSIONS|tx|43|entity|C0027358|Naloxone|orch,phsu|||naloxone||||1000|26|33
SE|00000000|CONCLUSIONS|tx|43|entity|C0178602|Dosage|qnco|||doses||||1000|38|42
SE|00000000|CONCLUSIONS|tx|43|entity|C0439211|microgram|qnco|||micrograms||||888|57|66
SE|00000000|CONCLUSIONS|tx|43|entity|C0178602|Dosage|qnco|||dose-||||851|77|81
SE|00000000|CONCLUSIONS|tx|43|entity|C0163712|Relate - vinyl resin|orch|||related||||851|82|88
SE|00000000|CONCLUSIONS|tx|43|entity|C0332206|Blocking|ftcn|||blockade||||851|90|97
SE|00000000|CONCLUSIONS|tx|43|entity|C1628982|Percent inhibition|qnco|||inhibition||||1000|106|115
SE|00000000|CONCLUSIONS|tx|43|entity|C0039259|Tail|bpoc|||tail-||||660|124|128
SE|00000000|CONCLUSIONS|tx|43|entity|C0021495|Injections, Intraventricular|topp|||intraventricular injection||||1000|155|180
SE|00000000|CONCLUSIONS|tx|43|entity|C0005210|beta-Endorphin|aapp,nsba|||beta-endorphin||||1000|185|198
SE|00000000|CONCLUSIONS|tx|43|entity|C0444956|High dose|qnco|||high dose||||1000|207|215
SE|00000000|CONCLUSIONS|tx|43|entity|C0027358|Naloxone|orch,phsu|||naloxone||||1000|220|227
SE|00000000|CONCLUSIONS|tx|43|entity|C0439211|microgram|qnco|||micrograms||||888|233|242
SE|00000000|CONCLUSIONS|tx|43|entity|C0039259|Tail|bpoc|||tail-||||802|268|272
SE|00000000|CONCLUSIONS|tx|43|entity|C1628982|Percent inhibition|qnco|||inhibition||||802|279|288
SE|00000000|CONCLUSIONS|tx|43|entity|C1517569|Intraventricular|blor|||intraventricular||||901|301|316
SE|00000000|CONCLUSIONS|tx|43|entity|C0005210|beta-Endorphin|aapp,nsba|||beta-endorphin||||901|318|331
SE|00000000|CONCLUSIONS|tx|43|entity|C0439211|microgram|qnco|||micrograms||||861|337|346
SE|00000000|CONCLUSIONS|tx|43|relation|8|1|C0021495|Injections, Intraventricular|topp|topp|||intraventricular injection||||1000|155|180|PREP|METHOD_OF||152|153|7|7|C1533685|Injection procedure|topp|topp|||injection||||861|13|21
SE|00000000|CONCLUSIONS|tx|43|relation|2|1|C0005210|beta-Endorphin|aapp,gngm,nsba|aapp|||beta-endorphin||||901|318|331|VERB|STIMULATES||290|296|13|3|C0027358|Naloxone|orch,phsu|orch|||naloxone||||1000|220|227
SE|00000000|CONCLUSIONS|tx|43|relation|0|0|C0005210|beta-Endorphin|aapp,gngm,nsba|gngm|||beta-endorphin||||901|318|331|MOD/HEAD|PART_OF||301|331|0|0|C1517569|Intraventricular|blor|blor|||intraventricular||||901|301|316

SE|00000000|CONCLUSIONS|tx|44|text|Rifampin and warfarin: a drug interaction.
SE|00000000|CONCLUSIONS|tx|44|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000|CONCLUSIONS|tx|44|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|14|21
SE|00000000|CONCLUSIONS|tx|44|entity|C0687133|Drug Interactions|moft|||drug interaction||||1000|26|41

SE|00000000|CONCLUSIONS|tx|45|text|Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy.
SE|00000000|CONCLUSIONS|tx|45|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||1000|1|10
SE|00000000|CONCLUSIONS|tx|45|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|17|25
SE|00000000|CONCLUSIONS|tx|45|entity|C0205169|Bad|qlco|||poorly||||1000|31|36
SE|00000000|CONCLUSIONS|tx|45|entity|C1550501|Subject -direct target|idcn|||subjects||||827|61|68
SE|00000000|CONCLUSIONS|tx|45|entity|C0087111|Therapeutic procedure|topp|||therapy||||1000|83|89

SE|00000000|CONCLUSIONS|tx|46|text|Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
SE|00000000|CONCLUSIONS|tx|46|entity|C0205458|Twelve|qnco|||Twelve||||888|1|6
SE|00000000|CONCLUSIONS|tx|46|entity|C0038172|Staphylococcus aureus|bact|||Staphylococcus aureus||||1000|19|39
SE|00000000|CONCLUSIONS|tx|46|entity|C0332183|Frequent|tmco|||frequent||||888|44|51
SE|00000000|CONCLUSIONS|tx|46|entity|C0015127|Etiology aspects|ftcn|||cause||||888|53|57
SE|00000000|CONCLUSIONS|tx|46|entity|C0021311|Infection|dsyn|||infection||||1000|62|70
SE|00000000|CONCLUSIONS|tx|46|entity|C0011892|Heroin|hops,orch,phsu|||heroin||||1000|75|80
SE|00000000|CONCLUSIONS|tx|46|entity|C1518422|Negation|ftcn|||not||||1000|87|89
SE|00000000|CONCLUSIONS|tx|46|entity|C0030873|Pentazocine|orch,phsu|||pentazocine||||1000|94|104
SE|00000000|CONCLUSIONS|tx|46|entity|C0041090|Tripelennamine|orch,phsu|||tripelennamine||||1000|110|123
SE|00000000|CONCLUSIONS|tx|46|entity|C0858354|addict|podg|||addicts||||1000|126|132
SE|00000000|CONCLUSIONS|tx|46|entity|C0013162|Drug Combinations|phsu|||drug combination||||1000|168|183
SE|00000000|CONCLUSIONS|tx|46|relation|5|1|C0011892|Heroin|hops,orch,phsu|hops|||heroin||||1000|75|80|PREP|COEXISTS_WITH|negation|91|92|4|1|C0030873|Pentazocine|orch,phsu|orch|||pentazocine||||1000|94|104
SE|00000000|CONCLUSIONS|tx|46|relation|5|1|C0011892|Heroin|hops,orch,phsu|hops|||heroin||||1000|75|80|PREP|COEXISTS_WITH|negation|91|92|4|1|C0041090|Tripelennamine|orch,phsu|orch|||tripelennamine||||1000|110|123

SE|00000000|CONCLUSIONS|tx|47|text|Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.
SE|00000000|CONCLUSIONS|tx|47|entity|C0386231|buforin II|aapp,phsu|||Buforin II||||1000|1|10
SE|00000000|CONCLUSIONS|tx|47|entity|C0205177|Active|ftcn|||active||||1000|19|24
SE|00000000|CONCLUSIONS|tx|47|entity|C0085319|Cryptosporidium parvum|euka|||Cryptosporidium parvum||||865|40|61
SE|00000000|CONCLUSIONS|tx|47|entity|C0151686|Growth retardation|patf|||inhibiting Cryptosporidium parvum growth||||865|29|68
SE|00000000|CONCLUSIONS|tx|47|entity|C0205195|Combined|qlco|||combination||||1000|84|94
SE|00000000|CONCLUSIONS|tx|47|entity|C0052796|Azithromycin|antb,orch|||azithromycin||||861|108|119
SE|00000000|CONCLUSIONS|tx|47|entity|C0026187|Minocycline|antb,orch|||minocycline||||1000|124|134
SE|00000000|CONCLUSIONS|tx|47|relation|0|0|C0151686|Growth retardation|patf|patf|||inhibiting Cryptosporidium parvum growth||||865|29|68|MOD/HEAD|PROCESS_OF||40|68|0|0|C0085319|Cryptosporidium parvum|euka|euka|||Cryptosporidium parvum||||865|40|61
SE|00000000|CONCLUSIONS|tx|47|relation|2|2|C0386231|buforin II|aapp,gngm,phsu|aapp|||Buforin II||||1000|1|10|PREP|ASSOCIATED_WITH||26|27|5|1|C0151686|Growth retardation|patf|patf|||inhibiting Cryptosporidium parvum growth||||865|29|68

SE|00000000|CONCLUSIONS|tx|48|text|We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
SE|00000000|CONCLUSIONS|tx|48|entity|C0003295|Antidotes|phsu|||antidotal||||853|39|47
SE|00000000|CONCLUSIONS|tx|48|entity|C0871161|Property (attribute)|qlco|||properties||||853|49|58
SE|00000000|CONCLUSIONS|tx|48|entity|C0048504|fomepizole|orch,phsu|||4-methylpyrazole||||1000|63|78
SE|00000000|CONCLUSIONS|tx|48|entity|C0003062|Animals|anim|||animals||||1000|88|94
SE|00000000|CONCLUSIONS|tx|48|entity|C0670480|1,3-difluoro-2-propanol|orch|||difluoro-2-propanol||||923|113|131
SE|00000000|CONCLUSIONS|tx|48|entity|C1516240|Capacity|qnco|||capacity||||861|149|156
SE|00000000|CONCLUSIONS|tx|48|entity|C0027270|Nicotinamide adenine dinucleotide (NAD)|bacs,nnon,phsu|||NAD+-||||851|173|177
SE|00000000|CONCLUSIONS|tx|48|entity|C1701901|Conditional|qlco|||dependent||||851|178|186
SE|00000000|CONCLUSIONS|tx|48|entity|C0030011|Oxidation|moft|||oxidation||||851|188|196
SE|00000000|CONCLUSIONS|tx|48|entity|C0670480|1,3-difluoro-2-propanol|orch|||difluoro-2-propanol||||923|229|247
SE|00000000|CONCLUSIONS|tx|48|entity|C1171947|Commit Lozenge|orch,phsu|||committed||||888|279|287
SE|00000000|CONCLUSIONS|tx|48|entity|C1705117|Increment|qnco|||step||||888|289|292
SE|00000000|CONCLUSIONS|tx|48|entity|C1407029|Toxic|qlco|||toxic||||694|301|305
SE|00000000|CONCLUSIONS|tx|48|relation|9|1|C0003062|Animals|anim|anim|||animals||||1000|88|94|PREP|LOCATION_OF||85|86|3|1|C0048504|fomepizole|orch,phsu|orch|||4-methylpyrazole||||1000|63|78
SE|00000000|CONCLUSIONS|tx|48|relation|6|5|C0003295|Antidotes|phsu|phsu|||antidotal||||853|39|47|VERB|DISRUPTS||161|167|6|1|C0030011|Oxidation|moft|moft|||oxidation||||851|188|196

SE|00000000|CONCLUSIONS|tx|49|text|ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
SE|00000000|CONCLUSIONS|tx|49|entity|C0963856|ADL 8-2698|orch,phsu|||ADL 8-2698||||1000|1|10
SE|00000000|CONCLUSIONS|tx|49|entity|C2826298|Transition Rule|idcn|||trans||||861|15|19
SE|00000000|CONCLUSIONS|tx|49|entity|C0031959|piperidine|orch|||piperidine||||1000|54|63
SE|00000000|CONCLUSIONS|tx|49|entity|C0521362|gastrointestinal|spco|||gastrointestinal||||888|75|90
SE|00000000|CONCLUSIONS|tx|49|entity|C1280500|Effect|qlco|||effects||||888|92|98
SE|00000000|CONCLUSIONS|tx|49|entity|C0348016|Intravenous|spco|||intravenous||||888|103|113
SE|00000000|CONCLUSIONS|tx|49|entity|C0026549|Morphine|orch,phsu|||morphine||||888|115|122
SE|00000000|CONCLUSIONS|tx|49|entity|C0392760|Affecting|ftcn|||affecting||||888|132|140
SE|00000000|CONCLUSIONS|tx|49|entity|C0344307|Absence of pain sensation|sosy|||analgesia||||888|142|150
SE|00000000|CONCLUSIONS|tx|49|relation|2|1|C0031959|piperidine|orch|orch|||piperidine||||1000|54|63|NOM|INTERACTS_WITH||92|98|2|1|C0026549|Morphine|orch,phsu|orch|||morphine||||888|115|122

SE|00000000|CONCLUSIONS|tx|50|text|Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
SE|00000000|CONCLUSIONS|tx|50|entity|C0011777|Dexamethasone|phsu,strd|||Dexamethasone||||1000|1|13
SE|00000000|CONCLUSIONS|tx|50|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||1000|31|45
SE|00000000|CONCLUSIONS|tx|50|entity|C1514485|Proliferation|ftcn|||proliferation||||1000|78|90
SE|00000000|CONCLUSIONS|tx|50|entity|||gngm|1950|EGF|EGF||||1000|106|108
SE|00000000|CONCLUSIONS|tx|50|relation|1|1|||gngm,aapp|gngm|1950|EGF|EGF||||1000|106|108|VERB|STIMULATES||92|101|5|3|C0073109|retinol acetate|orch,phsu,vita|orch|||retinyl acetate||||1000|31|45
SE|00000000|CONCLUSIONS|tx|50|relation|1|1|||gngm,aapp|gngm|1950|EGF|EGF||||1000|106|108|VERB|STIMULATES||92|101|5|3|C0011777|Dexamethasone|phsu,strd|phsu|||Dexamethasone||||1000|1|13

SE|00000000|CONCLUSIONS|tx|51|text|Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability.
SE|00000000|CONCLUSIONS|tx|51|entity|C1523814|anion binding|moft|||anionic-binding||||877|20|34
SE|00000000|CONCLUSIONS|tx|51|entity|C0035191|Resins, Plant|bodm|||resin||||877|36|40
SE|00000000|CONCLUSIONS|tx|51|entity|C1280500|Effect|qlco|||effect||||861|62|67
SE|00000000|CONCLUSIONS|tx|51|entity|C0441994|Lower - spatial qualifier|spco|||lowering||||1000|72|79
SE|00000000|CONCLUSIONS|tx|51|entity|C1521828|Rate|qnco|||rate||||1000|85|88
SE|00000000|CONCLUSIONS|tx|51|entity|C0439792|Extent|spco|||extent||||1000|94|99
SE|00000000|CONCLUSIONS|tx|51|entity|C0082608|fluvastatin|orch,phsu|||fluvastatin||||888|104|114
SE|00000000|CONCLUSIONS|tx|51|entity|C1706947|Bioavailability Study|resa|||bioavailability||||888|116|130

SE|00000000|CONCLUSIONS|tx|52|text|Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains.
SE|00000000|CONCLUSIONS|tx|52|entity|C0453882|Combinations|mnob|||Combinations||||1000|1|12
SE|00000000|CONCLUSIONS|tx|52|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|17|27
SE|00000000|CONCLUSIONS|tx|52|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|33|42
SE|00000000|CONCLUSIONS|tx|52|entity|C0332238|Indifferent|qlco|||indifferent||||1000|49|59
SE|00000000|CONCLUSIONS|tx|52|entity|C2986495|Synergistic|qlco|||synergistic||||1000|80|90

SE|00000000|RESULTS|tx|53|text|RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.
SE|00000000|RESULTS|tx|53|entity|C1274040|Result|ftcn|||RESULTS||||1000|1|7
SE|00000000|RESULTS|tx|53|entity|C2986759|Geometric Mean|qnco|||geometric mean||||1000|14|27
SE|00000000|RESULTS|tx|53|entity|C0439083|>90|qnco|||90%||||901|30|32
SE|00000000|RESULTS|tx|53|entity|C0009667|Confidence Intervals|qnco|||confidence interval||||901|34|52
SE|00000000|RESULTS|tx|53|entity|C1546552|Specimen Source Codes - Whole blood|inpr|||whole blood||||861|55|65
SE|00000000|RESULTS|tx|53|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||861|67|75
SE|00000000|RESULTS|tx|53|entity|C0205146|Area|spco|||area||||861|77|80
SE|00000000|RESULTS|tx|53|entity|C0683150|plasma drug concentration|qnco|||plasma concentration time||||861|92|116
SE|00000000|RESULTS|tx|53|entity|C0205134|Curved|spco|||curve||||861|118|122
SE|00000000|RESULTS|tx|53|entity|C0439083|>90|qnco|||90%||||861|143|145
SE|00000000|RESULTS|tx|53|entity|C1533072|ng/mL/hr|qnco|||ng x h/mL||||888|166|174
SE|00000000|RESULTS|tx|53|entity|C2347813|Cmax|qnco|||maximum concentration||||1000|181|201
SE|00000000|RESULTS|tx|53|entity|C0439275|Microgram per Liter|qnco|||ng/mL||||901|242|246
SE|00000000|RESULTS|tx|53|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||694|254|262
SE|00000000|RESULTS|tx|53|entity|C2348397|Elimination Half Life|qnco|||elimination half-life||||923|299|319
SE|00000000|RESULTS|tx|53|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|324|332
SE|00000000|RESULTS|tx|53|entity|C0750482|Slightly|idcn|||slightly||||1000|344|351
SE|00000000|RESULTS|tx|53|entity|C0439227|Hour|tmco|||hours||||861|368|372

SE|00000000|RESULTS|tx|54|text|The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.
SE|00000000|RESULTS|tx|54|entity|C1280500|Effect|qlco|||effects||||861|16|22
SE|00000000|RESULTS|tx|54|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|27|38
SE|00000000|RESULTS|tx|54|entity|C1550147|Pretreatment|sbst|||pretreatment||||1000|56|67
SE|00000000|RESULTS|tx|54|entity|C0055233|CGS 21680|orch,phsu|||CGS 21680||||1000|74|82
SE|00000000|RESULTS|tx|54|entity|C2987634|Agonist|phsu|||agonist||||827|101|107
SE|00000000|RESULTS|tx|54|entity|C1518422|Negation|ftcn|||not||||1000|114|116
SE|00000000|RESULTS|tx|54|entity|C0067224|N(6)-cyclopentyladenosine|nnon|||N6-cyclopentyladenosine||||1000|121|143
SE|00000000|RESULTS|tx|54|entity|C2987634|Agonist|phsu|||agonist||||827|168|174
SE|00000000|RESULTS|tx|54|relation|5|3|C2987634|Agonist|phsu|phsu|||agonist||||827|101|107|NOM|INTERACTS_WITH||16|22|5|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline||||1000|27|38

SE|00000000|RESULTS|tx|55|text|Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy.
SE|00000000|RESULTS|tx|55|entity|C0599918|nephrotoxicity|inpo|||nephrotoxicity||||1000|12|25
SE|00000000|RESULTS|tx|55|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|28|37
SE|00000000|RESULTS|tx|55|entity|C2347472|Percent of Abnormal Cells|qnco|||abnormal||||775|49|56
SE|00000000|RESULTS|tx|55|entity|C0022646|Kidney|bpoc|||renal||||775|58|62
SE|00000000|RESULTS|tx|55|entity|C0347980|% uptake|qnco|||uptake||||775|64|69
SE|00000000|RESULTS|tx|55|entity|C0039416|Technetium Tc 99m Medronate|irda,opco|||99mTc-MDP||||875|85|93
SE|00000000|RESULTS|tx|55|entity|C1266909|Entire bony skeleton|bdsy|||bone||||875|95|98
SE|00000000|RESULTS|tx|55|entity|C0034606|Radionuclide Imaging|diap|||scintigraphy||||875|100|111

SE|00000000|RESULTS|tx|56|text|Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics.
SE|00000000|RESULTS|tx|56|entity|C0035608|Rifampin|antb,orch|||Rifampin||||861|1|8
SE|00000000|RESULTS|tx|56|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|38|40
SE|00000000|RESULTS|tx|56|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||1000|49|58
SE|00000000|RESULTS|tx|56|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||1000|72|81
SE|00000000|RESULTS|tx|56|entity|C1280500|Effect|qlco|||effect||||1000|90|95
SE|00000000|RESULTS|tx|56|entity|C0035608|Rifampin|antb,orch|||rifampin||||888|100|107
SE|00000000|RESULTS|tx|56|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||888|109|124
SE|00000000|RESULTS|tx|56|relation|5|1|C0754188|Amprenavir|orch,phsu|orch|||amprenavir||||1000|72|81|NOM|INTERACTS_WITH|negation|90|95|1|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||888|100|107

SE|00000000|RESULTS|tx|57|text|The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
SE|00000000|RESULTS|tx|57|entity|C0243144|Uptake|phsf|||uptake||||851|5|10
SE|00000000|RESULTS|tx|57|entity|C0243077|inhibitors|chvf|||inhibitors||||851|12|21
SE|00000000|RESULTS|tx|57|entity|C0009170|Cocaine|hops,orch,phsu|||cocaine||||851|23|29
SE|00000000|RESULTS|tx|57|entity|C0011685|Desipramine|orch,phsu|||desipramine||||1000|35|45
SE|00000000|RESULTS|tx|57|entity|C0475211|liter|qnco|||liter||||827|56|60
SE|00000000|RESULTS|tx|57|entity|C0439178|percent positive cells|qnco|||positive||||802|79|86
SE|00000000|RESULTS|tx|57|entity|C1280500|Effect|qlco|||effects||||802|98|104
SE|00000000|RESULTS|tx|57|entity|C0028351|Norepinephrine|nsba,orch,phsu|||norepinephrine||||1000|109|122
SE|00000000|RESULTS|tx|57|entity|C0027061|Myocardium|tisu|||myocardium||||861|138|147
SE|00000000|RESULTS|tx|57|entity|C1518422|Negation|ftcn|||not||||1000|164|166
SE|00000000|RESULTS|tx|57|entity|C0205245|Functional|ftcn|||functional||||833|171|180
SE|00000000|RESULTS|tx|57|entity|C0456387|Class|inpr|||class||||833|182|186
SE|00000000|RESULTS|tx|57|entity|C0348016|Intravenous|spco|||IV||||833|188|189
SE|00000000|RESULTS|tx|57|entity|C0027061|Myocardium|tisu|||myocardium||||833|191|200
SE|00000000|RESULTS|tx|57|relation|3|1|C0027061|Myocardium|tisu|tisu|||myocardium||||861|138|147|PREP|LOCATION_OF||124|125|5|1|C0028351|Norepinephrine|nsba,orch,phsu|orch|||norepinephrine||||1000|109|122
SE|00000000|RESULTS|tx|57|relation|1|1|C0027061|Myocardium|tisu|tisu|||myocardium||||833|191|200|PREP|LOCATION_OF|negation|168|169|7|3|C0028351|Norepinephrine|nsba,orch,phsu|orch|||norepinephrine||||1000|109|122

SE|00000000|RESULTS|tx|58|text|Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
SE|00000000|RESULTS|tx|58|entity|C1720825|Therapeutic Drug Monitoring|topp|||Therapeutic drug monitoring||||1000|1|27
SE|00000000|RESULTS|tx|58|entity|C0439669|Iatrogenic|qlco|||iatrogenic||||872|39|48
SE|00000000|RESULTS|tx|58|entity|C1515926|Alteration|idcn|||alterations||||872|50|60
SE|00000000|RESULTS|tx|58|entity|C0039416|Technetium Tc 99m Medronate|irda,opco|||99mTc-methylene diphosphonate||||875|72|100
SE|00000000|RESULTS|tx|58|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||875|108|117
SE|00000000|RESULTS|tx|58|entity|C1704675|Interaction|ftcn|||interaction||||875|119|129

SE|00000000|RESULTS|tx|59|text|Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.
SE|00000000|RESULTS|tx|59|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|18|30
SE|00000000|RESULTS|tx|59|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||1000|36|50
SE|00000000|RESULTS|tx|59|entity|C1514485|Proliferation|ftcn|||proliferation||||1000|65|77
SE|00000000|RESULTS|tx|59|entity|C1179826|Prostatic epithelium|tisu|||prostatic epithelium||||1000|82|101
SE|00000000|RESULTS|tx|59|entity|C2700400|Contain (action)|acty|||containing||||790|115|124
SE|00000000|RESULTS|tx|59|entity|C0040679|Transferrin|aapp,bacs|||transferrin||||790|126|136
SE|00000000|RESULTS|tx|59|entity|C0205171|Singular|qnco|||alone||||1000|138|142
SE|00000000|RESULTS|tx|59|entity|C0026255|Mitosis|celf|||mitogenic||||853|161|169
SE|00000000|RESULTS|tx|59|entity|C1280500|Effect|qlco|||effect||||853|171|176
SE|00000000|RESULTS|tx|59|entity|||gngm|1950|EGF|EGF||||1000|181|183
SE|00000000|RESULTS|tx|59|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|189|195
SE|00000000|RESULTS|tx|59|relation|4|3|C0073109|retinol acetate|orch,phsu,vita|orch|||retinyl acetate||||1000|36|50|PREP|COEXISTS_WITH||103|104|5|1|C0040679|Transferrin|aapp,gngm,bacs|aapp|||transferrin||||790|126|136
SE|00000000|RESULTS|tx|59|relation|4|3|C0011777|Dexamethasone|phsu,strd|phsu|||dexamethasone||||1000|18|30|PREP|COEXISTS_WITH||103|104|5|1|C0040679|Transferrin|aapp,gngm,bacs|aapp|||transferrin||||790|126|136
SE|00000000|RESULTS|tx|59|relation|2|1|||gngm,aapp|gngm|1950|EGF|EGF||||1000|181|183|NOM|AFFECTS||171|176|6|0|C0026255|Mitosis|celf|celf|||mitogenic||||853|161|169
SE|00000000|RESULTS|tx|59|relation|2|1|C0021641|Insulin|aapp,gngm,horm,phsu|gngm|||insulin||||1000|189|195|NOM|AFFECTS||171|176|6|0|C0026255|Mitosis|celf|celf|||mitogenic||||853|161|169

SE|00000000|RESULTS|tx|60|text|Consequently, the effect of iron on the retention of cobalt was lower than on absorption.
SE|00000000|RESULTS|tx|60|entity|C1280500|Effect|qlco|||effect||||1000|19|24
SE|00000000|RESULTS|tx|60|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|29|32
SE|00000000|RESULTS|tx|60|entity|C0009148|Cobalt|elii|||cobalt||||1000|54|59
SE|00000000|RESULTS|tx|60|relation|5|3|C0009148|Cobalt|elii|elii|||cobalt||||1000|54|59|NOM|INTERACTS_WITH||19|24|5|1|C0302583|Iron|bacs,elii,phsu|bacs|||iron||||1000|29|32

SE|00000000|RESULTS|tx|61|text|ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
SE|00000000|RESULTS|tx|61|entity|C0963856|ADL 8-2698|orch,phsu|||ADL-8-2698||||1000|1|10
SE|00000000|RESULTS|tx|61|entity|C0205314|New|tmco|||novel||||794|17|21
SE|00000000|RESULTS|tx|61|entity|C0443288|Restricted|ftcn|||restricted||||794|36|45
SE|00000000|RESULTS|tx|61|entity|C0027410|Narcotic Antagonists|phsu|||opioid antagonist||||794|47|63
SE|00000000|RESULTS|tx|61|entity|C0242402|Opioids|hops,orch,phsu|||opioid||||833|94|99
SE|00000000|RESULTS|tx|61|entity|C0205263|Induce (action)|ftcn|||induced||||833|101|107
SE|00000000|RESULTS|tx|61|entity|C0521362|gastrointestinal|spco|||gastrointestinal||||833|109|124
SE|00000000|RESULTS|tx|61|entity|C1280500|Effect|qlco|||effects||||833|126|132
SE|00000000|RESULTS|tx|61|entity|C1555029|Reverse|idcn|||reversing||||872|142|150
SE|00000000|RESULTS|tx|61|entity|C0344307|Absence of pain sensation|sosy|||analgesia||||872|152|160

SE|00000000|RESULTS|tx|62|text|Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.
SE|00000000|RESULTS|tx|62|entity|C0042291|Valproic Acid|orch,phsu|||Valproic acid||||1000|1|13
SE|00000000|RESULTS|tx|62|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|37|49
SE|00000000|RESULTS|tx|62|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|56|58
SE|00000000|RESULTS|tx|62|entity|C0443172|Changed status|qnco|||change||||872|60|65
SE|00000000|RESULTS|tx|62|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||888|76|85
SE|00000000|RESULTS|tx|62|entity|C0442805|Increase|ftcn|||increase||||888|87|94
SE|00000000|RESULTS|tx|62|entity|C1880774|Financial Disclosure Form|mnob|||FDF||||1000|99|101
SE|00000000|RESULTS|tx|62|entity|C0439194|Micromole|qnco|||micromol||||660|119|126

SE|00000000|RESULTS|tx|63|text|When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin.
SE|00000000|RESULTS|tx|63|entity|C0028902|Ofloxacin|antb,orch|||ofloxacin||||1000|20|28
SE|00000000|RESULTS|tx|63|entity|C0124728|KRM 1648|orch,phsu|||KRM-1648||||769|31|38
SE|00000000|RESULTS|tx|63|entity|C0442821|Strong|qlco|||strong||||769|50|55
SE|00000000|RESULTS|tx|63|entity|C2986495|Synergistic|qlco|||synergistic||||769|57|67
SE|00000000|RESULTS|tx|63|entity|C0205177|Active|ftcn|||activity||||769|69|76
SE|00000000|RESULTS|tx|63|entity|C0205171|Singular|qnco|||only||||851|84|87
SE|00000000|RESULTS|tx|63|entity|C0442796|Additive|qlco|||additive||||851|89|96
SE|00000000|RESULTS|tx|63|entity|C1280500|Effect|qlco|||effects||||851|98|104
SE|00000000|RESULTS|tx|63|entity|C0205195|Combined|qlco|||combination||||1000|129|139
SE|00000000|RESULTS|tx|63|entity|C0035608|Rifampin|antb,orch|||rifampicin||||1000|144|153
SE|00000000|RESULTS|tx|63|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|159|167
SE|00000000|RESULTS|tx|63|entity|C0028902|Ofloxacin|antb,orch|||ofloxacin||||1000|174|182
SE|00000000|RESULTS|tx|63|relation|3|3|C0028902|Ofloxacin|antb,orch|antb|||ofloxacin||||1000|20|28|NOM|COEXISTS_WITH||129|139|3|1|C0035608|Rifampin|antb,orch|antb|||rifampicin||||1000|144|153
SE|00000000|RESULTS|tx|63|relation|3|3|C0028902|Ofloxacin|antb,orch|antb|||ofloxacin||||1000|20|28|NOM|COEXISTS_WITH||129|139|3|1|C0140575|Rifabutin|antb,orch|antb|||rifabutin||||1000|159|167
SE|00000000|RESULTS|tx|63|relation|3|3|C0028902|Ofloxacin|antb,orch|antb|||ofloxacin||||1000|174|182|NOM|COEXISTS_WITH||129|139|3|1|C0035608|Rifampin|antb,orch|antb|||rifampicin||||1000|144|153
SE|00000000|RESULTS|tx|63|relation|3|3|C0028902|Ofloxacin|antb,orch|antb|||ofloxacin||||1000|174|182|NOM|COEXISTS_WITH||129|139|3|2|C0140575|Rifabutin|antb,orch|antb|||rifabutin||||1000|159|167

SE|00000000|RESULTS|tx|64|text|We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
SE|00000000|RESULTS|tx|64|entity|C0234428|Disturbance of consciousness|sosy|||altered consciousness||||1000|42|62
SE|00000000|RESULTS|tx|64|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||888|74|86
SE|00000000|RESULTS|tx|64|entity|C0029944|overdose|inpo|||overdose||||888|88|95
SE|00000000|RESULTS|tx|64|entity|C1446409|Positive|qlco|||positive||||798|104|111
SE|00000000|RESULTS|tx|64|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressant||||798|113|136
SE|00000000|RESULTS|tx|64|entity|C2946261|Level|phsu|||level||||798|138|142
SE|00000000|RESULTS|tx|64|entity|C0871685|Clinician|prog|||clinicians||||1000|153|162
SE|00000000|RESULTS|tx|64|entity|C2828360|Traverse|cnce|||cross-||||853|171|176
SE|00000000|RESULTS|tx|64|entity|C0205332|Reactive|qlco|||reactivity||||853|177|186
SE|00000000|RESULTS|tx|64|entity|C0006949|Carbamazepine|orch,phsu|||carbamazepine||||1000|191|203
SE|00000000|RESULTS|tx|64|entity|C0430054|Toxicology screen, general (procedure)|lbpr|||toxicology screen||||1000|212|228
SE|00000000|RESULTS|tx|64|entity|C0003290|Tricyclic Antidepressive Agents|phsu|||tricyclic antidepressants||||1000|234|258

SE|00000000|RESULTS|tx|65|text|This might be explained by a blockade by probenecid of the elimination of cloxacillin by the liver.
SE|00000000|RESULTS|tx|65|entity|C0332206|Blocking|ftcn|||blockade||||1000|30|37
SE|00000000|RESULTS|tx|65|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|42|51
SE|00000000|RESULTS|tx|65|entity|C0009077|Cloxacillin|antb,orch|||cloxacillin||||1000|75|85
SE|00000000|RESULTS|tx|65|entity|C0023884|Liver|bpoc|||liver||||1000|94|98
SE|00000000|RESULTS|tx|65|relation|4|1|C0033209|Probenecid|orch,phsu|orch|||probenecid||||1000|42|51|NOM|INHIBITS||30|37|4|3|C0009077|Cloxacillin|antb,orch|antb|||cloxacillin||||1000|75|85

SE|00000000|RESULTS|tx|66|text|However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA.
SE|00000000|RESULTS|tx|66|entity|C0680242|antagonism|socb|||antagonism||||1000|14|23
SE|00000000|RESULTS|tx|66|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||775|32|43
SE|00000000|RESULTS|tx|66|entity|C0205263|Induce (action)|ftcn|||induced||||775|45|51
SE|00000000|RESULTS|tx|66|entity|C1280500|Effect|qlco|||effects||||775|64|70
SE|00000000|RESULTS|tx|66|entity|C0205171|Singular|qnco|||only||||1000|88|91
SE|00000000|RESULTS|tx|66|entity|C0040223|Time|tmco|||time||||1000|109|112
SE|00000000|RESULTS|tx|66|entity|C1710706|Zone|spco|||zone||||888|133|136
SE|00000000|RESULTS|tx|66|entity|C0088321|1,3-dipropyl-8-cyclopentylxanthine|orch,phsu|||DPCPX||||775|143|147
SE|00000000|RESULTS|tx|66|entity|C0205263|Induce (action)|ftcn|||induced||||775|149|155
SE|00000000|RESULTS|tx|66|entity|C1280500|Effect|qlco|||effects||||775|168|174
SE|00000000|RESULTS|tx|66|entity|C0055233|CGS 21680|orch,phsu|||CGS 21680||||1000|201|209

SE|00000000|RESULTS|tx|67|text|N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of morphine.
SE|00000000|RESULTS|tx|67|entity|C0131328|N-methyllevallorphan|orch,phsu|||N-methyllevallorphan||||1000|1|20
SE|00000000|RESULTS|tx|67|entity|C0439272|ug/g|qnco|||mg/kg||||901|25|29
SE|00000000|RESULTS|tx|67|entity|C0565930|per second|qnco|||s.c||||861|32|34
SE|00000000|RESULTS|tx|67|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||888|65|74
SE|00000000|RESULTS|tx|67|entity|C1280500|Effect|qlco|||effect||||888|76|81
SE|00000000|RESULTS|tx|67|entity|C0023992|Loperamide|orch,phsu|||loperamide||||1000|86|95
SE|00000000|RESULTS|tx|67|entity|C1280500|Effect|qlco|||effect||||1000|124|129
SE|00000000|RESULTS|tx|67|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|134|141
SE|00000000|RESULTS|tx|67|relation|3|1|C0023992|Loperamide|orch,phsu|phsu|||loperamide||||1000|86|95|NOM|AFFECTS||76|81|3|0|C0021469|Metabolic Inhibition|moft|moft|||inhibitory||||888|65|74

SE|00000000|RESULTS|tx|68|text|Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.
SE|00000000|RESULTS|tx|68|entity|C0025611|Methamphetamine|hops,orch|||Methamphetamine||||1000|1|15
SE|00000000|RESULTS|tx|68|entity|C0000097|1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|hops,orch|||MPTP||||1000|23|26
SE|00000000|RESULTS|tx|68|entity|C0333668|Depletion|ftcn|||depletions||||861|38|47
SE|00000000|RESULTS|tx|68|entity|C1269581|Entire corpus striatum|bpoc|||striatal||||853|52|59
SE|00000000|RESULTS|tx|68|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||853|61|68
SE|00000000|RESULTS|tx|68|entity|C0441472|Clinical action|ftcn|||actions||||1000|80|86
SE|00000000|RESULTS|tx|68|entity|C0030557|Pargyline|orch,phsu|||pargyline||||888|108|116
SE|00000000|RESULTS|tx|68|entity|C1550147|Pretreatment|sbst|||pretreatment||||888|118|129
SE|00000000|RESULTS|tx|68|relation|0|0|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||853|61|68|MOD/HEAD|PART_OF||52|68|0|0|C1269581|Entire corpus striatum|bpoc|bpoc|||striatal||||853|52|59

SE|00000000|RESULTS|tx|69|text|These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde;
SE|00000000|RESULTS|tx|69|entity|C1274040|Result|ftcn|||results||||1000|7|13
SE|00000000|RESULTS|tx|69|entity|C0001962|Ethanol|orch|||ethanol||||1000|48|54
SE|00000000|RESULTS|tx|69|entity|C0001967|Alcoholic Beverages|food|||alcoholic beverages||||1000|59|77
SE|00000000|RESULTS|tx|69|entity|C1704675|Interaction|ftcn|||interaction||||1000|94|104
SE|00000000|RESULTS|tx|69|entity|C0678518|congener|chvs|||congeners||||1000|115|123
SE|00000000|RESULTS|tx|69|entity|C0000966|Acetaldehyde|orch|||acetaldehyde||||1000|129|140

SE|00000000|RESULTS|tx|70|text|Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.
SE|00000000|RESULTS|tx|70|entity|C0059869|etofibrate|orch,phsu|||Etofibrate||||1000|1|10
SE|00000000|RESULTS|tx|70|entity|C2349975|Enhance (action)|acty|||enhancement||||861|25|35
SE|00000000|RESULTS|tx|70|entity|C0687676|Post|tmco|||post-||||815|40|44
SE|00000000|RESULTS|tx|70|entity|C0019134|Heparin|bacs,carb,phsu|||heparin||||815|45|51
SE|00000000|RESULTS|tx|70|entity|C0023796|Lipolysis|orgf|||lipolytic||||815|53|61
SE|00000000|RESULTS|tx|70|entity|C0205177|Active|ftcn|||activity||||815|63|70
SE|00000000|RESULTS|tx|70|entity|C0442805|Increase|ftcn|||increase||||861|81|88
SE|00000000|RESULTS|tx|70|entity|C0041004|Triglycerides|bacs,lipd|||triglyceride||||757|96|107
SE|00000000|RESULTS|tx|70|entity|C0449297|Clearance|qlco|||clearance||||757|120|128
SE|00000000|RESULTS|tx|70|entity|C1521828|Rate|qnco|||rate||||757|130|133
SE|00000000|RESULTS|tx|70|entity|C0032042|Placebos|topp|||placebo||||888|149|155

SE|00000000|RESULTS|tx|71|text|On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms).
SE|00000000|RESULTS|tx|71|entity|C0027358|Naloxone|orch,phsu|||naloxone||||861|32|39
SE|00000000|RESULTS|tx|71|entity|C0439211|microgram|qnco|||micrograms||||827|49|58
SE|00000000|RESULTS|tx|71|entity|C0205171|Singular|qnco|||only||||1000|65|68
SE|00000000|RESULTS|tx|71|entity|C0442824|Very|qlco|||very||||851|72|75
SE|00000000|RESULTS|tx|71|entity|C0004093|Asthenia|sosy|||weak||||851|77|80
SE|00000000|RESULTS|tx|71|entity|C1280500|Effect|qlco|||effect||||851|82|87
SE|00000000|RESULTS|tx|71|entity|C0039259|Tail|bpoc|||tail-||||802|96|100
SE|00000000|RESULTS|tx|71|entity|C1628982|Percent inhibition|qnco|||inhibition||||802|107|116
SE|00000000|RESULTS|tx|71|entity|C1517569|Intraventricular|blor|||intraventricular||||888|129|144
SE|00000000|RESULTS|tx|71|entity|C0026549|Morphine|orch,phsu|||morphine||||888|146|153
SE|00000000|RESULTS|tx|71|entity|C0439211|microgram|qnco|||micrograms||||888|159|168
SE|00000000|RESULTS|tx|71|relation|3|2|C0027358|Naloxone|orch,phsu|orch|||naloxone||||861|32|39|NOM|AFFECTS||82|87|3|0|C0004093|Asthenia|sosy|sosy|||weak||||851|77|80

SE|00000000|RESULTS|tx|72|text|The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.
SE|00000000|RESULTS|tx|72|entity|C1280500|Effect|qlco|||effect||||1000|5|10
SE|00000000|RESULTS|tx|72|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|15|22
SE|00000000|RESULTS|tx|72|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|31|38
SE|00000000|RESULTS|tx|72|entity|C1514873|Requirement|ftcn|||requirement||||888|40|50
SE|00000000|RESULTS|tx|72|entity|C0030705|Patients|podg|||patient||||1000|59|65
SE|00000000|RESULTS|tx|72|entity|C0806909|Maximum|qnco|||maximal||||861|82|88
SE|00000000|RESULTS|tx|72|entity|C1547085|7 days|tmco|||7 days||||1000|95|100
SE|00000000|RESULTS|tx|72|entity|C1704686|Initiation|ftcn|||initiation||||1000|112|121
SE|00000000|RESULTS|tx|72|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|126|133
SE|00000000|RESULTS|tx|72|entity|C2348205|Similarity|qlco|||similar||||888|150|156
SE|00000000|RESULTS|tx|72|entity|C1444754|Length|qnco|||length||||888|158|163
SE|00000000|RESULTS|tx|72|entity|C0040223|Time|tmco|||time||||1000|168|171
SE|00000000|RESULTS|tx|72|entity|C0035608|Rifampin|antb,orch|||rifampin||||888|179|186
SE|00000000|RESULTS|tx|72|entity|C2349954|Withdraw (activity)|acty|||withdrawal||||888|188|197
SE|00000000|RESULTS|tx|72|relation|9|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|15|22|NOM|INTERACTS_WITH||5|10|9|2|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|31|38
SE|00000000|RESULTS|tx|72|relation|7|1|C0030705|Patients|podg,humn|humn|||patient||||1000|59|65|PREP|LOCATION_OF||52|53|3|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|31|38

SE|00000000|RESULTS|tx|73|text|However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs.
SE|00000000|RESULTS|tx|73|entity|C0004268|Attention|menp|||attention||||861|18|26
SE|00000000|RESULTS|tx|73|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|54|61
SE|00000000|RESULTS|tx|73|entity|C0332149|Possible|qlco|||possible||||785|67|74
SE|00000000|RESULTS|tx|73|entity|C1704675|Interaction|ftcn|||interactions||||785|92|103
SE|00000000|RESULTS|tx|73|entity|C0003392|Antineoplastic Agents|orch,phsu|||antineoplastic drugs||||1000|132|151

SE|00000000|RESULTS|tx|74|text|(1968, 1970), the higher serum concentrations of penicillins and cephaloridine reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.
SE|00000000|RESULTS|tx|74|entity|C0205250|High|qlco|||higher||||879|19|24
SE|00000000|RESULTS|tx|74|entity|C0683149|serum drug concentration|qnco|||serum concentrations||||879|26|45
SE|00000000|RESULTS|tx|74|entity|C0030842|Penicillins|antb,orch|||penicillins||||1000|50|60
SE|00000000|RESULTS|tx|74|entity|C0007727|Cephaloridine|antb,orch|||cephaloridine||||1000|66|78
SE|00000000|RESULTS|tx|74|entity|C0033209|Probenecid|orch,phsu|||probenecid||||1000|112|121
SE|00000000|RESULTS|tx|74|entity|C3146286|Due|idcn|||due||||1000|127|129
SE|00000000|RESULTS|tx|74|entity|C1518422|Negation|ftcn|||not||||861|131|133
SE|00000000|RESULTS|tx|74|entity|C0439834|Slow|qlco|||slower||||840|143|148
SE|00000000|RESULTS|tx|74|entity|C0022646|Kidney|bpoc|||renal||||840|150|154
SE|00000000|RESULTS|tx|74|entity|C0392747|Changing|ftcn|||altered||||888|183|189
SE|00000000|RESULTS|tx|74|entity|C1704711|Distribution|ftcn|||distribution||||888|191|202

SE|00000000|RESULTS|tx|75|text|Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells.
SE|00000000|RESULTS|tx|75|entity|C0205171|Singular|qnco|||alone||||1000|12|16
SE|00000000|RESULTS|tx|75|entity|C1280500|Effect|qlco|||effect||||1000|39|44
SE|00000000|RESULTS|tx|75|entity|C1859316|CATARACT-ALOPECIA-SCLERODACTYLY SYNDROME|dsyn|||CAS||||966|49|51
SE|00000000|RESULTS|tx|75|entity|C0911731|contortrostatin|aapp|||contortrostatin||||851|79|93
SE|00000000|RESULTS|tx|75|entity|C0205263|Induce (action)|ftcn|||induced||||851|95|101
SE|00000000|RESULTS|tx|75|entity|C0031715|Phosphorylation|moft|||phosphorylation||||851|103|117
SE|00000000|RESULTS|tx|75|entity|C0033684|Proteins|aapp,bacs|||protein||||1000|127|133
SE|00000000|RESULTS|tx|75|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB||||791|138|143
SE|00000000|RESULTS|tx|75|entity|C0007634|Cells|cell|||cells||||791|149|153
SE|00000000|RESULTS|tx|75|relation|1|1|C0007634|Cells|cell|cell|||cells||||791|149|153|PREP|LOCATION_OF||135|136|6|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein||||1000|127|133

SE|00000000|RESULTS|tx|76|text|Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge.
SE|00000000|RESULTS|tx|76|entity|C0444669|Core|spco|||Core||||888|1|4
SE|00000000|RESULTS|tx|76|entity|C0039476|Temperature|qnco|||temperature||||888|6|16
SE|00000000|RESULTS|tx|76|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|35|38
SE|00000000|RESULTS|tx|76|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||734|45|58
SE|00000000|RESULTS|tx|76|entity|C0001962|Ethanol|orch|||ethanol||||1000|72|78
SE|00000000|RESULTS|tx|76|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|100|103
SE|00000000|RESULTS|tx|76|entity|C0012772|Disulfiram|orch,phsu|||disulfiram||||802|118|127
SE|00000000|RESULTS|tx|76|entity|C0439227|Hour|tmco|||hours||||802|131|135
SE|00000000|RESULTS|tx|76|entity|C0001962|Ethanol|orch|||ethanol||||888|148|154
SE|00000000|RESULTS|tx|76|entity|C0798503|Challenge:Type:Point in time:^Patient:Nominal|clna|||challenge||||888|156|164
SE|00000000|RESULTS|tx|76|relation|4|1|C0001962|Ethanol|orch|orch|||ethanol||||1000|72|78|VERB|ADMINISTERED_TO||84|95|3|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|100|103

SE|00000000|RESULTS|tx|77|text|These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.
SE|00000000|RESULTS|tx|77|entity|C1274040|Result|ftcn|||results||||1000|7|13
SE|00000000|RESULTS|tx|77|entity|C0014406|Environment|spco|||environmental||||888|40|52
SE|00000000|RESULTS|tx|77|entity|C0205460|biological|qlco|||biological||||1000|73|82
SE|00000000|RESULTS|tx|77|entity|C0004927|Behavior|inbe|||behavioral||||853|88|97
SE|00000000|RESULTS|tx|77|entity|C0205342|Responsive|ftcn|||responsiveness||||853|99|112
SE|00000000|RESULTS|tx|77|entity|C0003062|Animals|anim|||animal||||1000|120|125
SE|00000000|RESULTS|tx|77|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|130|136

SE|00000000|RESULTS|tx|78|text|Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
SE|00000000|RESULTS|tx|78|entity|C0018546|Haloperidol|orch,phsu|||Haloperidol||||1000|1|11
SE|00000000|RESULTS|tx|78|entity|C0442805|Increase|ftcn|||increases||||1000|39|47
SE|00000000|RESULTS|tx|78|entity|C0205103|Intermediate|spco|||intermediate||||888|78|89
SE|00000000|RESULTS|tx|78|entity|C0178602|Dosage|qnco|||doses||||888|91|95
SE|00000000|RESULTS|tx|78|entity|||gngm|649,5547,54858|BMP1,PRCP,PGPEP1|PCP||||1000|119|121
SE|00000000|RESULTS|tx|78|entity|C0325912|Columbidae|bird|||pigeons||||1000|126|132
SE|00000000|RESULTS|tx|78|entity|C1518422|Negation|ftcn|||not||||1000|143|145
SE|00000000|RESULTS|tx|78|entity|C0547047|Decrease|qnco|||decreases||||1000|162|170
SE|00000000|RESULTS|tx|78|entity|C0444956|High dose|qnco|||high doses||||983|207|216
SE|00000000|RESULTS|tx|78|entity|||gngm|649,5547,54858|BMP1,PRCP,PGPEP1|PCP||||1000|221|223
SE|00000000|RESULTS|tx|78|entity|C0376211|Stereoisomers|chvs|||stereoisomer||||1000|235|246

SE|00000000|RESULTS|tx|79|text|High-dose cisplatin with sodium thiosulfate protection.
SE|00000000|RESULTS|tx|79|entity|C0444956|High dose|qnco|||High-dose||||901|1|9
SE|00000000|RESULTS|tx|79|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||901|11|19
SE|00000000|RESULTS|tx|79|entity|C0074774|sodium thiosulfate|inch,phsu|||sodium thiosulfate||||901|26|43
SE|00000000|RESULTS|tx|79|entity|C1545588|Protection|fndg|||protection||||901|45|54
SE|00000000|RESULTS|tx|79|relation|1|1|C0008838|Cisplatin|inch,phsu|inch|||cisplatin||||901|11|19|NOM|INTERACTS_WITH||45|54|1|0|C0074774|sodium thiosulfate|inch,phsu|inch|||sodium thiosulfate||||901|26|43

SE|00000000|DISCUSSION|tx|80|text|DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism.
SE|00000000|DISCUSSION|tx|80|entity|C0055856|Clarithromycin|antb,orch|||Clarithromycin||||1000|13|26
SE|00000000|DISCUSSION|tx|80|entity|C3245505|Potential|qlco|||potent||||838|33|38
SE|00000000|DISCUSSION|tx|80|entity|C1999216|Inhibitor|qlco|||inhibitor||||838|40|48
SE|00000000|DISCUSSION|tx|80|entity|||gngm|1576|CYP3A4|CYP3A4||||1000|53|58
SE|00000000|DISCUSSION|tx|80|entity|C0205164|Major|qlco|||major||||888|65|69
SE|00000000|DISCUSSION|tx|80|entity|C0014442|Enzymes|enzy,orch|||enzyme||||888|71|76
SE|00000000|DISCUSSION|tx|80|entity|C0074554|Simvastatin|orch,phsu|||simvastatin||||888|94|104
SE|00000000|DISCUSSION|tx|80|entity|C0025520|metabolic aspects|ftcn|||metabolism||||888|106|115
SE|00000000|DISCUSSION|tx|80|relation|2|1|C0055856|Clarithromycin|antb,orch|antb|||Clarithromycin||||1000|13|26|NOM|INHIBITS||40|48|4|1|||gngm,aapp|gngm|1576|CYP3A4|CYP3A4||||1000|53|58

SE|00000000|DISCUSSION|tx|81|text|Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store.
SE|00000000|DISCUSSION|tx|81|entity|C0010738|Cytochalasin D|bacs,orch|||Cytochalasin D||||1000|1|14
SE|00000000|DISCUSSION|tx|81|entity|C0006945|Carbachol|orch,phsu|||carbachol||||851|30|38
SE|00000000|DISCUSSION|tx|81|entity|C1948023|Stimulation (motivation)|npop|||stimulated||||851|40|49
SE|00000000|DISCUSSION|tx|81|entity|C0175996|Protoplasm|celc|||intracellular||||851|51|63
SE|00000000|DISCUSSION|tx|81|entity|C0030685|Patient Discharge|hlca|||release||||1000|116|122
SE|00000000|DISCUSSION|tx|81|entity|C0596235|Calcium ion|elii|||Ca(2||||1000|133|136
SE|00000000|DISCUSSION|tx|81|entity|C1698986|Storage|ftcn|||store||||1000|140|144
SE|00000000|DISCUSSION|tx|81|relation|1|1|C0010738|Cytochalasin D|bacs,orch|bacs|||Cytochalasin D||||1000|1|14|VERB|DISRUPTS||16|24|5|1|C0175996|Protoplasm|celc|celc|||intracellular||||851|51|63

SE|00000000|DISCUSSION|tx|82|text|In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.
SE|00000000|DISCUSSION|tx|82|entity|C1707455|Comparison|acty|||comparison||||1000|6|15
SE|00000000|DISCUSSION|tx|82|entity|C1704410|Tolerance|qlco|||tolerance||||861|30|38
SE|00000000|DISCUSSION|tx|82|entity|C0012984|Canis familiaris|mamm|||dogs||||1000|43|46
SE|00000000|DISCUSSION|tx|82|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|66|73
SE|00000000|DISCUSSION|tx|82|entity|C0123569|Innovar-Vet|orch,phsu|||Innovar Vet||||1000|76|86
SE|00000000|DISCUSSION|tx|82|entity|C0030883|Pentobarbital|orch,phsu|||pentobarbital||||1000|92|104
SE|00000000|DISCUSSION|tx|82|entity|C0178602|Dosage|qnco|||dosage||||1000|111|116
SE|00000000|DISCUSSION|tx|82|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|121|127
SE|00000000|DISCUSSION|tx|82|entity|C0042514|Tachycardia, Ventricular|patf|||ventricular tachycardia||||1000|145|167
SE|00000000|DISCUSSION|tx|82|entity|C0205250|High|qlco|||higher||||827|187|192
SE|00000000|DISCUSSION|tx|82|entity|C0023378|Lethal Dose 50|qnco|||LD50||||1000|206|209
SE|00000000|DISCUSSION|tx|82|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|214|220
SE|00000000|DISCUSSION|tx|82|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|228|235
SE|00000000|DISCUSSION|tx|82|entity|C0063549|Innovar|orch,phsu|||Innovar||||1000|240|246
SE|00000000|DISCUSSION|tx|82|entity|C0030883|Pentobarbital|orch,phsu|||pentobarbital||||1000|258|270
SE|00000000|DISCUSSION|tx|82|relation|14|11|C0029904|Ouabain|carb,phsu,strd|carb|||ouabain||||1000|214|220|NOM|compared_with||6|15|14|12|C0022614|Ketamine|orch,phsu|orch|||ketamine||||1000|228|235
SE|00000000|DISCUSSION|tx|82|relation|8|1|C0029904|Ouabain|carb,phsu,strd|carb|||ouabain||||1000|121|127|VERB|CAUSES||139|143|7|1|C0042514|Tachycardia, Ventricular|patf|patf|||ventricular tachycardia||||1000|145|167

SE|00000000|DISCUSSION|tx|83|text|Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
SE|00000000|DISCUSSION|tx|83|entity|C0302523|Observation in research|resa|||observations||||861|9|20
SE|00000000|DISCUSSION|tx|83|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxicity||||1000|25|38
SE|00000000|DISCUSSION|tx|83|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|59|71
SE|00000000|DISCUSSION|tx|83|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|92|99

SE|00000000|DISCUSSION|tx|84|text|Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.
SE|00000000|DISCUSSION|tx|84|entity|C0001128|Acids|chem|||Acid||||606|1|4
SE|00000000|DISCUSSION|tx|84|entity|C0007382|Catalysis|npop|||catalyzed||||606|6|14
SE|00000000|DISCUSSION|tx|84|entity|C0039468|Temazepam|orch,phsu|||temazepam||||1000|31|39
SE|00000000|DISCUSSION|tx|84|entity|C0001962|Ethanol|orch|||ethanol||||890|66|72
SE|00000000|DISCUSSION|tx|84|entity|C3255993|aqueous solution|phsu|||aqueous ethanol solutions||||890|58|82

SE|00000000|DISCUSSION|tx|85|text|[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs]&#xd;&#xa;The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments.
SE|00000000|DISCUSSION|tx|85|entity|C1280500|Effect|qlco|||effect||||1000|6|11
SE|00000000|DISCUSSION|tx|85|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|16|25
SE|00000000|DISCUSSION|tx|85|entity|C0022646|Kidney|bpoc|||renal||||888|34|38
SE|00000000|DISCUSSION|tx|85|entity|C0221102|Excretory function|phsf|||excretion||||888|40|48
SE|00000000|DISCUSSION|tx|85|entity|C0733901|Verografin|irda,orch,phsu|||verografin||||1000|53|62
SE|00000000|DISCUSSION|tx|85|entity|C0021961|Iodamide|irda,orch|||iodamide||||1000|68|75
SE|00000000|DISCUSSION|tx|85|entity|C0012984|Canis familiaris|mamm|||dogs||||1000|80|83
SE|00000000|DISCUSSION|tx|86|entity|C0021494|Intravenous Injections|ftcn|||intravenous injection||||1000|5|25
SE|00000000|DISCUSSION|tx|86|entity|C0008783|Cimetidine|orch,phsu|||cimetidine||||1000|30|39
SE|00000000|DISCUSSION|tx|86|entity|C0178602|Dosage|qnco|||dose||||1000|46|49
SE|00000000|DISCUSSION|tx|86|entity|C0439272|ug/g|qnco|||mg/kg||||901|57|61
SE|00000000|DISCUSSION|tx|86|entity|C0021961|Iodamide|irda,orch|||iodamide||||888|88|95
SE|00000000|DISCUSSION|tx|86|entity|C0221102|Excretory function|phsf|||excretion||||888|97|105
SE|00000000|DISCUSSION|tx|86|entity|C0205191|chronic|tmco|||chronic||||851|110|116
SE|00000000|DISCUSSION|tx|86|entity|C0012984|Canis familiaris|mamm|||canine||||851|118|123
SE|00000000|DISCUSSION|tx|86|entity|C0681814|research study|resa|||experiments||||851|125|135
SE|00000000|DISCUSSION|tx|85|relation|7|3|C0733901|Verografin|irda,orch,phsu|irda|||verografin||||1000|53|62|NOM|INTERACTS_WITH||6|11|7|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|16|25
SE|00000000|DISCUSSION|tx|85|relation|7|3|C0021961|Iodamide|irda,orch|irda|||iodamide||||1000|68|75|NOM|INTERACTS_WITH||6|11|7|1|C0008783|Cimetidine|orch,phsu|orch|||cimetidine||||1000|16|25
SE|00000000|DISCUSSION|tx|85|relation|3|1|C0012984|Canis familiaris|mamm|mamm|||dogs||||1000|80|83|PREP|LOCATION_OF||77|78|5|1|C0021961|Iodamide|irda,orch|orch|||iodamide||||1000|68|75
SE|00000000|DISCUSSION|tx|85|relation|3|1|C0012984|Canis familiaris|mamm|mamm|||dogs||||1000|80|83|PREP|LOCATION_OF||77|78|5|1|C0733901|Verografin|irda,orch,phsu|orch|||verografin||||1000|53|62

SE|00000000|DISCUSSION|tx|87|text|In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
SE|00000000|DISCUSSION|tx|87|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|20|26
SE|00000000|DISCUSSION|tx|87|entity|C0030899|Pentoxifylline|orch,phsu|||PTX||||1000|40|42
SE|00000000|DISCUSSION|tx|87|entity|C1279901|Firstly|qlco|||first||||694|75|79

SE|00000000|DISCUSSION|tx|88|text|The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion.
SE|00000000|DISCUSSION|tx|88|entity|C1280500|Effect|qlco|||effects||||1000|5|11
SE|00000000|DISCUSSION|tx|88|entity|C0348016|Intravenous|spco|||IV||||861|20|21
SE|00000000|DISCUSSION|tx|88|entity|C0442824|Very|qlco|||very||||888|28|31
SE|00000000|DISCUSSION|tx|88|entity|C0442821|Strong|qlco|||strong||||888|33|38
SE|00000000|DISCUSSION|tx|88|entity|||gngm|649,5547,54858|BMP1,PRCP,PGPEP1|PCP-||||660|69|72
SE|00000000|DISCUSSION|tx|88|entity|C0205263|Induce (action)|ftcn|||induced||||660|73|79

SE|00000000|DISCUSSION|tx|89|text|Interaction of ketamine and halothane in rats.
SE|00000000|DISCUSSION|tx|89|entity|C1704675|Interaction|ftcn|||Interaction||||1000|1|11
SE|00000000|DISCUSSION|tx|89|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|16|23
SE|00000000|DISCUSSION|tx|89|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|29|37
SE|00000000|DISCUSSION|tx|89|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|42|45
SE|00000000|DISCUSSION|tx|89|relation|3|1|C0018549|Halothane|orch,phsu|phsu|||halothane||||1000|29|37|PREP|TREATS||39|40|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|42|45
SE|00000000|DISCUSSION|tx|89|relation|3|1|C0022614|Ketamine|orch,phsu|phsu|||ketamine||||1000|16|23|PREP|TREATS||39|40|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rats||||1000|42|45

SE|00000000|DISCUSSION|tx|90|text|Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine;
SE|00000000|DISCUSSION|tx|90|entity|C0020737|Ibogaine|bacs,orch,phsu|||Ibogaine||||1000|1|8
SE|00000000|DISCUSSION|tx|90|entity|C0205178|acute|tmco|||acute||||802|49|53
SE|00000000|DISCUSSION|tx|90|entity|C1280500|Effect|qlco|||effects||||802|65|71
SE|00000000|DISCUSSION|tx|90|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|76|83
SE|00000000|DISCUSSION|tx|90|relation|2|2|C0020737|Ibogaine|bacs,orch,phsu|bacs|||Ibogaine||||1000|1|8|NOM|INTERACTS_WITH||65|71|1|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|76|83

SE|00000000|DISCUSSION|tx|91|text|Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients.
SE|00000000|DISCUSSION|tx|91|entity|C0035648|risk factors|qnco|||risk factors||||1000|11|22
SE|00000000|DISCUSSION|tx|91|entity|C0205448|Two|qnco|||two||||1000|33|35
SE|00000000|DISCUSSION|tx|91|entity|C0035647|Risk|qlco|||risk||||1000|60|63
SE|00000000|DISCUSSION|tx|91|entity|C0033080|Prescription procedure|hlca|||prescription||||1000|77|88
SE|00000000|DISCUSSION|tx|91|entity|C0039832|Thiabendazole|orch,phsu|||thiabendazole||||861|93|105
SE|00000000|DISCUSSION|tx|91|entity|C0038463|Strongyloidiasis|dsyn|||strongyloidiasis||||1000|116|131
SE|00000000|DISCUSSION|tx|91|entity|C0025217|Melarsoprol|orch,phsu|||melarsoprol||||694|144|154
SE|00000000|DISCUSSION|tx|91|entity|C0205169|Bad|qlco|||bad||||825|169|171
SE|00000000|DISCUSSION|tx|91|entity|C0205246|Generalized|spco|||general||||825|173|179
SE|00000000|DISCUSSION|tx|91|entity|C0205210|Clinical|qlco|||clinical||||825|181|188
SE|00000000|DISCUSSION|tx|91|entity|C0012634|Disease|dsyn|||conditions||||825|190|199
SE|00000000|DISCUSSION|tx|91|entity|C0030705|Patients|podg|||patients||||1000|204|211
SE|00000000|DISCUSSION|tx|91|relation|5|1|C0039832|Thiabendazole|orch,phsu|phsu|||thiabendazole||||861|93|105|VERB|TREATS||110|114|4|1|C0038463|Strongyloidiasis|dsyn|dsyn|||strongyloidiasis||||1000|116|131
SE|00000000|DISCUSSION|tx|91|relation|5|1|C0039832|Thiabendazole|orch,phsu|phsu|||thiabendazole||||861|93|105|VERB|TREATS||110|114|4|1|C0012634|Disease|dsyn|dsyn|||conditions||||825|190|199

SE|00000000|DISCUSSION|tx|92|text|It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.
SE|00000000|DISCUSSION|tx|92|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|22|29
SE|00000000|DISCUSSION|tx|92|entity|C1518422|Negation|ftcn|||not||||1000|34|36
SE|00000000|DISCUSSION|tx|92|entity|C1282927|Shortened|qlco|||short||||802|40|44
SE|00000000|DISCUSSION|tx|92|entity|C0013227|Pharmaceutical Preparations|phsu|||drug||||802|53|56
SE|00000000|DISCUSSION|tx|92|entity|C0521115|Simultaneous|tmco|||concomitant||||888|67|77
SE|00000000|DISCUSSION|tx|92|entity|C0042153|utilization qualifier|ftcn|||use||||888|79|81
SE|00000000|DISCUSSION|tx|92|entity|C0018549|Halothane|orch,phsu|||halothane||||1000|88|96
SE|00000000|DISCUSSION|tx|92|entity|C1517331|Further|spco|||further||||1000|127|133
SE|00000000|DISCUSSION|tx|92|entity|C2926735|Duration|phsu|||duration||||1000|139|146
SE|00000000|DISCUSSION|tx|92|entity|C3266814|Action|acty|||action||||1000|155|160
SE|00000000|DISCUSSION|tx|92|entity|C0927232|Neuraxis|bdsy|||central nervous system||||1000|169|190
SE|00000000|DISCUSSION|tx|92|relation|0|0|C0022614|Ketamine|orch,phsu|orch|||ketamine||||1000|22|29|SPEC|ISA||22|56|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug||||802|53|56

SE|00000000|DISCUSSION|tx|93|text|Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively).
SE|00000000|DISCUSSION|tx|93|entity|C0014257|Endothelium|tisu|||Endothelium||||852|1|11
SE|00000000|DISCUSSION|tx|93|entity|C0205266|Intact|qlco|||intact||||852|13|18
SE|00000000|DISCUSSION|tx|93|entity|C0225957|Structure of anulus fibrosus of aorta|bpoc|||aortic rings||||852|20|31
SE|00000000|DISCUSSION|tx|93|entity|C0860851|estradiol high|fndg|||high-estradiol||||901|38|51
SE|00000000|DISCUSSION|tx|93|entity|C0034693|Rattus norvegicus|mamm|||rats||||901|53|56
SE|00000000|DISCUSSION|tx|93|entity|C0028351|Norepinephrine|nsba,orch,phsu|||noradrenaline||||1000|81|93
SE|00000000|DISCUSSION|tx|93|entity|C0033308|Progesterone|horm,phsu,strd|||progesterone||||1000|122|133
SE|00000000|DISCUSSION|tx|93|entity|C0033308|Progesterone|horm,phsu,strd|||progesterone||||840|140|151
SE|00000000|DISCUSSION|tx|93|entity|C0860851|estradiol high|fndg|||high-estradiol||||840|155|168
SE|00000000|DISCUSSION|tx|93|entity|C1522326|Treating|ftcn|||treated||||840|170|176
SE|00000000|DISCUSSION|tx|93|entity|C0034693|Rattus norvegicus|mamm|||rats||||840|178|181
SE|00000000|DISCUSSION|tx|93|entity|C1826536|PAF1 gene|gngm|54623|PAF1|pD2||||888|184|186
SE|00000000|DISCUSSION|tx|93|entity|C0042295|Values|qlco|||values||||888|188|193

SE|00000000|DISCUSSION|tx|94|text|The serum estrogen concentrations of estradiol + endotoxin-treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold).
SE|00000000|DISCUSSION|tx|94|entity|C0857965|serum estrogen|lbpr|||serum estrogen||||901|5|18
SE|00000000|DISCUSSION|tx|94|entity|C0086045|Mental concentration|menp|||concentrations||||901|20|33
SE|00000000|DISCUSSION|tx|94|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol||||833|38|46
SE|00000000|DISCUSSION|tx|94|entity|C0014264|Endotoxins|carb,hops,lipd|||endotoxin||||833|50|58
SE|00000000|DISCUSSION|tx|94|entity|C1522326|Treating|ftcn|||treated||||833|60|66
SE|00000000|DISCUSSION|tx|94|entity|C0034693|Rattus norvegicus|mamm|||rats||||833|68|71
SE|00000000|DISCUSSION|tx|94|entity|C0014264|Endotoxins|carb,hops,lipd|||endotoxin||||851|110|118
SE|00000000|DISCUSSION|tx|94|entity|C1522326|Treating|ftcn|||treated||||851|120|126
SE|00000000|DISCUSSION|tx|94|entity|C0034693|Rattus norvegicus|mamm|||rats||||851|128|131
SE|00000000|DISCUSSION|tx|94|entity|C0332462|Folded structure|spco|||fold||||888|152|155

SE|00000000|DISCUSSION|tx|95|text|Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
SE|00000000|DISCUSSION|tx|95|entity|C1704675|Interaction|ftcn|||interaction||||861|17|27
SE|00000000|DISCUSSION|tx|95|entity|C0205171|Singular|qnco|||single||||851|37|42
SE|00000000|DISCUSSION|tx|95|entity|C0442027|Oral|spco|||oral||||851|44|47
SE|00000000|DISCUSSION|tx|95|entity|C0178602|Dosage|qnco|||doses||||851|49|53
SE|00000000|DISCUSSION|tx|95|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||1000|58|66
SE|00000000|DISCUSSION|tx|95|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||1000|72|80
SE|00000000|DISCUSSION|tx|95|entity|C1708335|Healthy Subject|qlco|||healthy volunteers||||983|85|102

SE|00000000|DISCUSSION|tx|96|text|In vitro interaction of prostaglandin F2alpha and oxytocin in placental vessels.
SE|00000000|DISCUSSION|tx|96|entity|C1704675|Interaction|ftcn|||interaction||||861|10|20
SE|00000000|DISCUSSION|tx|96|entity|C0012471|Dinoprost|eico,horm,phsu|||prostaglandin F2alpha||||1000|25|45
SE|00000000|DISCUSSION|tx|96|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin||||1000|51|58
SE|00000000|DISCUSSION|tx|96|entity|C0459710|Placental vessel|bpoc|||placental vessels||||983|63|79
SE|00000000|DISCUSSION|tx|96|relation|1|1|C0459710|Placental vessel|bpoc|bpoc|||placental vessels||||983|63|79|PREP|LOCATION_OF||60|61|3|1|C0030095|Oxytocin|aapp,gngm,horm,phsu|aapp|||oxytocin||||1000|51|58
SE|00000000|DISCUSSION|tx|96|relation|1|1|C0459710|Placental vessel|bpoc|bpoc|||placental vessels||||983|63|79|PREP|LOCATION_OF||60|61|3|1|C0012471|Dinoprost|eico,horm,phsu|eico|||prostaglandin F2alpha||||1000|25|45

SE|00000000|DISCUSSION|tx|97|text|Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
SE|00000000|DISCUSSION|tx|97|entity|C0754188|Amprenavir|orch,phsu|||Amprenavir||||861|1|10
SE|00000000|DISCUSSION|tx|97|entity|C0205146|Area|spco|||area||||1000|40|43
SE|00000000|DISCUSSION|tx|97|entity|C0205134|Curved|spco|||curve||||1000|55|59
SE|00000000|DISCUSSION|tx|97|entity|C0678587|steady state|npop|||steady state||||1000|64|75
SE|00000000|DISCUSSION|tx|97|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|78|80
SE|00000000|DISCUSSION|tx|97|entity|C0140575|Rifabutin|antb,orch|||rifabutin||||1000|90|98
SE|00000000|DISCUSSION|tx|97|entity|C0332462|Folded structure|spco|||fold||||802|108|111
SE|00000000|DISCUSSION|tx|97|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|121|123
SE|00000000|DISCUSSION|tx|97|entity|C0663716|25-desacetylrifabutin|orch,phsu|||25-O-desacetylrifabutin||||913|132|154
SE|00000000|DISCUSSION|tx|97|entity|C0332462|Folded structure|spco|||fold||||827|164|167

SE|00000000|DISCUSSION|tx|98|text|Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments.
SE|00000000|DISCUSSION|tx|98|entity|C1524062|Additional|ftcn|||Additional||||790|1|10
SE|00000000|DISCUSSION|tx|98|entity|C0302583|Iron|bacs,elii,phsu|||iron||||790|12|15
SE|00000000|DISCUSSION|tx|98|entity|C0009148|Cobalt|elii|||cobalt||||1000|59|64
SE|00000000|DISCUSSION|tx|98|entity|C2348262|Dietary Cobalt|elii|||dietary cobalt||||901|74|87
SE|00000000|DISCUSSION|tx|98|entity|C0087111|Therapeutic procedure|topp|||treatments||||901|89|98

SE|00000000|DISCUSSION|tx|99|text|Interaction of clindamycin and gentamicin in vitro.
SE|00000000|DISCUSSION|tx|99|entity|C1704675|Interaction|ftcn|||Interaction||||1000|1|11
SE|00000000|DISCUSSION|tx|99|entity|C0008947|Clindamycin|antb,carb|||clindamycin||||1000|16|26
SE|00000000|DISCUSSION|tx|99|entity|C0017436|Gentamicins|antb,carb|||gentamicin||||1000|32|41

SE|00000000|DISCUSSION|tx|100|text|The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis.
SE|00000000|DISCUSSION|tx|100|entity|C1274040|Result|ftcn|||results||||1000|5|11
SE|00000000|DISCUSSION|tx|100|entity|C0443286|Reaction|ftcn|||reaction||||861|56|63
SE|00000000|DISCUSSION|tx|100|entity|C0038351|Stomach|bpoc|||stomach||||1000|82|88
SE|00000000|DISCUSSION|tx|100|entity|C0027361|Persons|popg|||people||||1000|93|98
SE|00000000|DISCUSSION|tx|100|entity|C0001975|Alcohols|orch,phsu|||alcohol||||1000|112|118
SE|00000000|DISCUSSION|tx|100|entity|C0700307|hydroxyl group|inch|||hydroxy||||827|126|132
SE|00000000|DISCUSSION|tx|100|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine||||888|138|151
SE|00000000|DISCUSSION|tx|100|entity|C0205272|Regular|qlco|||regular||||888|158|164
SE|00000000|DISCUSSION|tx|100|entity|C1874451|Basis|phsu|||basis||||888|166|170
SE|00000000|DISCUSSION|tx|100|relation|4|1|C0038351|Stomach|bpoc|bpoc|||stomach||||1000|82|88|PREP|PART_OF||90|91|4|1|C0027361|Persons|popg,humn|humn|||people||||1000|93|98

SE|00000000|DISCUSSION|tx|101|text|Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
SE|00000000|DISCUSSION|tx|101|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|12|19
SE|00000000|DISCUSSION|tx|101|entity|C1280500|Effect|qlco|||effect||||861|51|56
SE|00000000|DISCUSSION|tx|101|entity|C0012586|Dipyrone|orch,phsu|||metamizol||||1000|61|69
SE|00000000|DISCUSSION|tx|101|entity|C0205171|Singular|qnco|||only||||1000|72|75
SE|00000000|DISCUSSION|tx|101|entity|C0039259|Tail|bpoc|||tail-||||802|84|88
SE|00000000|DISCUSSION|tx|101|entity|C0022885|Laboratory Procedures|lbpr|||test||||802|95|98
SE|00000000|DISCUSSION|tx|101|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|105|116
SE|00000000|DISCUSSION|tx|101|relation|1|1|C0012010|Diazepam|orch,phsu|orch|||diazepam||||1000|12|19|NOM|INTERACTS_WITH||51|56|3|1|C0012586|Dipyrone|orch,phsu|orch|||metamizol||||1000|61|69

SE|00000000|DISCUSSION|tx|102|text|In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding.
SE|00000000|DISCUSSION|tx|102|entity|C1705920|Species|cnce|||species||||1000|9|15
SE|00000000|DISCUSSION|tx|102|entity|C1518422|Negation|ftcn|||not||||1000|32|34
SE|00000000|DISCUSSION|tx|102|entity|C1521828|Rate|qnco|||rate||||851|62|65
SE|00000000|DISCUSSION|tx|102|entity|C0442797|Decreasing|qlco|||decreasing||||851|67|76
SE|00000000|DISCUSSION|tx|102|entity|C1280500|Effect|qlco|||effects||||851|78|84
SE|00000000|DISCUSSION|tx|102|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|89|96

SE|00000000|DISCUSSION|tx|103|text|This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.
SE|00000000|DISCUSSION|tx|103|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000|DISCUSSION|tx|103|entity|C3245505|Potential|qlco|||potent||||805|34|39
SE|00000000|DISCUSSION|tx|103|entity|C0010762|Cytochrome P450|aapp,enzy|1555|CYP2B6|cytochrome P450 enzyme||||805|41|62
SE|00000000|DISCUSSION|tx|103|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||805|72|80
SE|00000000|DISCUSSION|tx|103|entity|C0522501|Massive|qlco|||marked||||888|100|105
SE|00000000|DISCUSSION|tx|103|entity|C1280500|Effect|qlco|||effect||||888|107|112
SE|00000000|DISCUSSION|tx|103|entity|C0025519|Metabolism|orgf|||metabolism||||1000|121|130
SE|00000000|DISCUSSION|tx|103|entity|C0123091|quetiapine|orch,phsu|||quetiapine||||1000|135|144
SE|00000000|DISCUSSION|tx|103|entity|C0332462|Folded structure|spco|||fold||||851|164|167
SE|00000000|DISCUSSION|tx|103|entity|C0442805|Increase|ftcn|||increase||||851|169|176
SE|00000000|DISCUSSION|tx|103|entity|C0449297|Clearance|qlco|||clearance||||1000|181|189
SE|00000000|DISCUSSION|tx|103|entity|C0030705|Patients|podg|||patients||||1000|226|233
SE|00000000|DISCUSSION|tx|103|entity|C0348016|Intravenous|spco|||IV||||775|244|245
SE|00000000|DISCUSSION|tx|103|entity|C0011900|Diagnosis|fndg|||diagnosed||||775|247|255
SE|00000000|DISCUSSION|tx|103|entity|C0036341|Schizophrenia|mobd|||schizophrenia||||775|257|269
SE|00000000|DISCUSSION|tx|103|entity|C0036337|Schizoaffective Disorder|mobd|||schizoaffective disorder||||1000|272|295
SE|00000000|DISCUSSION|tx|103|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder||||1000|301|316
SE|00000000|DISCUSSION|tx|103|relation|0|0|C0036341|Schizophrenia|mobd|mobd|||schizophrenia||||775|257|269|MOD/HEAD|ISA||247|269|0|0|C0011900|Diagnosis|fndg|fndg|||diagnosed||||775|247|255
SE|00000000|DISCUSSION|tx|103|relation|0|0|C0036337|Schizoaffective Disorder|mobd|mobd|||schizoaffective disorder||||1000|272|295|SPEC|ISA||257|295|0|0|C0036341|Schizophrenia|mobd|mobd|||schizophrenia||||775|257|269
SE|00000000|DISCUSSION|tx|103|relation|8|2|C0123091|quetiapine|orch,phsu|orch|||quetiapine||||1000|135|144|NOM|AFFECTS||107|112|8|1|C0025519|Metabolism|orgf|orgf|||metabolism||||1000|121|130
SE|00000000|DISCUSSION|tx|103|relation|7|6|C0031507|Phenytoin|orch,phsu|orch|||phenytoin||||805|72|80|VERB|ADMINISTERED_TO||196|207|4|1|C0030705|Patients|podg,humn|humn|||patients||||1000|226|233
SE|00000000|DISCUSSION|tx|103|relation|3|1|C0036341|Schizophrenia|mobd|mobd|||schizophrenia||||775|257|269|PREP|PROCESS_OF||235|238|8|1|C0030705|Patients|podg,humn|humn|||patients||||1000|226|233
SE|00000000|DISCUSSION|tx|103|relation|0|0|C0036337|Schizoaffective Disorder|mobd|mobd|||schizoaffective disorder||||1000|272|295|INFER|PROCESS_OF(SPEC)||257|295|0|0|C0030705|Patients|podg,humn|humn|||patients||||1000|226|233

SE|00000000|DISCUSSION|tx|104|text|Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin.
SE|00000000|DISCUSSION|tx|104|entity|C0042523|Verapamil|orch,phsu|||Verapamil||||827|1|9
SE|00000000|DISCUSSION|tx|104|entity|C0021149|Incidence|qnco|||incidence||||1000|44|52
SE|00000000|DISCUSSION|tx|104|entity|C1708790|Lymphatic Invasion|fndg|||lymphatic invasion||||1000|57|74
SE|00000000|DISCUSSION|tx|104|entity|C0001418|Adenocarcinoma|neop|||adenocarcinomas||||1000|79|93
SE|00000000|DISCUSSION|tx|104|entity|C0005919|Bombesin|aapp,horm,nsba|||bombesin||||1000|118|125
SE|00000000|DISCUSSION|tx|104|relation|0|0|C0042523|Verapamil|orch,phsu|phsu|||Verapamil||||827|1|9|VERB|INHIBITS||30|38|4|2|C1708790|Lymphatic Invasion|fndg|fndg|||lymphatic invasion||||1000|57|74
SE|00000000|DISCUSSION|tx|104|relation|1|1|C0005919|Bombesin|aapp,gngm,horm,nsba|aapp|||bombesin||||1000|118|125|VERB|STIMULATES||106|113|3|3|C0042523|Verapamil|orch,phsu|orch|||Verapamil||||827|1|9

SE|00000000|DISCUSSION|tx|105|text|Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;
SE|00000000|DISCUSSION|tx|105|entity|C0039771|Theophylline|bacs,orch,phsu|||Theophylline||||1000|1|12
SE|00000000|DISCUSSION|tx|105|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|39|51
SE|00000000|DISCUSSION|tx|105|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|58|60
SE|00000000|DISCUSSION|tx|105|entity|C0443172|Changed status|qnco|||change||||872|62|67
SE|00000000|DISCUSSION|tx|105|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||888|78|87
SE|00000000|DISCUSSION|tx|105|entity|C0442805|Increase|ftcn|||increase||||888|89|96
SE|00000000|DISCUSSION|tx|105|entity|C1880774|Financial Disclosure Form|mnob|||FDF||||1000|101|103
SE|00000000|DISCUSSION|tx|105|entity|C0439194|Micromole|qnco|||micromol||||645|121|128
SE|00000000|DISCUSSION|tx|105|relation|1|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||Theophylline||||1000|1|12|NOM|INTERACTS_WITH||28|34|5|1|C0000970|Acetaminophen|orch,phsu|orch|||acetaminophen||||1000|39|51

SE|00000000|DISCUSSION|tx|106|text|An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.
SE|00000000|DISCUSSION|tx|106|entity|C0021494|Intravenous Injections|ftcn|||intravenous injection||||1000|4|24
SE|00000000|DISCUSSION|tx|106|entity|C0136082|perchlorate|inch|||perchlorate||||1000|29|39
SE|00000000|DISCUSSION|tx|106|entity|C0205197|Complete|qlco|||complete||||1000|69|76
SE|00000000|DISCUSSION|tx|106|entity|C0205548|Stat (do immediately)|tmco|||immediately||||1000|82|92
SE|00000000|DISCUSSION|tx|106|entity|C0333668|Depletion|ftcn|||depletion||||1000|104|112
SE|00000000|DISCUSSION|tx|106|entity|C0205962|Pertechnetate|inch,phsu|||pertechnetate||||861|117|129
SE|00000000|DISCUSSION|tx|106|entity|C0439531|per period (qualifier value)|tmco|||period||||1000|176|181
SE|00000000|DISCUSSION|tx|106|entity|C0702093|/minute|tmco|||min||||861|190|192
SE|00000000|DISCUSSION|tx|106|entity|C1863925|Nonmedullary thyroid carcinoma, with or without cell oxyphilia|neop|||TcO||||763|204|206
SE|00000000|DISCUSSION|tx|106|entity|C1533685|Injection procedure|topp|||injection||||763|210|218
SE|00000000|DISCUSSION|tx|106|entity|C0442805|Increase|ftcn|||increase||||861|241|248
SE|00000000|DISCUSSION|tx|106|entity|C0005767|Blood|tisu|||blood||||861|253|257

SE|00000000|DISCUSSION|tx|107|text|Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.
SE|00000000|DISCUSSION|tx|107|entity|C0599739|synergism|moft|||Synergism||||1000|1|9
SE|00000000|DISCUSSION|tx|107|entity|C0007546|Cefazolin|antb,orch|||cefazolin||||1000|50|58
SE|00000000|DISCUSSION|tx|107|entity|C0004595|Bacillus subtilis|bact|||Bacillus subtilis||||1000|68|84
SE|00000000|DISCUSSION|tx|107|entity|C0315260|Klebsiella oxytoca|bact|||Klebsiella oxytoca||||1000|90|107

SE|00000000|DISCUSSION|tx|108|text|The drug interaction between warfarin and rifampin is not well known.
SE|00000000|DISCUSSION|tx|108|entity|C0687133|Drug Interactions|moft|||drug interaction||||1000|5|20
SE|00000000|DISCUSSION|tx|108|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|30|37
SE|00000000|DISCUSSION|tx|108|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|43|50
SE|00000000|DISCUSSION|tx|108|entity|C1518422|Negation|ftcn|||not||||851|55|57
SE|00000000|DISCUSSION|tx|108|entity|C0205170|Good|qlco|||well||||851|59|62
SE|00000000|DISCUSSION|tx|108|entity|C0205309|Known|qlco|||known||||851|64|68

SE|00000000|DISCUSSION|tx|109|text|Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.
SE|00000000|DISCUSSION|tx|109|entity|C0052796|Azithromycin|antb,orch|||Azithromycin||||1000|1|12
SE|00000000|DISCUSSION|tx|109|entity|C0237881|Statistical Significance|qnco|||significant||||888|21|31
SE|00000000|DISCUSSION|tx|109|entity|C1825598|IMPACT gene|gngm|55364|IMPACT|impact||||888|33|38
SE|00000000|DISCUSSION|tx|109|entity|C2347813|Cmax|qnco|||Cmax||||1000|47|50
SE|00000000|DISCUSSION|tx|109|entity|C0376690|Area Under Curve|qnco|||AUC||||1000|56|58
SE|00000000|DISCUSSION|tx|109|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||1000|63|72
SE|00000000|DISCUSSION|tx|109|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||888|115|124
SE|00000000|DISCUSSION|tx|109|entity|C2348796|Tmax|qnco|||tmax||||888|126|129
SE|00000000|DISCUSSION|tx|109|entity|C0178719|Intracellular|spco|||intracellular||||694|156|168
SE|00000000|DISCUSSION|tx|109|entity|C0043474|Zidovudine|nnon,phsu|||zidovudine||||861|197|206

SE|00000000|DISCUSSION|tx|110|text|Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses.
SE|00000000|DISCUSSION|tx|110|entity|C1550147|Pretreatment|sbst|||Pretreatment||||1000|1|12
SE|00000000|DISCUSSION|tx|110|entity|C0025166|Megakaryocytes|cell|||megakaryocytes||||1000|17|30
SE|00000000|DISCUSSION|tx|110|entity|C0521119|Extracellular|celc|||extracellular||||694|37|49
SE|00000000|DISCUSSION|tx|110|entity|C0205263|Induce (action)|ftcn|||induced||||750|89|95
SE|00000000|DISCUSSION|tx|110|entity|C0871261|Response process|orga|||responses||||750|97|105

SE|00000000|DISCUSSION|tx|111|text|Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
SE|00000000|DISCUSSION|tx|111|entity|C1704675|Interaction|ftcn|||Interaction||||1000|1|11
SE|00000000|DISCUSSION|tx|111|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine||||1000|21|27
SE|00000000|DISCUSSION|tx|111|entity|C0220839|Glutamate|aapp,bacs|||glutamate||||1000|33|41
SE|00000000|DISCUSSION|tx|111|entity|C1527148|Development|ftcn|||development||||1000|50|60
SE|00000000|DISCUSSION|tx|111|entity|C0205359|Spontaneous|ftcn|||spontaneous||||888|65|75
SE|00000000|DISCUSSION|tx|111|entity|C1510470|Motility|orgf|||motility||||888|77|84
SE|00000000|DISCUSSION|tx|111|entity|C0008046|Chick Embryo|emst|||chick embryos||||1000|89|101
SE|00000000|DISCUSSION|tx|111|relation|1|1|C0008046|Chick Embryo|emst|emst|||chick embryos||||1000|89|101|PREP|LOCATION_OF||86|87|5|3|C0220839|Glutamate|aapp,gngm,bacs|aapp|||glutamate||||1000|33|41
SE|00000000|DISCUSSION|tx|111|relation|1|1|C0008046|Chick Embryo|emst|emst|||chick embryos||||1000|89|101|PREP|LOCATION_OF||86|87|5|3|C0017890|Glycine|aapp,gngm,bacs,phsu|aapp|||glycine||||1000|21|27

SE|00000000|DISCUSSION|tx|112|text|Median gastric pH was significantly higher when indinavir was taken after didanosine administration;
SE|00000000|DISCUSSION|tx|112|entity|C0549183|Midline (qualifier value)|spco|||Median||||901|1|6
SE|00000000|DISCUSSION|tx|112|entity|C1168023|Gastric pH|diap|||gastric pH||||901|8|17
SE|00000000|DISCUSSION|tx|112|entity|C0205250|High|qlco|||higher||||827|37|42
SE|00000000|DISCUSSION|tx|112|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|49|57
SE|00000000|DISCUSSION|tx|112|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||888|75|84

SE|00000000|DISCUSSION|tx|113|text|Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals.
SE|00000000|DISCUSSION|tx|113|entity|C0332152|Before|tmco|||Prior||||888|1|5
SE|00000000|DISCUSSION|tx|113|entity|C0048504|fomepizole|orch,phsu|||4-methylpyrazole||||1000|25|40
SE|00000000|DISCUSSION|tx|113|entity|C0439272|ug/g|qnco|||mg kg||||901|46|50
SE|00000000|DISCUSSION|tx|113|entity|C0005910|Body Weight|orga|||body weight||||1000|56|66
SE|00000000|DISCUSSION|tx|113|entity|C0439836|Conversions|ftcn|||conversion||||1000|94|103
SE|00000000|DISCUSSION|tx|113|entity|C0670480|1,3-difluoro-2-propanol|orch|||difluoro-2-propanol||||923|112|130
SE|00000000|DISCUSSION|tx|113|entity|C0439272|ug/g|qnco|||mg kg||||901|137|141
SE|00000000|DISCUSSION|tx|113|entity|C0005910|Body Weight|orga|||body weight||||1000|147|157
SE|00000000|DISCUSSION|tx|113|entity|C0699343|erythro|antb,carb|||erythro||||888|167|173
SE|00000000|DISCUSSION|tx|113|entity|C0060559|fluorocitrate|irda,orch|||fluorocitrate||||888|175|187
SE|00000000|DISCUSSION|tx|113|entity|C0016327|Fluorides|inch,phsu|||fluoride||||1000|218|225
SE|00000000|DISCUSSION|tx|113|entity|C0008857|Citrates|orch|||citrate||||888|231|237
SE|00000000|DISCUSSION|tx|113|entity|C0702240|Elevation|spco|||elevations||||888|239|248
SE|00000000|DISCUSSION|tx|113|entity|C0670480|1,3-difluoro-2-propanol|orch|||difluoro-2-propanol||||817|262|280
SE|00000000|DISCUSSION|tx|113|entity|C0003062|Animals|anim|||animals||||817|294|300

SE|00000000|DISCUSSION|tx|114|text|Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.
SE|00000000|DISCUSSION|tx|114|entity|C0000970|Acetaminophen|orch,phsu|||Acetaminophen||||1000|1|13
SE|00000000|DISCUSSION|tx|114|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|41|52
SE|00000000|DISCUSSION|tx|114|entity|C0086418|Homo sapiens|humn|||human||||888|57|61
SE|00000000|DISCUSSION|tx|114|entity|C0229671|Serum|bdsu|||serum||||888|63|67
SE|00000000|DISCUSSION|tx|114|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|74|76
SE|00000000|DISCUSSION|tx|114|entity|C0443172|Changed status|qnco|||change||||872|78|83
SE|00000000|DISCUSSION|tx|114|entity|C0439084|>5|qnco|||5.7||||861|88|90
SE|00000000|DISCUSSION|tx|114|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||888|94|103
SE|00000000|DISCUSSION|tx|114|entity|C0442805|Increase|ftcn|||increase||||888|105|112
SE|00000000|DISCUSSION|tx|114|entity|C0678752|free drug fraction|qnco|||free drug fraction||||1000|117|134
SE|00000000|DISCUSSION|tx|114|entity|C1880774|Financial Disclosure Form|mnob|||FDF||||1000|137|139
SE|00000000|DISCUSSION|tx|114|entity|C0439194|Micromole|qnco|||micromol||||660|157|164
SE|00000000|DISCUSSION|tx|114|entity|C1423506|SPINK5 gene|gngm|11005|SPINK5|net||||872|177|179
SE|00000000|DISCUSSION|tx|114|entity|C0443172|Changed status|qnco|||change||||872|181|186
SE|00000000|DISCUSSION|tx|114|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||888|197|206
SE|00000000|DISCUSSION|tx|114|entity|C0442805|Increase|ftcn|||increase||||888|208|215
SE|00000000|DISCUSSION|tx|114|entity|C1880774|Financial Disclosure Form|mnob|||FDF||||1000|220|222
SE|00000000|DISCUSSION|tx|114|entity|C0439194|Micromole|qnco|||micromol||||660|240|247

SE|00000000|DISCUSSION|tx|115|text|Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.
SE|00000000|DISCUSSION|tx|115|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|16|28
SE|00000000|DISCUSSION|tx|115|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||1000|35|46
SE|00000000|DISCUSSION|tx|115|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|49|61
SE|00000000|DISCUSSION|tx|115|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|68|80
SE|00000000|DISCUSSION|tx|115|entity|C0042291|Valproic Acid|orch,phsu|||valproic acid||||1000|87|99
SE|00000000|DISCUSSION|tx|115|entity|C0031412|Phenobarbital|orch,phsu|||phenobarbital||||1000|106|118
SE|00000000|DISCUSSION|tx|115|entity|C0205250|High|qlco|||high||||1000|123|126
SE|00000000|DISCUSSION|tx|115|entity|C1407029|Toxic|qlco|||toxic||||888|131|135
SE|00000000|DISCUSSION|tx|115|entity|C0086045|Mental concentration|menp|||concentrations||||888|137|150
SE|00000000|DISCUSSION|tx|115|entity|C0085104|Drug Delivery Systems|medd|||target drug||||1000|181|191

SE|00000000|DISCUSSION|tx|116|text|It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue.
SE|00000000|DISCUSSION|tx|116|entity|C0027930|Neurotensin|aapp,horm,nsba|||neurotensin||||1000|19|29
SE|00000000|DISCUSSION|tx|116|entity|C1280500|Effect|qlco|||effect||||861|73|78
SE|00000000|DISCUSSION|tx|116|entity|C0014298|Enkephalins|aapp,nsba|||enkephalins||||1000|83|93
SE|00000000|DISCUSSION|tx|116|entity|C0243071|Analog|chvs|||analogue||||1000|105|112

SE|00000000|DISCUSSION|tx|117|text|Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min.
SE|00000000|DISCUSSION|tx|117|entity|C0010738|Cytochalasin D|bacs,orch|||Cytochalasin D||||1000|1|14
SE|00000000|DISCUSSION|tx|117|entity|C1327616|Cell secretion|celf|||secretory||||888|56|64
SE|00000000|DISCUSSION|tx|117|entity|C1280500|Effect|qlco|||effect||||888|66|71
SE|00000000|DISCUSSION|tx|117|entity|C0006945|Carbachol|orch,phsu|||carbachol||||1000|76|84
SE|00000000|DISCUSSION|tx|117|entity|C0599739|synergism|moft|||synergism||||1000|94|102
SE|00000000|DISCUSSION|tx|117|entity|C0050063|8-chloro-cyclic adenosine monophosphate|nnon,phsu|||cAMP||||1000|109|112
SE|00000000|DISCUSSION|tx|117|entity|C1280500|Effect|qlco|||effect||||1000|133|138
SE|00000000|DISCUSSION|tx|117|entity|C0019588|Histamine|nsba,orch|||histamine||||1000|143|151
SE|00000000|DISCUSSION|tx|117|entity|C0050063|8-chloro-cyclic adenosine monophosphate|nnon,phsu|||cAMP||||857|157|160
SE|00000000|DISCUSSION|tx|117|entity|C1948023|Stimulation (motivation)|npop|||stimulated||||857|162|171
SE|00000000|DISCUSSION|tx|117|entity|C1160577|acid secretion|celf|||acid secretion||||857|173|186
SE|00000000|DISCUSSION|tx|117|entity|C0702093|/minute|tmco|||min||||861|198|200
SE|00000000|DISCUSSION|tx|117|relation|7|3|C0050063|8-chloro-cyclic adenosine monophosphate|nnon,phsu|nnon|||cAMP||||1000|109|112|NOM|INTERACTS_WITH||66|71|7|1|C0006945|Carbachol|orch,phsu|orch|||carbachol||||1000|76|84
SE|00000000|DISCUSSION|tx|117|relation|6|6|C0010738|Cytochalasin D|bacs,orch|bacs|||Cytochalasin D||||1000|1|14|NOM|INTERACTS_WITH|negation|133|138|3|1|C0019588|Histamine|nsba,orch|nsba|||histamine||||1000|143|151

SE|00000000|DISCUSSION|tx|118|text|Interaction of gentamycin and atracurium in anaesthetised horses.
SE|00000000|DISCUSSION|tx|118|entity|C1704675|Interaction|ftcn|||Interaction||||1000|1|11
SE|00000000|DISCUSSION|tx|118|entity|C0017436|Gentamicins|antb,carb|||gentamycin||||1000|16|25
SE|00000000|DISCUSSION|tx|118|entity|C0004234|Atracurium|orch,phsu|||atracurium||||1000|31|40
SE|00000000|DISCUSSION|tx|118|entity|C1720436|Under anesthesia|fndg|||anaesthetised||||888|45|57
SE|00000000|DISCUSSION|tx|118|entity|C0019944|Equus caballus|mamm|||horses||||888|59|64
SE|00000000|DISCUSSION|tx|118|relation|3|1|C0004234|Atracurium|orch,phsu|phsu|||atracurium||||1000|31|40|PREP|TREATS||42|43|1|1|C0019944|Equus caballus|mamm|mamm|||horses||||888|59|64
SE|00000000|DISCUSSION|tx|118|relation|3|1|C0017436|Gentamicins|antb,carb|antb|||gentamycin||||1000|16|25|PREP|TREATS||42|43|1|1|C0019944|Equus caballus|mamm|mamm|||horses||||888|59|64

SE|00000000|DISCUSSION|tx|119|text|It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.
SE|00000000|DISCUSSION|tx|119|entity|C0027930|Neurotensin|aapp,horm,nsba|||neurotensin||||1000|22|32
SE|00000000|DISCUSSION|tx|119|entity|C1521805|Opposite|spco|||opposite||||694|50|57
SE|00000000|DISCUSSION|tx|119|entity|C0542341|Function|ftcn|||function||||1000|67|74
SE|00000000|DISCUSSION|tx|119|entity|C0027882|Neurons|cell|||neurons||||861|99|105
SE|00000000|DISCUSSION|tx|119|entity|C1879652|Central Minus|lbpr|||central||||888|115|121
SE|00000000|DISCUSSION|tx|119|entity|C3266814|Action|acty|||action||||888|123|128
SE|00000000|DISCUSSION|tx|119|entity|C0041350|Tuftsin|aapp,imft|||tuftsin||||1000|133|139

SE|00000000|DISCUSSION|tx|120|text|Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.
SE|00000000|DISCUSSION|tx|120|entity|C0205217|Increased|qnco|||Increased||||888|1|9
SE|00000000|DISCUSSION|tx|120|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxicity||||888|11|24
SE|00000000|DISCUSSION|tx|120|entity|C0000970|Acetaminophen|orch,phsu|||acetaminophen||||1000|29|41
SE|00000000|DISCUSSION|tx|120|entity|C0521115|Simultaneous|tmco|||concomitant||||888|46|56
SE|00000000|DISCUSSION|tx|120|entity|C0006644|Caffeine|orch,phsu|||caffeine||||1000|76|83
SE|00000000|DISCUSSION|tx|120|entity|C0034693|Rattus norvegicus|mamm|||rat||||1000|92|94
SE|00000000|DISCUSSION|tx|120|relation|4|1|C0006644|Caffeine|orch,phsu|phsu|||caffeine||||1000|76|83|PREP|TREATS||85|86|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rat||||1000|92|94

SE|00000000|RESULTS|tx|121|text|RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
SE|00000000|RESULTS|tx|121|entity|C1274040|Result|ftcn|||RESULTS||||1000|1|7
SE|00000000|RESULTS|tx|121|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|17|25
SE|00000000|RESULTS|tx|121|entity|C0085228|Fluvoxamine|orch,phsu|||fluvoxamine||||1000|32|42
SE|00000000|RESULTS|tx|121|entity|C0237881|Statistical Significance|qnco|||statistically significant||||901|57|81
SE|00000000|RESULTS|tx|121|entity|C0547047|Decrease|qnco|||decrease||||901|83|90
SE|00000000|RESULTS|tx|121|entity|C0549183|Midline (qualifier value)|spco|||median||||1000|99|104
SE|00000000|RESULTS|tx|121|entity|C0439175|% of total|qnco|||total||||888|113|117
SE|00000000|RESULTS|tx|121|entity|C0449297|Clearance|qlco|||clearance||||888|119|127
SE|00000000|RESULTS|tx|121|entity|C0040374|Tolbutamide|orch,phsu|||tolbutamide||||1000|132|142
SE|00000000|RESULTS|tx|121|entity|C0439391|mL/h|qnco|||mL/h||||901|154|157
SE|00000000|RESULTS|tx|121|entity|C0439391|mL/h|qnco|||mL/h||||901|166|169
SE|00000000|RESULTS|tx|121|entity|C0042960|Voluntary Workers|prog|||volunteers||||1000|182|191
SE|00000000|RESULTS|tx|121|entity|C0439423|Milligram per 24 Hours|qnco|||mg/d||||901|209|212
SE|00000000|RESULTS|tx|121|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||treatment||||1000|17|25|PREP|USES||27|30|9|1|C0085228|Fluvoxamine|orch,phsu|phsu|||fluvoxamine||||1000|32|42

SE|00000000|RESULTS|tx|122|text|There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
SE|00000000|RESULTS|tx|122|entity|C2349975|Enhance (action)|acty|||enhancement||||888|18|28
SE|00000000|RESULTS|tx|122|entity|C1280500|Effect|qlco|||effect||||888|30|35
SE|00000000|RESULTS|tx|122|entity|C0012471|Dinoprost|eico,horm,phsu|||PGF2alpha||||1000|40|48
SE|00000000|RESULTS|tx|122|entity|C0443286|Reaction|ftcn|||reaction||||1000|59|66
SE|00000000|RESULTS|tx|122|entity|C0459710|Placental vessel|bpoc|||placental vessels||||983|71|87
SE|00000000|RESULTS|tx|122|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin||||1000|92|99

SE|00000000|RESULTS|tx|123|text|Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for atracurium alone and 13.7 +/- 1.2 min for atracurium plus gentamycin.
SE|00000000|RESULTS|tx|123|entity|C0702093|/minute|tmco|||min||||804|65|67
SE|00000000|RESULTS|tx|123|entity|C0004234|Atracurium|orch,phsu|||atracurium||||1000|73|82
SE|00000000|RESULTS|tx|123|entity|C0205171|Singular|qnco|||alone||||1000|84|88
SE|00000000|RESULTS|tx|123|entity|C0702093|/minute|tmco|||min||||804|107|109
SE|00000000|RESULTS|tx|123|entity|C0004234|Atracurium|orch,phsu|||atracurium||||802|115|124
SE|00000000|RESULTS|tx|123|entity|C0017436|Gentamicins|antb,carb|||gentamycin||||802|131|140

SE|00000000|RESULTS|tx|124|text|This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.
SE|00000000|RESULTS|tx|124|entity|C2603343|Study|resa|||study||||1000|6|10
SE|00000000|RESULTS|tx|124|entity|C0205420|Concurrent|tmco|||concurrent||||888|30|39
SE|00000000|RESULTS|tx|124|entity|C0039950|Thiosulfates|inch|||thiosulfate||||1000|59|69
SE|00000000|RESULTS|tx|124|entity|C0547044|Smaller|qlco|||least||||966|82|86
SE|00000000|RESULTS|tx|124|entity|C0442805|Increase|ftcn|||increase||||861|98|105
SE|00000000|RESULTS|tx|124|entity|C0178602|Dosage|qnco|||dose||||1000|110|113
SE|00000000|RESULTS|tx|124|entity|C0439810|Total|qlco|||total||||694|119|123
SE|00000000|RESULTS|tx|124|entity|C0008838|Cisplatin|inch,phsu|||cisplatin||||1000|137|145

SE|00000000|RESULTS|tx|125|text|Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension.
SE|00000000|RESULTS|tx|125|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|12|15
SE|00000000|RESULTS|tx|125|entity|C0027603|Neomycin|antb,carb|||neomycin||||888|33|40
SE|00000000|RESULTS|tx|125|entity|C1704787|Definitely Related to Intervention|qlco|||certain||||888|68|74
SE|00000000|RESULTS|tx|125|entity|C0332307|Type - attribute|qlco|||types||||888|76|80
SE|00000000|RESULTS|tx|125|entity|C2986474|Adrenocortical|qlco|||adrenocortical||||833|85|98
SE|00000000|RESULTS|tx|125|entity|C0038317|Steroids|strd|||steroid||||833|100|106
SE|00000000|RESULTS|tx|125|entity|C3244310|dependent|ftcn|||dependent||||833|108|116
SE|00000000|RESULTS|tx|125|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||833|118|129
SE|00000000|RESULTS|tx|125|entity|||gngm|5443|POMC|ACTH||||861|142|145
SE|00000000|RESULTS|tx|125|entity|C0020538|Hypertensive disease|dsyn|||hypertension||||861|147|158

SE|00000000|RESULTS|tx|126|text|Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
SE|00000000|RESULTS|tx|126|entity|C2827666|Variability|cnce|||variability||||827|40|50
SE|00000000|RESULTS|tx|126|entity|C0439792|Extent|spco|||extent||||1000|59|64
SE|00000000|RESULTS|tx|126|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||851|73|81
SE|00000000|RESULTS|tx|126|entity|C0012373|Diltiazem|orch,phsu|||diltiazem||||851|83|91
SE|00000000|RESULTS|tx|126|entity|C1704675|Interaction|ftcn|||interaction||||851|93|103
SE|00000000|RESULTS|tx|126|entity|C0444667|Whole|qnco|||whole||||861|106|110
SE|00000000|RESULTS|tx|126|entity|C0072980|Sirolimus|antb,orch|||sirolimus||||861|118|126
SE|00000000|RESULTS|tx|126|entity|C1313904|Blood concentration test|lbpr|||blood sirolimus concentrations||||861|112|141
SE|00000000|RESULTS|tx|126|entity|C0030705|Patients|podg|||patients||||1000|174|181
SE|00000000|RESULTS|tx|126|entity|C0205448|Two|qnco|||two||||888|200|202
SE|00000000|RESULTS|tx|126|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs||||888|204|208
SE|00000000|RESULTS|tx|126|relation|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs||||888|204|208|VERB|TREATS||183|189|5|1|C0030705|Patients|podg,humn|podg|||patients||||1000|174|181

SE|00000000|RESULTS|tx|127|text|Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
SE|00000000|RESULTS|tx|127|entity|C0439181|% suppression|qnco|||Suppression||||1000|1|11
SE|00000000|RESULTS|tx|127|entity|C0042523|Verapamil|orch,phsu|||verapamil||||1000|16|24
SE|00000000|RESULTS|tx|127|entity|C0005919|Bombesin|aapp,horm,nsba|||bombesin||||833|29|36
SE|00000000|RESULTS|tx|127|entity|C2349975|Enhance (action)|acty|||enhanced||||833|38|45
SE|00000000|RESULTS|tx|127|entity|C0442034|peritoneal|blor|||peritoneal||||833|47|56
SE|00000000|RESULTS|tx|127|entity|C2939420|Metastatic Neoplasm|neop|||metastasis||||833|58|67
SE|00000000|RESULTS|tx|127|entity|C0948209|intestinal adenocarcinoma|neop|||intestinal adenocarcinomas||||983|72|97
SE|00000000|RESULTS|tx|127|entity|C0004519|Azoxymethane|hops,orch|||azoxymethane||||1000|110|121
SE|00000000|RESULTS|tx|127|entity|C0034716|Rats, Wistar|mamm|||wistar rats||||1000|126|136
SE|00000000|RESULTS|tx|127|relation|5|1|C0042523|Verapamil|orch,phsu|orch|||verapamil||||1000|16|24|NOM|DISRUPTS||1|11|5|2|C2939420|Metastatic Neoplasm|neop|neop|||metastasis||||833|58|67
SE|00000000|RESULTS|tx|127|relation|2|1|C0004519|Azoxymethane|hops,orch|hops|||azoxymethane||||1000|110|121|VERB|CAUSES||99|105|4|1|C0948209|intestinal adenocarcinoma|neop|neop|||intestinal adenocarcinomas||||983|72|97
SE|00000000|RESULTS|tx|127|relation|5|3|C2939420|Metastatic Neoplasm|neop|neop|||metastasis||||833|58|67|PREP|PROCESS_OF||123|124|1|1|C0034716|Rats, Wistar|mamm|mamm|||wistar rats||||1000|126|136

SE|00000000|RESULTS|tx|128|text|Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.
SE|00000000|RESULTS|tx|128|entity|C0008318|Cholecalciferol|phsu,strd,vita|||Vitamin D3||||901|1|10
SE|00000000|RESULTS|tx|128|entity|C0035579|Rickets|dsyn|||rachitic||||638|30|37
SE|00000000|RESULTS|tx|128|entity|C1704419|Effective|qlco|||effective||||1000|50|58
SE|00000000|RESULTS|tx|128|entity|C0013303|Duodenum|bpoc|||duodenal||||623|87|94
SE|00000000|RESULTS|tx|128|entity|C0104238|arsenate|inch|||arsenate||||623|96|103
SE|00000000|RESULTS|tx|128|entity|C0521344|Serosal|blor|||serosal||||694|145|151

SE|00000000|RESULTS|tx|129|text|These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
SE|00000000|RESULTS|tx|129|entity|C1515926|Alteration|idcn|||alterations||||966|7|17
SE|00000000|RESULTS|tx|129|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||888|22|28
SE|00000000|RESULTS|tx|129|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||888|30|45
SE|00000000|RESULTS|tx|129|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||1000|59|68
SE|00000000|RESULTS|tx|129|entity|C0442805|Increase|ftcn|||increase||||1000|82|89
SE|00000000|RESULTS|tx|129|entity|C1306421|Serum digoxin measurement|lbpr|||serum digoxin level||||1000|94|112
SE|00000000|RESULTS|tx|129|entity|C0013162|Drug Combinations|phsu|||drug combination||||1000|147|162
SE|00000000|RESULTS|tx|129|relation|5|5|C0013162|Drug Combinations|phsu|phsu|||drug combination||||1000|147|162|NOM|INTERACTS_WITH||7|17|5|1|C0012265|Digoxin|carb,phsu,strd|carb|||digoxin||||888|22|28

SE|00000000|RESULTS|tx|130|text|At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for atracurium plus gentamycin.
SE|00000000|RESULTS|tx|130|entity|C0019908|Hoof|bpoc|||hoof||||694|26|29
SE|00000000|RESULTS|tx|130|entity|C0004234|Atracurium|orch,phsu|||atracurium||||1000|56|65
SE|00000000|RESULTS|tx|130|entity|C0205171|Singular|qnco|||alone||||1000|67|71
SE|00000000|RESULTS|tx|130|entity|C0004234|Atracurium|orch,phsu|||atracurium||||802|91|100
SE|00000000|RESULTS|tx|130|entity|C0017436|Gentamicins|antb,carb|||gentamycin||||802|107|116

SE|00000000|RESULTS|tx|131|text|Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
SE|00000000|RESULTS|tx|131|entity|C0205420|Concurrent|tmco|||Concurrent||||888|1|10
SE|00000000|RESULTS|tx|131|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|30|38
SE|00000000|RESULTS|tx|131|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||861|44|53
SE|00000000|RESULTS|tx|131|entity|C2946261|Level|phsu|||level||||1000|81|85
SE|00000000|RESULTS|tx|131|entity|C0376637|Indinavir|orch,phsu|||indinavir||||1000|102|110
SE|00000000|RESULTS|tx|131|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||851|146|155
SE|00000000|RESULTS|tx|131|entity|C0376637|Indinavir|orch,phsu|||indinavir||||851|172|180
SE|00000000|RESULTS|tx|131|relation|3|1|C0012133|Didanosine|nnon,phsu|phsu|||didanosine||||861|44|53|VERB|INHIBITS||69|75|4|1|C2946261|Level|phsu|phsu|||level||||1000|81|85
SE|00000000|RESULTS|tx|131|relation|3|1|C0376637|Indinavir|orch,phsu|phsu|||indinavir||||1000|30|38|VERB|INHIBITS||69|75|4|1|C2946261|Level|phsu|phsu|||level||||1000|81|85

SE|00000000|RESULTS|tx|132|text|During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01).
SE|00000000|RESULTS|tx|132|entity|C0002598|Amiodarone|orch,phsu|||amiodarone||||888|8|17
SE|00000000|RESULTS|tx|132|entity|C0205373|Systemic|ftcn|||systemic||||888|35|42
SE|00000000|RESULTS|tx|132|entity|C0449297|Clearance|qlco|||clearance||||888|44|52
SE|00000000|RESULTS|tx|132|entity|C0012265|Digoxin|carb,phsu,strd|||digoxin||||1000|57|63
SE|00000000|RESULTS|tx|132|entity|C0439445|mL/min|qnco|||ml/min (||||769|93|100
SE|00000000|RESULTS|tx|132|entity|C0205419|Variant|qlco|||deviation||||769|119|127
SE|00000000|RESULTS|tx|132|entity|C0439445|mL/min|qnco|||ml/min (||||595|144|151

SE|00000000|RESULTS|tx|133|text|It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment.
SE|00000000|RESULTS|tx|133|entity|C0000097|1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine|hops,orch|||MPTP||||1000|22|25
SE|00000000|RESULTS|tx|133|entity|C0205166|Long|qlco|||long||||802|35|38
SE|00000000|RESULTS|tx|133|entity|C0333668|Depletion|ftcn|||depletions||||802|48|57
SE|00000000|RESULTS|tx|133|entity|C1269581|Entire corpus striatum|bpoc|||striatal||||828|62|69
SE|00000000|RESULTS|tx|133|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||828|71|78
SE|00000000|RESULTS|tx|133|entity|C0086045|Mental concentration|menp|||concentrations||||828|80|93
SE|00000000|RESULTS|tx|133|entity|C0235032|Neurotoxicity Syndromes|inpo|||neurotoxic effect||||1000|104|120
SE|00000000|RESULTS|tx|133|entity|C0030557|Pargyline|orch,phsu|||pargyline||||888|144|152
SE|00000000|RESULTS|tx|133|entity|C1550147|Pretreatment|sbst|||pretreatment||||888|154|165
SE|00000000|RESULTS|tx|133|relation|0|0|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine||||828|71|78|MOD/HEAD|PART_OF||62|78|0|0|C1269581|Entire corpus striatum|bpoc|bpoc|||striatal||||828|62|69

SE|00000000|RESULTS|tx|134|text|Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous opiate such as morphine.
SE|00000000|RESULTS|tx|134|entity|C0205156|Previous|tmco|||Previous||||888|1|8
SE|00000000|RESULTS|tx|134|entity|C0237881|Statistical Significance|qnco|||significant||||888|38|48
SE|00000000|RESULTS|tx|134|entity|C0392756|Reduced|qlco|||reduction||||888|50|58
SE|00000000|RESULTS|tx|134|entity|C0442027|Oral|spco|||oral||||888|67|70
SE|00000000|RESULTS|tx|134|entity|C1706947|Bioavailability Study|resa|||bioavailability||||888|72|86
SE|00000000|RESULTS|tx|134|entity|C0379881|trovafloxacin|antb,orch|||trovafloxacin||||1000|91|103
SE|00000000|RESULTS|tx|134|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin||||1000|109|121
SE|00000000|RESULTS|tx|134|entity|C0348016|Intravenous|spco|||intravenous||||888|163|173
SE|00000000|RESULTS|tx|134|entity|C0376196|Opiates|hops,phsu|||opiate||||888|175|180
SE|00000000|RESULTS|tx|134|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|190|197
SE|00000000|RESULTS|tx|134|relation|0|0|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|190|197|SPEC|ISA||175|197|0|0|C0376196|Opiates|hops,phsu|hops|||opiate||||888|175|180

SE|00000000|RESULTS|tx|135|text|Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
SE|00000000|RESULTS|tx|135|entity|C1704675|Interaction|ftcn|||Interaction||||1000|1|11
SE|00000000|RESULTS|tx|135|entity|C1280500|Effect|qlco|||effect||||861|36|41
SE|00000000|RESULTS|tx|135|entity|C0027930|Neurotensin|aapp,horm,nsba|||neurotensin||||1000|51|61
SE|00000000|RESULTS|tx|135|entity|C0014298|Enkephalins|aapp,nsba|||enkephalins||||1000|67|77
SE|00000000|RESULTS|tx|135|entity|C0041350|Tuftsin|aapp,imft|||tuftsin||||1000|82|88

SE|00000000|RESULTS|tx|136|text|Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. only ibogaine enhances cocaine-induced increases in accumbal dopamine.
SE|00000000|RESULTS|tx|136|entity|C0016365|Fluoxetine|orch,phsu|||fluoxetine||||744|21|30
SE|00000000|RESULTS|tx|136|entity|C0205216|Decreased|qnco|||decreased||||744|46|54
SE|00000000|RESULTS|tx|136|entity|C0072916|Cisapride|orch,phsu|||cisapride||||744|56|64
SE|00000000|RESULTS|tx|136|entity|C0683150|plasma drug concentration|qnco|||plasma concentrations||||744|66|86
SE|00000000|RESULTS|tx|136|entity|C0030705|Patients|podg|||patients||||1000|98|105
SE|00000000|RESULTS|tx|136|entity|C1881878|Moderation|qlco|||moderate||||1000|112|119
SE|00000000|RESULTS|tx|136|entity|C1515187|Take|hlca|||taking||||840|163|168
SE|00000000|RESULTS|tx|136|entity|C0028125|Nitrates|chvs|||nitrate||||840|170|176
SE|00000000|RESULTS|tx|136|entity|C0205217|Increased|qnco|||increased||||888|193|201
SE|00000000|RESULTS|tx|136|entity|C0035647|Risk|qlco|||risk||||888|203|206
SE|00000000|RESULTS|tx|136|entity|C0205404|Serious|qlco|||serious||||790|224|230
SE|00000000|RESULTS|tx|136|entity|C0879626|Adverse effects|patf|||adverse effects||||790|247|261
SE|00000000|RESULTS|tx|136|entity|C0529793|sildenafil|orch,phsu|||sildenafil||||775|268|277
SE|00000000|RESULTS|tx|136|entity|C0020737|Ibogaine|bacs,orch,phsu|||ibogaine||||775|293|300
SE|00000000|RESULTS|tx|136|entity|C0009170|Cocaine|hops,orch,phsu|||cocaine||||851|311|317
SE|00000000|RESULTS|tx|136|entity|C0205263|Induce (action)|ftcn|||induced||||851|319|325
SE|00000000|RESULTS|tx|136|entity|C0442805|Increase|ftcn|||increases||||851|327|335
SE|00000000|RESULTS|tx|136|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine||||861|349|356
SE|00000000|RESULTS|tx|136|relation|4|2|C0020737|Ibogaine|bacs,orch,phsu|bacs|||ibogaine||||775|293|300|NOM|PREDISPOSES||203|206|4|1|C0879626|Adverse effects|patf|patf|||adverse effects||||790|247|261

SE|00000000|RESULTS|tx|137|text|Enhanced theophylline clearance secondary to phenytoin therapy.
SE|00000000|RESULTS|tx|137|entity|C2349975|Enhance (action)|acty|||Enhanced||||851|1|8
SE|00000000|RESULTS|tx|137|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline||||851|10|21
SE|00000000|RESULTS|tx|137|entity|C0449297|Clearance|qlco|||clearance||||851|23|31
SE|00000000|RESULTS|tx|137|entity|C0205436|second (number)|qnco|||secondary||||1000|33|41
SE|00000000|RESULTS|tx|137|entity|C0031507|Phenytoin|orch,phsu|||phenytoin||||888|46|54

SE|00000000|RESULTS|tx|138|text|The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
SE|00000000|RESULTS|tx|138|entity|C1136254|Microbicides|phsu|||antimicrobial||||888|5|17
SE|00000000|RESULTS|tx|138|entity|C0453882|Combinations|mnob|||combinations||||888|19|30
SE|00000000|RESULTS|tx|138|entity|C0205450|Four|qnco|||four||||888|43|46
SE|00000000|RESULTS|tx|138|entity|C0003232|Antibiotics|antb|||antibiotics||||888|48|58
SE|00000000|RESULTS|tx|138|entity|C0442796|Additive|qlco|||additive||||888|72|79
SE|00000000|RESULTS|tx|138|entity|C1280500|Effect|qlco|||effect||||888|81|86
SE|00000000|RESULTS|tx|138|entity|C1550608|Instance|idcn|||instances||||966|96|104
SE|00000000|RESULTS|tx|138|entity|C0599739|synergism|moft|||synergism||||1000|107|115
SE|00000000|RESULTS|tx|138|entity|C0205448|Two|qnco|||two||||872|120|122
SE|00000000|RESULTS|tx|138|entity|C1550608|Instance|idcn|||instances||||872|124|132
SE|00000000|RESULTS|tx|138|entity|C0680242|antagonism|socb|||antagonism||||1000|139|148
SE|00000000|RESULTS|tx|138|entity|C0205448|Two|qnco|||two||||872|153|155
SE|00000000|RESULTS|tx|138|entity|C1550608|Instance|idcn|||instances||||872|157|165
SE|00000000|RESULTS|tx|138|relation|8|2|C0003232|Antibiotics|antb|antb|||antibiotics||||888|48|58|NOM|COEXISTS_WITH||19|30|0|0|C1136254|Microbicides|phsu|phsu|||antimicrobial||||888|5|17

SE|00000000|RESULTS|tx|139|text|In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present.
SE|00000000|RESULTS|tx|139|entity|C0699762|ewes|mamm|||ewes||||1000|4|7
SE|00000000|RESULTS|tx|139|entity|C0282303|Phenobarbital Sodium|orch,phsu|||phenobarbital sodium||||901|24|43
SE|00000000|RESULTS|tx|139|entity|C1442466|5 Days|tmco|||5 days||||901|52|57
SE|00000000|RESULTS|tx|139|entity|C0008425|Cholinesterase Inhibitors|orch,phsu|||anticholinesterase||||888|87|104
SE|00000000|RESULTS|tx|139|entity|C1280500|Effect|qlco|||effect||||888|106|111
SE|00000000|RESULTS|tx|139|entity|C0010203|Coumaphos|hops,opco,phsu|||coumaphos||||888|124|132
SE|00000000|RESULTS|tx|139|entity|C0220913|Manufactured sign|mnob|||signs||||1000|167|171
SE|00000000|RESULTS|tx|139|entity|C0600688|Toxic effect|inpo|||toxicity||||1000|176|183
SE|00000000|RESULTS|tx|139|entity|C1518422|Negation|ftcn|||not||||1000|190|192

SE|00000000|RESULTS|tx|140|text|This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
SE|00000000|RESULTS|tx|140|entity|C1280500|Effect|qlco|||effect||||1000|6|11
SE|00000000|RESULTS|tx|140|entity|C0085732|Ability|orga|||ability||||1000|36|42
SE|00000000|RESULTS|tx|140|entity|C0035608|Rifampin|antb,orch|||rifampin||||861|47|54
SE|00000000|RESULTS|tx|140|entity|C0815014|microsomal enzymes|aapp,enzy|||microsomal enzymes||||1000|66|83
SE|00000000|RESULTS|tx|140|entity|C0699900|Catabolism|orgf|||catabolism||||1000|100|109
SE|00000000|RESULTS|tx|140|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|114|121
SE|00000000|RESULTS|tx|140|relation|3|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||861|47|54|VERB|STIMULATES||59|64|3|1|C0815014|microsomal enzymes|aapp,gngm,enzy|gngm|||microsomal enzymes||||1000|66|83

SE|00000000|RESULTS|tx|141|text|Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for atracurium plus gentamycin (P = 0.03).
SE|00000000|RESULTS|tx|141|entity|C0019908|Hoof|bpoc|||hoof||||694|13|16
SE|00000000|RESULTS|tx|141|entity|C0702093|/minute|tmco|||min||||804|58|60
SE|00000000|RESULTS|tx|141|entity|C0004234|Atracurium|orch,phsu|||atracurium||||1000|66|75
SE|00000000|RESULTS|tx|141|entity|C0205171|Singular|qnco|||alone||||1000|77|81
SE|00000000|RESULTS|tx|141|entity|C0702093|/minute|tmco|||min||||804|100|102
SE|00000000|RESULTS|tx|141|entity|C0004234|Atracurium|orch,phsu|||atracurium||||802|108|117
SE|00000000|RESULTS|tx|141|entity|C0017436|Gentamicins|antb,carb|||gentamycin||||802|124|133

SE|00000000|RESULTS|tx|142|text|Withdrawal of rifampin decreased the warfarin requirement by 50%.
SE|00000000|RESULTS|tx|142|entity|C2349954|Withdraw (activity)|acty|||Withdrawal||||1000|1|10
SE|00000000|RESULTS|tx|142|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|15|22
SE|00000000|RESULTS|tx|142|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||888|38|45
SE|00000000|RESULTS|tx|142|entity|C1514873|Requirement|ftcn|||requirement||||888|47|57
SE|00000000|RESULTS|tx|142|relation|2|1|C0035608|Rifampin|antb,orch|antb|||rifampin||||1000|15|22|VERB|INHIBITS||24|32|1|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||888|38|45

SE|00000000|RESULTS|tx|143|text|Interactions of cobalt and iron in absorption and retention.
SE|00000000|RESULTS|tx|143|entity|C1704675|Interaction|ftcn|||Interactions||||966|1|12
SE|00000000|RESULTS|tx|143|entity|C0009148|Cobalt|elii|||cobalt||||1000|17|22
SE|00000000|RESULTS|tx|143|entity|C0302583|Iron|bacs,elii,phsu|||iron||||1000|28|31

SE|00000000|RESULTS|tx|144|text|The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
SE|00000000|RESULTS|tx|144|entity|C1521828|Rate|qnco|||rate||||861|11|14
SE|00000000|RESULTS|tx|144|entity|C0441833|Groups|idcn|||groups||||1000|37|42
SE|00000000|RESULTS|tx|144|entity|C0012155|Diet|food|||diet||||888|94|97
SE|00000000|RESULTS|tx|144|entity|C0205216|Decreased|qnco|||decreased||||851|113|121
SE|00000000|RESULTS|tx|144|entity|C0022646|Kidney|bpoc|||renal||||851|123|127
SE|00000000|RESULTS|tx|144|entity|C0221102|Excretory function|phsf|||excretion||||851|129|137
SE|00000000|RESULTS|tx|144|entity|C0009148|Cobalt|elii|||cobalt||||1000|142|147

SE|00000000|RESULTS|tx|145|text|Combined treatment with 1,25(OH)2D3 and TAM enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation.
SE|00000000|RESULTS|tx|145|entity|C0009429|Combined Modality Therapy|topp|||Combined treatment||||1000|1|18
SE|00000000|RESULTS|tx|145|entity|C0039286|Tamoxifen|orch,phsu|||TAM||||1000|41|43
SE|00000000|RESULTS|tx|145|entity|C0441889|Levels (qualifier value)|qlco|||degree||||1000|58|63
SE|00000000|RESULTS|tx|145|entity|C0162638|Apoptosis|celf|||apoptosis||||1000|68|76
SE|00000000|RESULTS|tx|145|entity|C0543482|morphological|spco|||morphological||||872|93|105
SE|00000000|RESULTS|tx|145|entity|C0005516|Biological Markers|clna|||markers||||872|107|113
SE|00000000|RESULTS|tx|145|entity|C0008546|Chromatin|aapp|||chromatin||||1000|129|137
SE|00000000|RESULTS|tx|145|entity|C0133195|Nuclear Matrix-Associated Proteins|aapp,bacs|||nuclear matrix protein||||756|143|164

SE|00000000|RESULTS|tx|146|text|Misonidazole has a complex effect on oral CCNU pharmacokinetics.
SE|00000000|RESULTS|tx|146|entity|C0026218|Misonidazole|orch,phsu|||Misonidazole||||1000|1|12
SE|00000000|RESULTS|tx|146|entity|C0439855|Complex|qlco|||complex||||888|20|26
SE|00000000|RESULTS|tx|146|entity|C1280500|Effect|qlco|||effect||||888|28|33
SE|00000000|RESULTS|tx|146|entity|C0442027|Oral|spco|||oral||||851|38|41
SE|00000000|RESULTS|tx|146|entity|C0687700|CCNU|orch,phsu|||CCNU||||851|43|46
SE|00000000|RESULTS|tx|146|entity|C0031328|Pharmacokinetic aspects|ftcn|||pharmacokinetics||||851|48|63
SE|00000000|RESULTS|tx|146|relation|1|1|C0026218|Misonidazole|orch,phsu|orch|||Misonidazole||||1000|1|12|NOM|INTERACTS_WITH||28|33|1|1|C0687700|CCNU|orch,phsu|orch|||CCNU||||851|43|46

SE|00000000|RESULTS|tx|147|text|Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine.
SE|00000000|RESULTS|tx|147|entity|C0683162|dose-response curve|qnco|||Dose-response curves||||966|1|20
SE|00000000|RESULTS|tx|147|entity|C1274040|Result|ftcn|||results||||1000|40|46
SE|00000000|RESULTS|tx|147|entity|C0039225|Tablet Dosage Form|bodm|||tablets||||1000|61|67
SE|00000000|RESULTS|tx|147|entity|C2247561|5-(carboxyamino)imidazole ribonucleotide mutase activity|moft|||pure||||888|80|83
SE|00000000|RESULTS|tx|147|entity|C0032861|Powder dose form|bodm|||powders||||888|85|91
SE|00000000|RESULTS|tx|147|entity|C0041090|Tripelennamine|orch,phsu|||tripelennamine||||1000|106|119
SE|00000000|RESULTS|tx|147|entity|C0021469|Metabolic Inhibition|moft|||inhibitory||||888|145|154
SE|00000000|RESULTS|tx|147|entity|C0439167|Percent Activity|qnco|||activity||||888|156|163
SE|00000000|RESULTS|tx|147|entity|C0030873|Pentazocine|orch,phsu|||pentazocine||||1000|201|211
SE|00000000|RESULTS|tx|147|relation|5|1|C0041090|Tripelennamine|orch,phsu|phsu|||tripelennamine||||1000|106|119|ADJ|AFFECTS||125|135|2|1|C0021469|Metabolic Inhibition|moft|moft|||inhibitory||||888|145|154
SE|00000000|RESULTS|tx|147|relation|1|1|C0030873|Pentazocine|orch,phsu|phsu|||pentazocine||||1000|201|211|VERB|DISRUPTS||186|196|7|1|C0021469|Metabolic Inhibition|moft|moft|||inhibitory||||888|145|154

SE|00000000|RESULTS|tx|148|text|In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone;
SE|00000000|RESULTS|tx|148|entity|C0026447|Monkeys|mamm|||monkeys||||1000|4|10
SE|00000000|RESULTS|tx|148|entity|C1280500|Effect|qlco|||effects||||1000|17|23
SE|00000000|RESULTS|tx|148|entity|C1518422|Negation|ftcn|||not||||1000|42|44
SE|00000000|RESULTS|tx|148|entity|||gngm|649,5547,54858|BMP1,PRCP,PGPEP1|PCP||||1000|58|60
SE|00000000|RESULTS|tx|148|entity|C0027358|Naloxone|orch,phsu|||naloxone||||1000|83|90

SE|00000000|RESULTS|tx|149|text|Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
SE|00000000|RESULTS|tx|149|entity|C0026218|Misonidazole|orch,phsu|||Misonidazole||||1000|1|12
SE|00000000|RESULTS|tx|149|entity|C2986475|Antitumor|qlco|||antitumour||||888|26|35
SE|00000000|RESULTS|tx|149|entity|C0439167|Percent Activity|qnco|||activity||||888|37|44
SE|00000000|RESULTS|tx|149|entity|C0442027|Oral|spco|||oral||||888|49|52
SE|00000000|RESULTS|tx|149|entity|C0687700|CCNU|orch,phsu|||CCNU||||888|54|57
SE|00000000|RESULTS|tx|149|entity|C0178602|Dosage|qnco|||dose||||829|62|65
SE|00000000|RESULTS|tx|149|entity|C0392747|Changing|ftcn|||modifying||||829|67|75
SE|00000000|RESULTS|tx|149|entity|C1521761|Factor|ftcn|||factors||||829|77|83
SE|00000000|RESULTS|tx|149|relation|1|1|C0026218|Misonidazole|orch,phsu|orch|||Misonidazole||||1000|1|12|VERB|INHIBITS||14|20|3|2|C0687700|CCNU|orch,phsu|orch|||CCNU||||888|54|57

SE|00000000|RESULTS|tx|150|text|Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.
SE|00000000|RESULTS|tx|150|entity|C0026056|Midazolam|orch,phsu|||Midazolam||||1000|1|9
SE|00000000|RESULTS|tx|150|entity|C0178602|Dosage|qnco|||doses||||1000|19|23
SE|00000000|RESULTS|tx|150|entity|C0439272|ug/g|qnco|||mg/kg||||824|33|37
SE|00000000|RESULTS|tx|150|entity|C0450346|2/5|qnco|||2.5||||888|43|45
SE|00000000|RESULTS|tx|150|entity|C0439272|ug/g|qnco|||mg/kg||||888|47|51
SE|00000000|RESULTS|tx|150|entity|C1280500|Effect|qlco|||effect||||861|83|88
SE|00000000|RESULTS|tx|150|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|93|100
SE|00000000|RESULTS|tx|150|entity|C0012586|Dipyrone|orch,phsu|||metamizol||||1000|103|111
SE|00000000|RESULTS|tx|150|entity|C0205171|Singular|qnco|||only||||1000|114|117
SE|00000000|RESULTS|tx|150|entity|C0039259|Tail|bpoc|||tail-||||802|126|130
SE|00000000|RESULTS|tx|150|entity|C0022885|Laboratory Procedures|lbpr|||test||||802|137|140
SE|00000000|RESULTS|tx|150|entity|C0021246|Indomethacin|orch,phsu|||indomethacin||||1000|147|158
SE|00000000|RESULTS|tx|150|relation|4|2|C0012586|Dipyrone|orch,phsu|orch|||metamizol||||1000|103|111|NOM|INTERACTS_WITH||83|88|4|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|93|100

SE|00000000|RESULTS|tx|151|text|Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure.
SE|00000000|RESULTS|tx|151|entity|C0529793|sildenafil|orch,phsu|||Sildenafil||||1000|1|10
SE|00000000|RESULTS|tx|151|entity|C0030705|Patients|podg|||patients||||1000|34|41
SE|00000000|RESULTS|tx|151|entity|C0205166|Long|qlco|||long-||||802|49|53
SE|00000000|RESULTS|tx|151|entity|C0028125|Nitrates|chvs|||nitrates||||802|61|68
SE|00000000|RESULTS|tx|151|entity|C1282927|Shortened|qlco|||short||||802|93|97
SE|00000000|RESULTS|tx|151|entity|C0028125|Nitrates|chvs|||nitrates||||802|106|113
SE|00000000|RESULTS|tx|151|entity|C0205195|Combined|qlco|||combination||||1000|128|138
SE|00000000|RESULTS|tx|151|entity|C1539835|SPEN gene|gngm|23013|SPEN|sharp||||888|152|156
SE|00000000|RESULTS|tx|151|entity|C0238715|Autumn|tmco|||fall||||888|158|161
SE|00000000|RESULTS|tx|151|entity|C0005823|Blood Pressure|orgf|||blood pressure||||1000|170|183
SE|00000000|RESULTS|tx|151|relation|1|1|C0529793|sildenafil|orch,phsu|phsu|||Sildenafil||||1000|1|10|PREP|TREATS||31|32|6|1|C0030705|Patients|podg,humn|podg|||patients||||1000|34|41

SE|00000000|RESULTS|tx|152|text|[The GABA-ergic system and brain edema]&#xd;&#xa;It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine.
SE|00000000|RESULTS|tx|152|entity|C0016904|gamma-Aminobutyric Acid|aapp,nsba|||GABA-||||851|6|10
SE|00000000|RESULTS|tx|152|entity|C1166849|ER-Golgi intermediate compartment|celc|||ergic||||851|11|15
SE|00000000|RESULTS|tx|152|entity|C0449913|System|ftcn|||system||||851|17|22
SE|00000000|RESULTS|tx|152|entity|C1527311|Brain Edema|dsyn|||brain edema||||1000|28|38
SE|00000000|RESULTS|tx|153|entity|C0034693|Rattus norvegicus|mamm|||rats||||1000|22|25
SE|00000000|RESULTS|tx|153|entity|C1517586|Investigational|qlco|||experimental||||888|32|43
SE|00000000|RESULTS|tx|153|entity|C1407029|Toxic|qlco|||toxic||||888|45|49
SE|00000000|RESULTS|tx|153|entity|C0332663|Traumatic|ftcn|||traumatic||||888|55|63
SE|00000000|RESULTS|tx|153|entity|C0013604|Edema|patf|||edemas||||888|65|70
SE|00000000|RESULTS|tx|153|entity|C0031890|Picrotoxin|hops,orch,phsu|||picrotoxin||||1000|77|86
SE|00000000|RESULTS|tx|153|entity|C0439272|ug/g|qnco|||mg/kg||||901|91|95
SE|00000000|RESULTS|tx|153|entity|C3266814|Action|acty|||action||||861|124|129
SE|00000000|RESULTS|tx|153|entity|C0012010|Diazepam|orch,phsu|||diazepam||||1000|134|141
SE|00000000|RESULTS|tx|153|entity|C0070543|phenazepam|orch,phsu|||phenazepam||||1000|144|153
SE|00000000|RESULTS|tx|153|entity|C0048007|4-amino-3-phenylbutyric acid|orch,phsu|||phenibut||||1000|156|163
SE|00000000|RESULTS|tx|153|entity|C0002605|Amizyl|orch,phsu|||amizyl||||1000|169|174
SE|00000000|RESULTS|tx|153|entity|C3266814|Action|acty|||action||||1000|192|197
SE|00000000|RESULTS|tx|153|entity|C0031448|Phentolamine|orch,phsu|||phentolamine||||1000|202|213

SE|00000000|RESULTS|tx|154|text|We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole.
SE|00000000|RESULTS|tx|154|entity|C0443172|Changed status|qnco|||changes||||827|34|40
SE|00000000|RESULTS|tx|154|entity|C0392756|Reduced|qlco|||reduction||||1000|81|89
SE|00000000|RESULTS|tx|154|entity|C0442027|Oral|spco|||oral||||851|94|97
SE|00000000|RESULTS|tx|154|entity|C0687700|CCNU|orch,phsu|||CCNU||||851|99|102
SE|00000000|RESULTS|tx|154|entity|C0596402|cytotoxicity|comd|||cytotoxicity||||851|104|115
SE|00000000|RESULTS|tx|154|entity|C0026218|Misonidazole|orch,phsu|||misonidazole||||1000|120|131
SE|00000000|RESULTS|tx|154|relation|2|2|C0026218|Misonidazole|orch,phsu|phsu|||misonidazole||||1000|120|131|NOM|PREVENTS||81|89|2|1|C0596402|cytotoxicity|comd|comd|||cytotoxicity||||851|104|115

SE|00000000|RESULTS|tx|155|text|However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im.
SE|00000000|RESULTS|tx|155|entity|C0018549|Halothane|orch,phsu|||halothane||||851|10|18
SE|00000000|RESULTS|tx|155|entity|C0002932|Anesthetics|phsu|||anesthetic||||851|20|29
SE|00000000|RESULTS|tx|155|entity|C1514873|Requirement|ftcn|||requirement||||851|31|41
SE|00000000|RESULTS|tx|155|entity|C0599662|magnetic cell separation system|lbpr|||MAC)||||966|50|53
SE|00000000|RESULTS|tx|155|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||734|74|87
SE|00000000|RESULTS|tx|155|entity|C0205172|More|ftcn|||much||||966|100|103
SE|00000000|RESULTS|tx|155|entity|C0439227|Hour|tmco|||hours||||812|116|120
SE|00000000|RESULTS|tx|155|entity|C0205172|More|ftcn|||much||||966|129|132
SE|00000000|RESULTS|tx|155|entity|C0439227|Hour|tmco|||hours||||812|145|149
SE|00000000|RESULTS|tx|155|entity|C1533685|Injection procedure|topp|||injection||||1000|157|165
SE|00000000|RESULTS|tx|155|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|170|177
SE|00000000|RESULTS|tx|155|entity|C0439272|ug/g|qnco|||mg/kg||||901|183|187
SE|00000000|RESULTS|tx|155|relation|0|0|C0018549|Halothane|orch,phsu|orch|||halothane||||851|10|18|MOD/HEAD|ISA||10|29|0|0|C0002932|Anesthetics|phsu|phsu|||anesthetic||||851|20|29

SE|00000000|RESULTS|tx|156|text|Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated.
SE|00000000|RESULTS|tx|156|entity|C0035608|Rifampin|antb,orch|||Rifampin||||888|1|8
SE|00000000|RESULTS|tx|156|entity|C0522501|Massive|qlco|||markedly||||888|10|17
SE|00000000|RESULTS|tx|156|entity|C2707259|Metabolic:-:Point in time:^Patient:-|clna|||metabolic||||888|33|41
SE|00000000|RESULTS|tx|156|entity|C0449297|Clearance|qlco|||clearance||||888|43|51
SE|00000000|RESULTS|tx|156|entity|C0754188|Amprenavir|orch,phsu|||amprenavir||||1000|56|65
SE|00000000|RESULTS|tx|156|relation|1|1|C0035608|Rifampin|antb,orch|antb|||Rifampin||||888|1|8|VERB|STIMULATES||19|27|3|2|C0754188|Amprenavir|orch,phsu|orch|||amprenavir||||1000|56|65

SE|00000000|RESULTS|tx|157|text|Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital. the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine.
SE|00000000|RESULTS|tx|157|entity|C0042514|Tachycardia, Ventricular|patf|||Ventricular tachycardia||||1000|1|23
SE|00000000|RESULTS|tx|157|entity|C0029904|Ouabain|carb,phsu,strd|||ouabain||||1000|36|42
SE|00000000|RESULTS|tx|157|entity|C0232201|Sinus rhythm|fndg|||sinus rhythm||||1000|71|82
SE|00000000|RESULTS|tx|157|entity|C0063549|Innovar|orch,phsu|||Innovar||||1000|112|118
SE|00000000|RESULTS|tx|157|entity|C0022614|Ketamine|orch,phsu|||ketamine||||1000|121|128
SE|00000000|RESULTS|tx|157|entity|C0013136|Droperidol|orch,phsu|||droperidol||||1000|134|143
SE|00000000|RESULTS|tx|157|entity|C1518422|Negation|ftcn|||not||||1000|149|151
SE|00000000|RESULTS|tx|157|entity|C0205171|Singular|qnco|||alone||||1000|185|189
SE|00000000|RESULTS|tx|157|entity|C0030883|Pentobarbital|orch,phsu|||pentobarbital||||1000|200|212
SE|00000000|RESULTS|tx|157|entity|C0178602|Dosage|qnco|||doses||||1000|219|223
SE|00000000|RESULTS|tx|157|entity|C0027358|Naloxone|orch,phsu|||naloxone||||1000|228|235
SE|00000000|RESULTS|tx|157|entity|C1280500|Effect|qlco|||effects||||1000|264|270
SE|00000000|RESULTS|tx|157|entity|C0205172|More|ftcn|||more||||1000|289|292
SE|00000000|RESULTS|tx|157|entity|C1632851|Times|qnco|||times||||861|303|307
SE|00000000|RESULTS|tx|157|entity|C0205250|High|qlco|||higher||||966|309|314
SE|00000000|RESULTS|tx|157|entity|C1280500|Effect|qlco|||effects||||1000|354|360
SE|00000000|RESULTS|tx|157|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|365|372
SE|00000000|RESULTS|tx|157|relation|18|1|C0029904|Ouabain|carb,phsu,strd|carb|||ouabain||||1000|36|42|VERB|CAUSES||25|31|1|1|C0042514|Tachycardia, Ventricular|patf|patf|||Ventricular tachycardia||||1000|1|23
SE|00000000|RESULTS|tx|157|relation|17|5|C0027358|Naloxone|orch,phsu|orch|||naloxone||||1000|228|235|NOM|INTERACTS_WITH||354|360|1|1|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|365|372

SE|00000000|RESULTS|tx|158|text|Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously.
SE|00000000|RESULTS|tx|158|entity|C0058926|echistatin|aapp,phsu|||Echistatin||||1000|1|10
SE|00000000|RESULTS|tx|158|entity|C0205171|Singular|qnco|||alone||||1000|12|16
SE|00000000|RESULTS|tx|158|entity|C1280500|Effect|qlco|||effect||||1000|25|30
SE|00000000|RESULTS|tx|158|entity|C1519726|Tyrosine Phosphorylation|moft|||tyrosine phosphorylation||||1000|35|58
SE|00000000|RESULTS|tx|158|entity|C0007634|Cells|cell|||cells||||861|67|71
SE|00000000|RESULTS|tx|158|entity|C0178602|Dosage|qnco|||dose-||||861|78|82
SE|00000000|RESULTS|tx|158|entity|C1280500|Effect|qlco|||effects||||1000|108|114
SE|00000000|RESULTS|tx|158|entity|C0911731|contortrostatin|aapp|||contortrostatin||||1000|119|133
SE|00000000|RESULTS|tx|158|entity|C0521115|Simultaneous|tmco|||simultaneously||||1000|155|168
SE|00000000|RESULTS|tx|158|relation|2|2|C0058926|echistatin|aapp,gngm,phsu|aapp|||Echistatin||||1000|1|10|NOM|AFFECTS|negation|25|30|4|1|C1519726|Tyrosine Phosphorylation|moft|moft|||tyrosine phosphorylation||||1000|35|58

SE|00000000|RESULTS|tx|159|text|Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
SE|00000000|RESULTS|tx|159|entity|C0376637|Indinavir|orch,phsu|||Indinavir||||1000|1|9
SE|00000000|RESULTS|tx|159|entity|C0012133|Didanosine|nnon,phsu|||didanosine||||1000|88|97

SE|00000000|RESULTS|tx|160|text|The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day.
SE|00000000|RESULTS|tx|160|entity|C0087111|Therapeutic procedure|topp|||treatment||||1000|5|13
SE|00000000|RESULTS|tx|160|entity|C0699762|ewes|mamm|||ewes||||1000|18|21
SE|00000000|RESULTS|tx|160|entity|C0021494|Intravenous Injections|ftcn|||intravenous (IV) injection||||1000|31|56
SE|00000000|RESULTS|tx|160|entity|C0040898|Trichlorfon|hops,opco|||trichlorfon||||1000|61|71
SE|00000000|RESULTS|tx|160|entity|C0205412|Inadequate (qualifier)|qlco|||insufficient||||861|74|85
SE|00000000|RESULTS|tx|160|entity|C0237881|Statistical Significance|qnco|||significant||||888|98|108
SE|00000000|RESULTS|tx|160|entity|C1628982|Percent inhibition|qnco|||inhibition||||888|110|119
SE|00000000|RESULTS|tx|160|entity|C0014792|Erythrocytes|cell|||erythrocyte||||901|124|134
SE|00000000|RESULTS|tx|160|entity|C1149827|acetylcholinesterase activity|moft|||acetylcholinesterase (AChE) activity||||901|136|171
SE|00000000|RESULTS|tx|160|entity|C0442796|Additive|qlco|||additive||||888|194|201
SE|00000000|RESULTS|tx|160|entity|C1280500|Effect|qlco|||effects||||888|203|209
SE|00000000|RESULTS|tx|160|entity|C0332282|Following|tmco|||subsequent||||888|234|243
SE|00000000|RESULTS|tx|160|entity|C0010203|Coumaphos|hops,opco,phsu|||coumaphos||||901|268|276
SE|00000000|RESULTS|tx|160|entity|C0439418|kg/day|qnco|||kg/day||||901|278|283
SE|00000000|RESULTS|tx|160|relation|4|1|C0040898|Trichlorfon|hops,opco|hops|||trichlorfon||||1000|61|71|NOM|DISRUPTS||110|119|5|1|C1149827|acetylcholinesterase activity|moft|moft|||acetylcholinesterase (AChE) activity||||901|136|171

SE|00000000|RESULTS|tx|161|text|Exogenous estradiol also appeared to influence the percentage of endotoxin-induced deaths in a dose-dependent manner.
SE|00000000|RESULTS|tx|161|entity|C0205228|Exogenous|ftcn|||Exogenous||||790|1|9
SE|00000000|RESULTS|tx|161|entity|C0014912|Estradiol|horm,phsu,strd|||estradiol||||790|11|19
SE|00000000|RESULTS|tx|161|entity|C0439165|Percent (qualifier value)|qnco|||percentage||||1000|52|61
SE|00000000|RESULTS|tx|161|entity|C0014264|Endotoxins|carb,hops,lipd|||endotoxin||||851|66|74
SE|00000000|RESULTS|tx|161|entity|C0205263|Induce (action)|ftcn|||induced||||851|76|82
SE|00000000|RESULTS|tx|161|entity|C0011065|Cessation of life|orgf|||deaths||||851|84|89
SE|00000000|RESULTS|tx|161|entity|C1512045|Dose-dependent|qnco|||dose-dependent||||734|96|109

SE|00000000|RESULTS|tx|162|text|Loperamide and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats.
SE|00000000|RESULTS|tx|162|entity|C0023992|Loperamide|orch,phsu|||Loperamide||||1000|1|10
SE|00000000|RESULTS|tx|162|entity|C0026549|Morphine|orch,phsu|||morphine||||1000|16|23
SE|00000000|RESULTS|tx|162|entity|C0439272|ug/g|qnco|||mg/kg||||824|38|42
SE|00000000|RESULTS|tx|162|entity|C0565930|per second|qnco|||s.c||||861|45|47
SE|00000000|RESULTS|tx|162|entity|C2827527|16,16-Dimethyl Prostaglandin E2|orch,phsu|||dmPGE2||||1000|65|70
SE|00000000|RESULTS|tx|162|entity|C0439272|ug/g|qnco|||mg/kg||||861|77|81
SE|00000000|RESULTS|tx|162|entity|C2603361|P prime|clna|||p.o.||||775|84|87
SE|00000000|RESULTS|tx|162|entity|C0205263|Induce (action)|ftcn|||induced||||775|90|96
SE|00000000|RESULTS|tx|162|entity|C0011991|Diarrhea|sosy|||diarrhea||||775|98|105
SE|00000000|RESULTS|tx|162|entity|C0034693|Rattus norvegicus|mamm|||rats||||861|123|126
SE|00000000|RESULTS|tx|162|relation|4|3|C0026549|Morphine|orch,phsu|orch|||morphine||||1000|16|23|VERB|INHIBITS||51|59|4|1|C2827527|16,16-Dimethyl Prostaglandin E2|orch,phsu|orch|||dmPGE2||||1000|65|70
SE|00000000|RESULTS|tx|162|relation|4|3|C0023992|Loperamide|orch,phsu|orch|||Loperamide||||1000|1|10|VERB|INHIBITS||51|59|4|1|C2827527|16,16-Dimethyl Prostaglandin E2|orch,phsu|orch|||dmPGE2||||1000|65|70

SE|00000000|RESULTS|tx|163|text|Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously.
SE|00000000|RESULTS|tx|163|entity|C0035608|Rifampin|antb,orch|||Rifampin||||1000|1|8
SE|00000000|RESULTS|tx|163|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||872|44|51
SE|00000000|RESULTS|tx|163|entity|C1514873|Requirement|ftcn|||requirements||||872|53|64
SE|00000000|RESULTS|tx|163|entity|C0178693|human study|resa|||human subjects||||983|69|82
SE|00000000|RESULTS|tx|163|entity|C1254351|Pharmacologic Substance|phsu|||agents||||872|100|105
SE|00000000|RESULTS|tx|163|entity|C0521115|Simultaneous|tmco|||simultaneously||||872|107|120
SE|00000000|RESULTS|tx|163|relation|1|1|C0035608|Rifampin|antb,orch|antb|||Rifampin||||1000|1|8|VERB|STIMULATES||31|38|3|1|C0043031|Warfarin|hops,orch,phsu|hops|||warfarin||||872|44|51

SE|00000000|RESULTS|tx|164|text|These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
SE|00000000|RESULTS|tx|164|entity|C1274040|Result|ftcn|||results||||1000|7|13
SE|00000000|RESULTS|tx|164|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone||||1000|33|45
SE|00000000|RESULTS|tx|164|entity|C0073109|retinol acetate|orch,phsu,vita|||retinyl acetate||||1000|51|65
SE|00000000|RESULTS|tx|164|entity|C2362652|Possible diagnosis|qlco|||possibly||||1000|72|79
SE|00000000|RESULTS|tx|164|entity|C0017710|Glucocorticoids|horm,strd|||glucocorticoids||||1000|87|101
SE|00000000|RESULTS|tx|164|entity|C0035339|Retinoids|bacs,orch,phsu|||retinoids||||1000|107|115
SE|00000000|RESULTS|tx|164|entity|C1514485|Proliferation|ftcn|||proliferation||||1000|135|147
SE|00000000|RESULTS|tx|164|entity|C1179826|Prostatic epithelium|tisu|||prostate epithelium||||964|152|170
SE|00000000|RESULTS|tx|164|entity|C1701901|Conditional|qlco|||dependent||||901|182|190
SE|00000000|RESULTS|tx|164|entity|C1707811|Dose Modification|resa|||dose-dependent modification||||901|177|203
SE|00000000|RESULTS|tx|164|entity|C0205177|Active|ftcn|||activity||||1000|212|219
SE|00000000|RESULTS|tx|164|entity|C0021641|Insulin|aapp,horm,phsu|||insulin||||1000|224|230
SE|00000000|RESULTS|tx|164|entity|||gngm|1950|EGF|EGF||||1000|236|238
SE|00000000|RESULTS|tx|164|relation|7|3|C0035339|Retinoids|bacs,orch,phsu|bacs|||retinoids||||1000|107|115|ADJ|STIMULATES||182|190|3|2|C0021641|Insulin|aapp,gngm,horm,phsu|gngm|||insulin||||1000|224|230
SE|00000000|RESULTS|tx|164|relation|7|3|C0035339|Retinoids|bacs,orch,phsu|bacs|||retinoids||||1000|107|115|ADJ|STIMULATES||182|190|3|2|||gngm,aapp|gngm|1950|EGF|EGF||||1000|236|238
SE|00000000|RESULTS|tx|164|relation|7|3|C0017710|Glucocorticoids|horm,strd|horm|||glucocorticoids||||1000|87|101|ADJ|STIMULATES||182|190|3|2|C0021641|Insulin|aapp,gngm,horm,phsu|gngm|||insulin||||1000|224|230
SE|00000000|RESULTS|tx|164|relation|7|4|C0017710|Glucocorticoids|horm,strd|horm|||glucocorticoids||||1000|87|101|ADJ|STIMULATES||182|190|3|3|||gngm,aapp|gngm|1950|EGF|EGF||||1000|236|238

SE|00000000|RESULTS|tx|165|text|The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
SE|00000000|RESULTS|tx|165|entity|C0521115|Simultaneous|tmco|||concomitant||||888|5|15
SE|00000000|RESULTS|tx|165|entity|C0035608|Rifampin|antb,orch|||rifampin||||1000|35|42
SE|00000000|RESULTS|tx|165|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|48|55
SE|00000000|RESULTS|tx|165|entity|C0027552|Needs|qlco|||need||||1000|73|76
SE|00000000|RESULTS|tx|165|entity|C0024501|Maintenance|acty|||maintenance||||824|100|110
SE|00000000|RESULTS|tx|165|entity|C0444956|High dose|qnco|||high maintenance dose||||824|95|115
SE|00000000|RESULTS|tx|165|entity|C0043031|Warfarin|hops,orch,phsu|||warfarin||||1000|120|127
SE|00000000|RESULTS|tx|165|entity|C0439228|day|tmco|||day||||1000|140|142
SE|00000000|RESULTS|tx|165|entity|C1882348|Permutation|qlco|||order||||861|148|152
SE|00000000|RESULTS|tx|165|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effect||||1000|167|184

SE|00000000|RESULTS|tx|166|text|The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.
SE|00000000|RESULTS|tx|166|entity|C0185125|Application procedure|hlca|||application||||861|16|26
SE|00000000|RESULTS|tx|166|entity|C0017890|Glycine|aapp,bacs,phsu|||glycine||||1000|31|37
SE|00000000|RESULTS|tx|166|entity|C0439272|ug/g|qnco|||mg/kg||||798|48|52
SE|00000000|RESULTS|tx|166|entity|C0029974|Ovum|cell|||egg||||798|54|56
SE|00000000|RESULTS|tx|166|entity|C0043100|Weight|qnco|||weight||||798|58|63
SE|00000000|RESULTS|tx|166|entity|C0220839|Glutamate|aapp,bacs|||glutamate||||1000|76|84
SE|00000000|RESULTS|tx|166|entity|C0439272|ug/g|qnco|||mg/kg||||673|90|94
SE|00000000|RESULTS|tx|166|entity|C0052080|antineoplaston A10|orch,phsu|||a 10||||798|105|108
SE|00000000|RESULTS|tx|166|entity|C0702093|/minute|tmco|||min||||798|110|112
SE|00000000|RESULTS|tx|166|entity|C1272706|Interval|tmco|||interval||||798|114|121
SE|00000000|RESULTS|tx|166|entity|C0205359|Spontaneous|ftcn|||spontaneous||||888|165|175
SE|00000000|RESULTS|tx|166|entity|C1510470|Motility|orgf|||motility||||888|177|184
SE|00000000|RESULTS|tx|166|entity|C0439228|day|tmco|||day||||798|192|194
SE|00000000|RESULTS|tx|166|entity|C0580836|Old|tmco|||old||||798|196|198
SE|00000000|RESULTS|tx|166|entity|C0008046|Chick Embryo|emst|||chick embryos||||798|200|212
SE|00000000|RESULTS|tx|166|entity|C1707455|Comparison|acty|||comparison||||1000|217|226
SE|00000000|RESULTS|tx|166|entity|C1280500|Effect|qlco|||effect||||1000|237|242
SE|00000000|RESULTS|tx|166|entity|C0220839|Glutamate|aapp,bacs|||glutamate||||1000|247|255
SE|00000000|RESULTS|tx|166|entity|C0205171|Singular|qnco|||alone||||1000|257|261
SE|00000000|RESULTS|tx|166|relation|6|5|C0220839|Glutamate|aapp,gngm,bacs|aapp|||glutamate||||1000|247|255|NOM|AUGMENTS||151|160|6|1|C1510470|Motility|orgf|orgf|||motility||||888|177|184

SE|00000000|RESULTS|tx|167|text|Cypermethrin-induced oxidative stress in rat brain and liver is prevented by vitamin E or allopurinol.
SE|00000000|RESULTS|tx|167|entity|C0056849|cypermethrin|hops,orch|||Cypermethrin||||861|1|12
SE|00000000|RESULTS|tx|167|entity|C0205263|Induce (action)|ftcn|||induced||||861|14|20
SE|00000000|RESULTS|tx|167|entity|C0242606|Oxidative Stress|comd|||oxidative stress||||861|22|37
SE|00000000|RESULTS|tx|167|entity|C1882598|Rat Brain|bpoc|||rat brain||||1000|42|50
SE|00000000|RESULTS|tx|167|entity|C0023884|Liver|bpoc|||liver||||1000|56|60
SE|00000000|RESULTS|tx|167|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E||||1000|78|86
SE|00000000|RESULTS|tx|167|entity|C0002144|Allopurinol|orch,phsu|||allopurinol||||1000|91|101
SE|00000000|RESULTS|tx|167|relation|2|1|C0042874|Vitamin E|lipd,phsu,vita|phsu|||vitamin E||||1000|78|86|VERB|PREVENTS||65|73|3|3|C0242606|Oxidative Stress|comd|comd|||oxidative stress||||861|22|37
SE|00000000|RESULTS|tx|167|relation|2|1|C0002144|Allopurinol|orch,phsu|phsu|||allopurinol||||1000|91|101|VERB|PREVENTS||65|73|3|3|C0242606|Oxidative Stress|comd|comd|||oxidative stress||||861|22|37

SE|00000000|RESULTS|tx|168|text|It was concluded that, although gentamycin did augment the neuromuscular blockade of atracurium, the effect was minimal.
SE|00000000|RESULTS|tx|168|entity|C0017436|Gentamicins|antb,carb|||gentamycin||||1000|33|42
SE|00000000|RESULTS|tx|168|entity|C0700323|Observation of Neuromuscular Block|dsyn|||neuromuscular blockade||||1000|60|81
SE|00000000|RESULTS|tx|168|entity|C0004234|Atracurium|orch,phsu|||atracurium||||1000|86|95
SE|00000000|RESULTS|tx|168|entity|C1280500|Effect|qlco|||effect||||1000|102|107
SE|00000000|RESULTS|tx|168|entity|C0547040|Minimal|qlco|||minimal||||1000|113|119
SE|00000000|RESULTS|tx|168|relation|1|1|C0017436|Gentamicins|antb,carb|antb|||gentamycin||||1000|33|42|VERB|AUGMENTS||48|54|4|1|C0700323|Observation of Neuromuscular Block|dsyn|dsyn|||neuromuscular blockade||||1000|60|81

